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Chapter 1 
Introduction 
 
1. Human skin 
1.1 Anatomy and physiology  
The skin is one of the human body´s most mesmerizing components, as it combines several 
essential and vital functions. It is a sensitive sensory organ, regulates the body´s 
temperature, controls the loss of water from the body and provides protection against 
external and environmental impacts like microorganisms, UV radiation or simple mechanical 
harm [1–3].  
Mammalian skin is composed of three distinct layers, the epidermis, the dermis and the 
subcutis (Fig. 1-1) [1,4,5].  Starting on the outside, the epidermis with a thickness of up to 
180 µm plays an important part in the skin´s regeneration process and barrier properties. 
With a thickness of 15 to 20 µm, the outermost layer of the epidermis, the stratum corneum 
(SC), presents the main barrier towards exogenous impacts. The SC has a unique structure 
consisting of 10 to 15 layers of non-viable, flattened and tightly packed corneocytes which 
are embedded into a lipophilic lipid matrix. During the skin´s life-cycle and regeneration, 
keratinocytes are developed by cell division in the stratum basale, the innermost layer of the 
viable epidermis. During their transition to the skin surface, the terminally differentiated 
keratinocytes undergo apoptosis, a process where they are transformed to corneocytes. 
These dead, anucleated and cornified cells are mainly built up from keratin filaments as well 
as lipids, fatty acids and ceramides. Cross-connected by corneodesmosomes, the 
overlapping corneocytes form a tightly arranged layer that further contributes to the extensive 
SC barrier characteristics [6]. In-between the corneocytes, a multilamellar matrix mainly 
composed of cholesterol (25%), cholesterol sulfate (less than 5%), free fatty acids (10 to 
15%) and ceramides (45 to 50%) further defines the barrier properties [7]. Compared to other 
biological membranes, the lipid matrix does not contain phospholipids. The ceramides, which 
can be categorized into 9 sub-lasses, are of special interest, as previous studies have 
demonstrated a relationship between ceramide composition and impaired skin barrier [8]. 
Because the ceramides and also the fatty acids are non-branched and without double bonds, 
the components are able to be laterally packed tightly, which leads to the formation of highly 
ordered bi-layered gel-phase membrane domains, as described by Madison et al. (2003). 
These membrane domains are less fluid and permeable than the typical phospholipid-based 
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biological membranes [7,9]. This intercellular lipid matrix is crucial for the formation of the 
skin barrier and also influences the percutaneous absorption of exogenous substances [7].  
Next to the epidermis lies the dermis (up to 2000 µm). The dermis is a connective tissue that 
consists of elastic and collagen fiber networks. These networks provide and support the 
skin´s elasticity, the epidermal structure and embed nerves as well as blood and lymphatic 
vessels, which are necessary for the skin´s immune system and nutrition. In addition, the 
nerves and blood vessels are needed for the regulation of sensory sensations like pain, 
pressure or temperature [5,10,11]. Besides these components, the skin includes also 
appendages like hair follicles and sebaceous glands as well as apocrine and endocrine 
sweat glands [12]. Further specialized cells are located in the stratum basale of the 
epidermis, including melanocytes and Merkel cells. The melanocytes provide the skin with 
pigments, which play a role in UV radiation protection, and the Merkel cells are necessary for 
the skin´s mechano-sensoric system. Additionally, the macrophage-like antigen-presenting 
Langerhans cells and the dendritic epidermal T cells are essential to protect the body from 
allergens in terms of the skin´s immune system [13].    
 
 
  
Figure 1-1 Schematic depiction of the different skin layers, appendages and vessels (printed with 
permission from Van der Maaden et al., 2012 [11]). 
 
1.2 Genetic skin disorders 
Healthy skin is commonly characterized by a well-functioning skin barrier, regular skin 
shedding and moderate hydration, where the skin barrier prevents the intrusion of exogens 
and allergens as well as regulates the skin´s water balance [1–3]. In case of an impaired skin 
barrier, severe consequences can occur that not only restrict an individual’s well-being but 
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often also involve serious health implications. Classified as skin diseases, the different 
manifestations of impaired skin often have multifactorial causes and are frequently tied to 
genetic factors as well [14]. Two common and one rare but well discussed genetically derived 
skin diseases as well as their current treatment strategies are introduced below. 
1.2.1 Atopic dermatitis 
Atopic dermatitis (AD) is one of the most common atopic and inflammatory skin diseases and 
even one of the most common chronic disorders in children besides allergic rhinitis and 
asthma [15]. Up to 20% of children and up to 3% of adults suffer from AD, commonly starting 
at an early age. Typical AD symptoms include for instance reddish or brownish scaly, dry, 
itchy and cracked skin patches, lesions and eczema [14]. The cause of AD is not fully 
understood yet. However, 50% of affected individuals show a genetic predisposition. It has 
been discovered that loss-of-function mutations in the FLG gene result in a reduced 
production of the epidermal barrier protein filaggrin and thus impair the skin barrier integrity. 
Furthermore, the lack of filaggrin negatively impacts the corneocyte and skin lipid formation 
as well as skin pH and hydration adjustment, as the filaggrin derived metabolites urocanic 
acid and pyrrolidoncarboxylic acid are likewise reduced [14,16]. However, environmental 
factors like nutrition and allergens seem to be of pivotal relevance for AD manifestation, too. 
[14]  
1.2.2 Psoriasis 
Similarly to AD, the chronic inflammatory skin disorder psoriasis also derives from a mixture 
of genetic predisposition and exogenous triggers, but stays unraveled concerning its exact 
etiology. It affects about 2-3% of the European population and is characterized by a 
sporadical outbreak that typically is initialized in individuals in their twenties [17]. The most 
common form of psoriasis with approximately 90% sufferers is psoriasis vulgaris (PV) or 
plaque psoriasis. The PV symptoms include inflammations, extensive skin cell proliferation 
(leading to a desquamation every 6-8 days compared to the normal regeneration cycle of 40 
days) and abnormal differentiation resulting in silvery skin plaques that are often found in the 
elbow and knee regions. In rare cases, the disease can spread systemically and causes 
synovitis or arthritis-like symptoms. 10-30% of the affected patients develop an inflammatory 
arthritis, psoriatic arthritis, which progressively destroys the joints if it is not treated correctly 
[17]. As the likeliness to develop the disease is 4 to 6 fold increased in individuals with a 
family history, a genetic or hereditary component is discussed [17]. Genes that are normally 
only expressed in the basal layer where found to be expressed also in the thickened spinous 
layer, e.g. the genes encoding for filaggrin, corneodesmosin, epidermal transglutaminase, 
involucrin or loricrin. Furthermore, an increased release of pro-inflammatory factors like 
interleukins, tumor necrosis factor α and interferons is often observed [17,18]. 
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1.2.3 Ichthyosis vulgaris 
Ichthyosis vulgaris (IV) is a severe skin disease that is characterized by hyperkeratosis, 
excessive scaling, xerosis (abnormally dry skin), keratosis pilaris, and palmar/plantar 
hyperlinearity. In addition, patients suffering from IV also express a strong association with 
further atopic disorders [19]. IV is genetically linked to a loss-of-function mutation in the 
filaggrin gene and that condition can be inherited in a semi dominant manner with 83 to 96% 
penetrance [19]. Here, the produced profilaggrin is truncated, which inhibits the further 
processing to functional filaggrin subunits. The reduced filaggrin level affects the formation of 
the cornified envelope of the corneocytes, the correct loading of lamellar bodies and the 
organization of the lipid bilayers. This ultimately leads to a destabilized and deranged stratum 
corneum skin barrier [19,20]. Furthermore, the amount of proteolysed filaggrin products like 
diverse amino acids, polycarboxylic acid and precursors to urocanic acid, which contribute to 
the natural moisturizing factor (NMF) of the skin, are reduced, which results in dry skin with 
increased UV sensitivity [19].  
1.2.4 Current pharmacotherapy for PV, AD and IV 
The treatment of skin diseases is a complex and sometimes challenging task that often 
needs close collaboration between patients and physicians. Most often a chosen treatment 
might merely address the symptoms, as the route cause is either barely known or the cause 
itself can´t be treated due to the skin disease complexity or its origin.  
Hence, physicians and patients aim for a holistic treatment approach, where on one side 
external trigger factors need to be avoided and on the other side an optimal skin care needs 
to be combined with a suited pharmacotherapy [21]. Patients with a less severe course of the 
skin disease might only need topical treatment, whereas more severe cases may require a 
potent oral or intravenous therapy [22]. 
Atopic Dermatitis 
A basic skin care routine is advised for AD patients with an extra dry skin. Here, hydrating 
and moisturizing emollients with a high lipid content and ointments with urea (2 to 10%) and 
propylene glycol (10 to 25%) are recommended to restore and maintain a throughout 
moisturized skin [19,23]. Sometimes, combinations with UV phototherapy can additionally 
improve and ameliorate lighter AD courses [23]. 
Topical corticosteroids are the number one choice in medical treatment due to their 
efficiency. Used in acute and chronic inflammations, their immunosuppressive and anti-
inflammatory properties are used to down-regulate the production of proinflammatory factors 
like the nuclear factor kappa-light-chain-enhancer of activated B cells and TNFα or to inhibit 
genes that code for the cytokines IL-1 to 6, IL-8 and IFN-γ. The topical application of GCs is, 
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as said, very effective but also implies severe side effects upon long-term use like skin 
atrophy [24–27]. 
To further suppress the immune system and to circumvent skin atrophy, macrolide 
immunosuppressants like pimecrolimus or tacrolimus, also known as calcineurin-inhibitors, 
are used. They intervene by suppressing the transcription of cytokine (IL-2 to 5, TNFα) 
producing genes and thus help normalizing the patient´s immune system response [23,28]. 
For severe cases a systemic therapy might be necessary. Here, cyclosporin A is one of the 
best known calcineurin-inhibitor medications. For both short and long term therapy, 
Cyclosporin A shows a quick response, but needs to be closely monitored due to its nephron- 
and hepatotoxicity [23]. 
As a third choice medication, Mycophenolatmofetil is sometimes used in cases where 
patients didn´t respond to any other medication. Despite its efficacy for severe AD, 
drawbacks are its teratogenicity, the often associated gastrointestinal implications as well as 
cytopenias [23].  
Ichthyosis vulgaris  
For patients with Ichthyosis vulgaris, therapy options are very limited and primarily focus on 
skin care and reduction of the skin areas with hyperkeratosis. Besides creams with 
keratolytic (salicylic acid) and hydrating (urea) agents, baths in sodium bicarbonate solution 
can help soften and remove the scales combined with mechanical exfoliation. For severe 
cases, the retinoid acitretin can be used for severe cases of skin hornification as well as the 
vitamin-A acid tretinoin [29].  
Psoriasis  
An adapted skin care regiment can help soothing the skin related symptoms like dryness, 
itchiness and hyperkeratosis. Using keratolytica such as salicylic, lactic or glycolic acid (5 up 
to 20%) can help shedding the excess skin. Anthralin (Anthra-Derm) creams can help 
reducing the cell growth of keratinocytes in addition [22]. 
For light to moderate severe cases, topical corticosteroids remain one of the most widely 
used treatment options for psoriasis [22]. Despite their usefulness due to a rapid onset, their 
application is strictly limited to certain doses throughout the week, as side effects like acne, 
tachyphylaxis and skin atrophy are very likely to occur [22]. 
Topical (tazaroten) and systemically applied (acitretin, isotretinoin) retinoids may further 
contribute, as they intervene with the epidermal proliferation and thus down regulate the 
hyperkeratinization. Another option is the use of vitamin D3 analogues like calcipotriene, 
calcitriol and  tacalcitol, as vitamin D3 acts as both vitamin and hormone and thus is able to 
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regulate cell growth, differentiation, and immune function as well as calcium and phosphorus 
metabolism [30].  
Functioning as a systemic administered immunosuppressant, Methotrexat is administered 
once-weekly and showed to be a save, well-conversant and effective medication. Due to its 
teratogenicity, strict contraception is inevitable [23,31].  
Since patients with mild to severe PV are often struggling a lifetime, new targeted and 
sophisticated treatment options needed to be introduced that enabled a continuous and 
potentially more effective therapy with less side effects [18]. Biologic agents have been 
developed that target crucial biophysiological pathways and immune cells in the genesis of 
PV. Adalimumab (Humira®), a human monoclonal immunoglobulin G1 antibody against 
TNFα, is an approved biologic in the treatment of rheumatoid arthritis, psoriatic arthritis and 
chronic plaque psoriasis. It is administered every 2 weeks subcutaneously and, after 
systemic uptake, binds to TNFα and thus blocks the interaction with cell surface TNFα 
receptors with significant patient responses. Although adalimumab was able to relief both 
skin and arthritis conditions, the general immunosuppressant properties and reactivated 
tuberculosis cases accompanied by the systemic administration  need to be considered [18]. 
Similar to adalimumab further biologics targeting TNFα antibodies, e.g. etanercept (Enbrel®), 
infliximab (Remicade®), also achieve good results in PV treatment [32,33]. Etanercept, a 
fusion protein composed of human IgG1 Fc region and human TNF type II receptor (TNF-
Rp75), binds to soluble TNFα, whereas the i.v. administered infliximab, a chimeric 
monoclonal antibody, also binds to membrane-bound TNFα. But as seen for adalimumab, 
etanercept and infliximap unfortunately also bear a high risk of opportunistic infections 
associated with the suppressed immune system [18,32,33]. Ustekinumab (Stelara®) is a 
relatively new developed monoclonal IgG1k antibody that binds to the p40 subunit of IL-12 
and IL-23, thus blocking their interactions with their receptors[31].Here, Ustekinumab is 
administered every 12 Weeks (after an initial application and a consecutive second dose 
after 4 weeks) and adverse effects were limited to minor infections [31]. 
Hence, biologically derived therapeutics and antibodies represent an important and 
constructive pillar in severe genetic skin disease treatment and need to be the focus of 
attention in future therapeutic development. To eradicate side effects associated with s.c. 
and i.v. administration, the application of these biologics could be shifted to topical and 
dermal administration options. 
 
 
 
7 
 
2. Dermal drug delivery and skin penetration 
2.1 Characteristics of skin penetration 
The increasing interest of the pharmaceutical industry in dermally applied products is 
reflected in the number of drugs that are investigated for topical application in clinical trials, 
which currently represent one third of all investigated drugs [34]. Although dermally applied 
drugs may offer many advantages, like by-passing the enterohepatic cycle, painless 
application, controlled drug release, dermal drug delivery and less systemic side effects, they 
also oppose some challenges [35,36]. 
The dermal penetration of a drug after topical application is highly dependent on the skin´s 
main barrier, the SC and occurs mainly via passive diffusion [12]. As previously described, 
the dense packing of the corneocytes, their tight interconnection by desmosomes and the 
corneocyte surrounding lipid matrix are in charge for the restricted and limited uptake of 
applied substances [7,35,37]. In general, there are three pathways known through which a 
drug can penetrate into the skin: the shunt or transappendageal route (including the 
penetration through the sweat glands, the hair follicles, and the sebaceous glands, which is 
most suitable for hydrophilic compounds), the intercellular (for the mainly lipophilic 
compounds), and the transcellular route, which most of the hydrophilic compounds have to 
follow [5,38]. Furthermore, the penetration of a drug is highly dependent on the drug´s 
physico-chemical properties. Concerning the size, small substances with a molecular weight 
of less than 500 Da are preferred due to the skin´s distinct total cut-off of 800 Da [38]. For an 
easy passive diffusion, a moderate lipophilicity (logP = 1 to 3) is supportive. As the drugs 
mostly have to travel through the intercellular lipid matrix, water-soluble or hydrophilic 
compounds will be highly restricted in their penetration via certain routes [38]. On the other 
hand, high lipophilicity displayed by an octanol-water partitioning coefficient larger than logP 
3 may eventually result in trapping of the drug in the intercellular matrix, as these high 
lipophilic compounds may be impeded by by the hydrophilic regions in the lipid bilayer [5,38–
41]. After the dermal application, the drugs penetrate depending on Fick´s first law, which 
describes the passive diffusion of the drug across the skin with the following equation [5]: 
 
c
h
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J 


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J = diffusion velocity/ steady-state flux (μg / cm²*h) 
K = distribution coefficient (cm/h) 
D = diffusion coefficient of the membrane (cm² /h) 
h = thickness of membrane (cm) 
∆c = concentration differences (μg/cm³ 
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Hence, the permeation is determined by factors like the area of treated skin, the body region 
reflected in the skin thickness, the drug concentration and solubility in its vehicle and the 
release from it. Additionally, skin hydration, temperature, pH are also relevant influencing 
parameters that need to be considered [42].  
Although the majority of drugs and substances penetrate the skin via the intercellular and 
transcellular route, the transappendageal route offers a potential alternative. Despite only 0.1 
to 1% of the total skin surface is covered with hair follicles and sweat glands, especially the 
hair follicles are considered as potential “shunts”, areas that offer less resistance to the 
penetration of mainly hydrophilic compounds [12,37,38]. With a thinner SC layer at the base 
and a surrounding network of blood capillaries, a more rapid passage through the hair 
follicles and uptake into the blood stream is discussed for nanoparticles and liposomes [12]. 
The likeliness of a nanoparticle-based system to penetrate skin is not clearly revealed yet. 
But it is assumed that particles > 10 nm are unlikely to penetrate the SC directly. Instead they 
tend to accumulate in hair follicles and may enter or deliver the drug into the viable epidermis 
via the transappendageal route [12]. But as the number of those porous orifices is rather low, 
the quantitative benefit of the transappendageal route has to be questioned [43]. 
2.2 Systems for dermal drug delivery testing 
To evaluate skin permeation and penetration of drugs in order to study new dermal drug 
delivery systems, in-vitro experiments are an attractive alternative to in-vivo studies. The 
latter are often ethically questionable or need a safe and sound rationale to be fully 
acknowledged by the regulatory authorities. The validated approach for in-vitro set-ups is the 
use of diffusion cells (Franz diffusion cells) that can be either used in a static or flow-through 
mode. To mimic bio-physiological conditions, different types of membranes or barriers are 
used to study drug permeation / penetration [44]. Excised animal skin, most commonly from 
pigs or rats, can serve as cost effective and simple experimental model. Pig skin is favored 
as it has a similar structural composition as human skin and depicts the same epidermal 
properties as well as amount of hair coat in its morphology. Although pig skin is established 
for in-vitro testing [44–46], it still holds some disadvantages. Compared to human skin, pig 
skin has a higher degree of vascularization and sebaceous glad distribution. Furthermore, 
the SC is thicker, which may lead to altered diffusion characteristics compared to human 
conditions. The skin of furry animals, such as rats and mice, is also an alternative for testing, 
but is disadvised due to a different skin morphology including many skin appendages, hair 
follicles and different SC lipid composition, which makes the skin more permeable compared 
to pig or human skin [44]. Although working with human skin is preferred, the access to 
human skin is restricted since the main sources are limited and originate from skin removal 
surgery (breast or abdomen) or post-mortem skin donations. Therefore, reconstructed human 
skin is commonly used as a substitute and was developed to achieve skin models with 
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humanized features [44,45]. Reconstructed human skin can be divided into epidermal (SC 
and viable epidermis) and full thickness skin models (SC, viable epidermis and dermal 
equivalent) [44]. Some of the commercially available models were subjected to validation 
processes concerning phototoxicity, irritation and corrosion testing and are now implemented 
in the OECD (Organization for Economic Co-operation and Development) guidelines for 
these tests [44,47,48], e.g. EpiSkin™ SM (SkinEthic, Lyon, France) and EpiDerm™ SCT 
(MatTek, Ashland, MA). Unfortunately, these models are not yet fully acknowledged by the 
OECD for skin absorption testing [44]. One of the main reasons is the higher permeability of 
reconstructed human skin, as it still shows differences in the skin lipid composition and the 
skin barrier properties [44]. Compared to native human SC some of the models show 
significantly different lamellar ordering of SC lipids, the lack of polar ceramides or less 
triglycerides, which all contributes to an altered skin barrier. In addition, reduced expression 
of differentiation-related keratins was observed, leading to disturbed keratinocyte 
differentiation [44]. However, reconstructed human skin allows for specific alterations, e.g. 
gene modifications to mimic selected skin diseases like AD  [16,49,50] or psoriasis [51]. This 
enables customized and patient oriented research towards the development of new 
therapeutics or therapeutic drug delivery systems. 
 
2.3 Expectations and challenges of dermal biomacromolecule delivery 
Biomacromolecules as therapeutic compounds are very important and highly researched in 
pharmaceutical industry, as they often offer a higher efficiency, potency and specifity in the 
treatment of severe diseases with complex and heterogenic  characteristics, e.g. infections, 
cancer or autoimmune diseases [36,52,53]. Marketed products like Herceptin®  
(trastuzumab), an antibody used in the successful treatment of HER2-positive breast cancer 
patients where it selectively blocks the overexpressed human epidermal growth factor 
receptor 2 (HER2) [54], Humira® (adalimumab), an inhibitor for the TNFα used in the 
treatment of chronic inflammatory diseases [55], and others [56] show the importance of this 
class of therapeutics for developing a patient oriented and personalized treatment [57,58]. 
But as promising biomacromolecules and specifically proteins are for fighting severe 
diseases, they are challenging due to their physicochemical characteristics. They are 
typically hydrophilic and complex structures with high molecular weights, starting for peptides 
at 300 Da and going up to 1000 kDa for proteins [36,59]. Because of their fragile nature, 
proteins often suffer from instability and are prone to chemical change, denaturation, and 
aggregation. Common risks are presented through factors like shear or agitation stress, pH 
or ionic strength changes, light and higher temperatures. Chemical modifications include 
processes like oxidation, disulfide bond breakage, hydrolysis, deamidation and N-terminal 
and C-terminal changes [60,61]. Upon unfolding, the higher order structure is changed and 
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proteins also become prone to form aggregates, which can lead to a loss in biological activity 
or may enhance the patients´ immune response to the protein drug molecules [61–65].  
Because of their size and hydrophilicity, biomacromolecules are classically administered 
parenterally. But for treatments of topical diseases, local dermal delivery of proteins proposes 
an appealing alternative. The dermal route shows an increased patient compliance due to the 
painless and easy application. The administered therapeutics can be actively controlled for 
sustained delivery or for a discontinuation of treatment. Additionally, the targeted 
administration of the drug into the skin tissue without systemic uptake reduces the associated 
side effects. But the mentioned physicochemical properties of proteins pose a significant 
problem for the penetration through biological barriers, especially the SC. With their high 
molecular weight they are clearly above the SCs cut-off (800 Da) and their hydrophilic 
properties almost completely restrict skin penetration or permeation [5,36,66,67]. 
In summary, as biomacromolecules are an essential source for the treatment of severe 
diseases, further research is necessary to develop smart drug delivery systems, which may 
enable to treat skin diseases locally instead of parenterally [55]. They could hypothetically 
benefit from locally applied protein drugs in terms of a low dose substitution therapy, by 
which disease specific deficient proteins could be replaced by administration without or with 
less systemic side effects compared to the i.v. route. Aufenvenne et al. (2013) investigated 
the efficacy of liposomes loaded with transglutaminase-1 (TGase-1) for local topical enzyme 
replacement in TGase-1 deficient skin grafts. The authors could show that the protein activity 
as well as the correct skin architecture and skin barrier could be restored upon enzyme 
replacement [68]. Similarly, Stout et al. (2013) developed a filaggrin-cell penetrating peptide 
conjugate, which was able to restore a normal phenotype in filaggrin-deficient flaky tail mice 
after application and uptake of the conjugate [69].  
3. Systems for dermal drug delivery 
The main obstacle for an efficient protein delivery into human skin is to overcome of the skin 
barrier represented by the SC without damaging the biomacromolecules or compromising 
their biological activity. The most noteworthy formulation attempts and drug delivery systems 
or vehicles for this are summarized in figure 1-2 and representative systems are introduced 
below.   
Delivery enhancers, which include chemical penetration enhancers and substances that 
increase the SC hydration, are a useful tool to increase a drugs´ skin permeability, solubility 
and partitioning into the skin in general [66,67]. Alcohols (ethanol), surfactants 
(sodiumlaurylsulfate, N-decylmethyl sulfoxide), phospholipids, esters, amines, amides and 
fatty acids act by altering the SC lipid bilayer by either fluidizing or extracting the lipids. Co-
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solvents like polypropylene glycol enhance these effects as they help dissolving the 
penetration enhancers in the SC [42,70,71]. Substances like paraffin, oils from emulsions, as 
well as gelling agents like  hyaluronic acid act as a water reservoir and partially as occlusive 
agents on the SC surface and thus increase the SC hydration and consequently the 
permeability of mostly hydrophilic but also lipophilic drugs [5,72]. However, as proteins are 
rather large, a high quantity of chemical enhancers would be necessary to achieve 
penetration effects, which is a concern in terms of toxicity, skin irritation induction, and 
protein stability in the vehicle [71].  
 
Figure 1-2 Dermal drug delivery strategies for proteins. 
 
Delivery enhancers, which include chemical penetration enhancers and substances that 
increase the SC hydration, are a useful tool to increase a drugs´ skin permeability, solubility 
and partitioning into the skin in general [66,67]. Alcohols (ethanol), surfactants 
(sodiumlaurylsulfate, N-decylmethyl sulfoxide), phospholipids, esters, amines, amides and 
fatty acids act by altering the SC lipid bilayer by either fluidizing or extracting the lipids. Co-
solvents like polypropylene glycol enhance these effects as they help dissolving the 
penetration enhancers in the SC [42,70,71]. Substances like paraffin, oils from emulsions, as 
well as gelling agents like  hyaluronic acid act as a water reservoir and partially as occlusive 
agents on the SC surface and thus increase the SC hydration and consequently the 
permeability of mostly hydrophilic but also lipophilic drugs [5,72]. However, as proteins are 
rather large, a high quantity of chemical enhancers would be necessary to achieve 
penetration effects, which is a concern in terms of toxicity, skin irritation induction, and 
protein stability in the vehicle [71].  
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Colloidal carrier systems such as liposomes, solid lipid nanoparticles (SLN), dendrimer 
nanoparticles and microemulsions are considered to assist and enhance the localized 
delivery of biomacromolecules and have been in focus of research for many years [66,71]. 
For instance, liposomes and lipid-based carriers are known to interact with the SC lipids and 
have been shown to deposit their payload in the SC and the upper skin layers [12,66,70,71].  
Within the group of the physical and mechanical systems, iontophoresis is one of the most 
extensively researched and more successful techniques for biomacromolecule delivery [67]. 
Iontophoresis has been investigated and established for small molecule drugs like lidocaine 
or fentanyl with good results in anesthesia and analgesia, where drug delivery is mediated by 
SC disruption caused by applying continuous low-voltage currents [66]. As iontophoresis 
offers a non-invasive and continuous skin delivery, its potential for protein and peptide skin 
delivery has also been investigated [67,73,74], but was restricted to molecules with sizes 
between 10 to 15 kDa and a high isoelectric point, as a positively charged protein is more 
effectively delivered into the negatively charged surface of the skin using anodal 
iontophoresis [67].  
Dermal drug delivery systems and devices for proteins need to combine an easy preparation, 
easy application, good patient compliance, efficient and steady drug administration during the 
treatment, as well as protein stability. In the following sections, three different drug delivery 
vehicles and systems are introduced that include these attributes. To our knowledge, these 
systems have not been investigated in terms of localized and targeted dermal delivery of 
proteins with regard to replacement therapy in skin diseases yet and were selected as 
candidates for this thesis. 
 
3.1 Nanoparticle-based release systems 
Nanoparticles and nanoparticle-based release systems have been increasingly used over the 
last thirty to fifty years due to their versatility and flexibility in preparation and use. Basically, 
nanoparticles vary broadly with respect to the used material, their morphology and in size. 
Popular nanoparticles include e.g.  solid lipid nanoparticles, virus-like nanoparticles, quantum 
dots, liposomes and dendrimers [12,75]. Further diverse nanoparticulate carriers may also be 
prepared from natural polymers (ovalbumin, chitosan, hyaluronic acid, modified chondroitin 
sulfate) or synthetic polymers (poly (ethylene glycol)-b-poly (methacrylic acid), poly 
(Nisopropylacrylamide- co-acrylic acid), poly (N-isopropylacrylamide)) [76]. Recently, 
nanoparticles and nanogels based of dendritic or hyperbranched polyglycerol chains gained 
interest in the development of protein-compatible drug delivery systems [77]. 
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3.1.1 Polyglycerol-based nanogels 
Polyglycerol is a very versatile and flexible compound that can easily be modified to yield 
hyperbranched dendrimer-like structures. Its advantages for drug delivery include a very 
good biocompatibility, non-cytotoxicity, haemocompatibility, adjustability in size with narrow 
polydispersities, good solubility in polar and aqueous solutions and good compatibility with 
proteins [78–82]. Hyperbranched or dendritic polyglycerols (dPG) can be defined as globular 
PG structures that display a single core from which multiple branches radiate in a dandelion-
like setting (Fig. 1-3).  
 
 
Figure 1-3 Synthesis and schematic structure of dendritic polyglycerol (modified and reprinted with 
permission from [77]. 
 
They are traditionally prepared by ring opening polymerization of glycidol by either anionic or 
cationic means. Polymers of 10 to 100 nm (diameter ~ 10nm) can be obtained [81,83]. In 
aqueous solution, dPGs take up water, swell and thus show the characteristics of both a 
hyperbranched polymer and a cross-linked macroscopic gel. Hence, dPG solutions can be 
classified as nanogels: nano scaled polymer networks that are able to absorb water into the 
network when surrounded by an aqueous environment. Additionally, the generally mild 
reaction conditions allow the incorporation of proteins without damage [79]. Hence, these 
dPG-based are suitable candidates for local topical delivery and other drug delivery 
applications of proteins [75,79,82].   
3.1.2 Functionalization and targeted drug delivery 
One of the most interesting characteristic of the dPG nanogels is the opportunity to introduce 
dPG-chain functionalization or macro-crosslinkers. Tackling the crosslinkers, a  stimuli-
responsive payload release can be achieved, e.g. upon change in pH, temperature, or by an 
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electrical or magnetic field [81,84–88]. Depending on the introduced functional group, the 
release kinetics of the dPG can be tuned. Whereas functional groups like acetals or ketals 
are cleaved by pH stimuli, reductive environments act on groups such as disulfide bridges 
[82]. Upon the stimuli, the dPGs respond with degradation into lower molecular weight 
fragments and release of the incorporated drug [89]. The pH triggered drug release is 
especially interesting for targeted drug delivery to inflamed or cancerous tissue, where the 
pH is slightly acidic (solid tumors ~ pH 6.0; inflamed tissues ~ pH 6.5-6.0; endosome/ 
lysozyme cellular compartments ~ pH 5.0 -5.5) [82,90]. The nanogel degradation appears 
upon contact of the acetal or ketal macro-crosslinkers  with peripheral protons present at the 
site of action by means of acid-catalyzed hydrolysis [82,91]. Introducing thermoresponsive 
polymers like poly(N-isopropylacrylamide) (PNIPAM), the dPG can be combined with a 
temperature trigger, where the dPG responds with a rapid change in conformation due to 
drastic swelling or de-swelling. In this case, the drug release kinetics depend highly on the 
rate at which the nanogel shrinks, as the drug is literally squeezed out from the network 
[83,84,92].  
3.1.3 The potential of dPG-based nanogels in drug delivery 
The main therapeutic focus is application of dPG-based nanogels in cancer therapy. The 
nanogels loaded with cytotoxic drugs are administered i.v. and the release is triggered at the 
tumor tissue site [84,88,90,93]. Nagasaki et al. (2007) worked with core-shell type PEGylated 
nanogels made from core-cross-linked poly[2-(N,N-diethylamino)ethyl methacrylate] and 
tethered PEG chains for half-life extension. Equipped with a swelling mechanism upon pH 
trigger, they were able to demonstrate successful and controlled release of doxorubicin into 
endosomal compartments of a drug-resistant HuH-7 tumor cell line (hepatic cellular 
carcinoma) [94]. Combining PNIPAM with dPG-based polyglycerol, Cuggino et al. (2011) 
introduced a precipitation polymerization method for the preparation of thermoresponsive 
nanogel systems of 50 to 200 nm that showed structural phase transitions at a temperature 
of 32.5 to 34.6 °C. Although cell compatibility and viability tests revealed a non-cytotoxic and 
even cell-penetrating behavior, unfortunately no drug delivery experiments were carried out 
[84].  Steinhilber et al. (2011) demonstrated the biological compatibility for encapsulated 
biomaterials. The authors encapsulated yeast cells during the free-radical polymerization of 
dPG-decaacrylate and polyethylene glycol-diacrylate with cell viabilities up to 80% [79]. 
Furthermore, different research groups used diverse nanogels to incorporate proteins like 
insulin/ BSA/ ß-galactosidase [95], horseradish peroxidase [96], and lysozyme [97]. 
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3.2 Hyaluronic acid for dermal drug delivery 
3.2.1 Structure and physico-chemical characteristics of HA 
Hyaluronic acid (HA), or hyaluronan when present as polyanion in-vivo, is a polysaccharide 
found in the intercellular matrix in  vertebrates and bacteria [98,99]. Extracted from rooster 
combs, umbilical cords, or bacteria, HA is generated at various molecular weights (~ 5 kDa 
up to ~ 5 MDa) [99]. HA has many advantageous properties like good biocompatibility, non-
immunogenicity, biodegradability and viscoelasticity. These properties render a perfect 
biomaterial for the pharmaceutical and cosmetic sector [99] 
Built from repeating units of D-glucuronic acid and N-acetyl-D-glucosamine, HA´s primary 
structure arranges into an unbranched linear chain with the monosaccharides linked together 
through alternating β1,3 andβ1,4 glycosidic bonds (Fig. 1-4) [72,99].  
 
 
Figure 1-4 Chemical structure of the disaccharide unit of hyaluronic acid (printed with permission from 
[100]). 
In aqueous solution, HA molecules are suggested to assume an expanded random coil 
structure with a highly entangled network, which is strongly hydrated with up to 15 water 
molecules bound per disaccharide unit [99,101]. The swelling behavior depends on factors 
such as pH, ionic strength and degree of cross-linking [101]. With an isoelectric point of 8.6 
and an intrinsic pK value of the carboxyl group of 3.21, HA gels reach their swelling 
equilibrium at pH 6, while they collapse at lower pH. With the addition of salt, the equilibrium 
swelling at pH 7 is decreased due to charge shielding. Looking at the temperature, the 
swelling behavior was only affected to minor degrees [101].  
The viscosity of HA gels increases substantially with HA molecular weight and concentration 
and strongly depends on the pH. The addition of phospholipids, which compete with HA 
molecules for the hydrophobic binding sites, and sodium chloride, which shields electrostatic 
repulsion between HA molecules, decrease both the viscous and the elastic modulus. In 
contrast, sugars appear to promote the HA gel structure, enhancing the interaction between 
HA molecules and decreasing their hydrodynamic radius [99].  
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3.2.2 HA in drug delivery 
3.2.2.1 General drug delivery aspects of HA  
HA has found its way into many drug delivery areas including ophthalmic, nasal, pulmonary 
and parenteral drug delivery due to its either hydration-rendering, wound healing or lubricant 
properties, where HA was able to increase the bioavailability, e.g. for ophthalmically 
administered drugs like pilocarpine, and the local tissue adhesion of the incorporated drug 
[99]. In addition, HA also provides a stabilizing network surrounding [102,103]. 
Very unique is the use of HA conjugates in cancer treatment for specific site targeting into the 
lymphatic tissues [99,100]. Luo et al. (2005) report the use of a HA – taxol conjugate, which 
selectively targeted the cancer tissue in the breast, colon and ovarian cancer cells [104]. 
Other interesting approaches address the HA cell receptor CD44 that is often overexpressed 
in drug-resistant cancer cells and cancer stem cells [105]. Wei et al. (2012) investigated the 
efficiency of a cholesterol modified HA-drug conjugated nanogels using etoposite and 
salinomycin and curcumin. The small nanogel (20 to 40 nm) and a drug load of approx. 20% 
showed 2 to 7 times higher cytotoxicity in CD44-expressing drug-resistant breast and 
pancreatic cancer cell compared to the free drugs. Due to the binding of HA to the CD44 
receptor and the sustained drug release following ester linkage hydrolysis, the drug 
accumulated to much higher extent in the cancer cells [105].  
3.2.2.2 Transdermal and dermal drug delivery of HA  
HA is widely used as topical and dermal drug delivery vehicle and formulation excipient in the 
treatment of various skin conditions and diseases, providing improved skin hydration, 
regenerating skin elasticity and enhancing wound healing [72,98,106,107]. HA is also known 
to act as a topical drug delivery enhancer for NSAIDs like diclofenac. Solaraze® (3% 
diclofenac in 2.5 % HA), is an alternative to surgery in the treatment of actinic keratosis [72]. 
Concerning the mode of action, different hypotheses are discussed. Firstly, the skin 
absorption of diclofenac may be facilitated due to increased skin hydration through the 
swollen SC, providing an increased hydrophilic environment for the drug permeation [72]. 
Secondly, co-transport of the active and HA is discussed [108]. Additionally, HA and the drug 
may be actively transported via HA receptors (hyaladherins, CD44) expressed on the cell 
surface  of keratinocytes [103]. The theory also provides the basis for the testing of a HA – 
human growth hormone conjugate (HA-hGH), which was investigated by Yang et al. (2012) 
[103]. Proliferative effects in keratinocytes and fibroblasts could be demonstrated and 
elevated levels of phosphorylated Janus kinase 2 (p-JAK2) also confirmed the biological 
activity of the HA-hGH conjugate in fibroblasts [103]. As these experiments were carried out 
in cultured cells, the efficacy of the HA conjugate still needs to be evaluated in dermal 
application. Concerning the HA mediated dermal delivery of high molecular weight 
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biomolecules into the skin, scarcely any research is published that does not include the use 
of microneedles (MN) or other penetration-facilitating devices. This highlights the need for 
further research on both the HA drug delivery vehicle and the mode of action of HA-mediated 
biomacromolecule delivery, which will be covered in this thesis.      
 
3.3 Solid microneedles for dermal drug delivery  
3.3.1 MN fabrication and characterization 
As mentioned earlier, dermal drug delivery is limited to a small group of drugs due to the 
extensive barrier properties of the SC. The easiest way to overcome the SC barrier is 
mechanical perforation. Besides techniques like electroporation, microdermabrasion or 
needle-free jet injectors, microneedles (MN) are a straightforward approach to selectively 
pierce the SC  [66,109,110]. Shorter needles improve the patient´s safety but still enable 
drug delivery to the target site. They are designed to avoid the stimulation of nociceptors, 
which are located  in the upper dermis, making MN application practically pain free [110]. To 
increase the effectiveness of drug application, MNs are usually designed as arrays. As 
single-use units, the use of MN can help to prevent infections or the transfer of contagious 
diseases [111]. Many types of MN made of diverse materials emerged (Fig. 1-6), e.g. solid 
MN made of silicon, metal, glass, ceramics and polymers. They are classically produced by 
either lithographic, and wet or dry etching techniques [111].  
3.3.2 Drug application techniques and formulation aspects 
When the SC is pierced with a MN arrays, a micro channel is generated whose depth 
depends on the MN needle length and manner of application [112,113]. To deliver a drug, the 
drugs are either applied onto the skin before or after MN application as solutions, gels, 
creams, ointments or drug infused patches [111,113]. The drug reaches the epidermis and 
deeper dermal layers by diffusion into and through the microchannels [110]. Alternatively, the 
drug is directly coated onto the MNs. Upon application, the solid coatings dissolve in the 
interstitial fluid [110,111]. Typically, the coating is produced by dipping processes, generating 
a thin film on the needle tips. To achieve a uniform and reproducible coating, the appropriate 
excipients need to be selected [114]. Mixtures of different viscosity enhancers or gelling 
agents (e.g. carboxymethyl cellulose, hyaluronic acid, sodium alginate, xanthan gum), sugars 
(e.g. sucrose, saccharose, trehalose) and surfactants (e.g. diverse polysorbates and 
poloxamers) were successfully developed to form a reproducible coating providing adequate 
stability for incorporated proteins [114–117]. 
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Figure 1-5 Schematic display of four MN types after skin application (A) and their mode of action in 
drug delivery (B) (printed with permission from [110]). 
 
Another different approach is the embedding of the drugs into dissolvable MN made of 
preferentially polymers (e.g. carboxymethyl cellulose, hyaluronic acid, poly(lactic-co-glycolic) 
acid) and sugars, such as dextrans, dextrins and sucrose. These MN are prepared 
commonly by micro-molding of polymer/sugar solutions or tip drawing of polymer/sugar melts 
[111,118,119]. As the amounts of drugs that can be delivered by these three described 
approaches are limited, hollow microneedles have been developed, which offer the 
opportunity to apply larger quantities. The  application of 0.2 up to 15 mL drug solution may 
be possible as presented by Becton Dickinson Technologies (Microinfusor™) [111].  
3.3.3 Dermal drug delivery mediated by MN 
MNs offer a low-cost, easy-to-manufacture and flexible delivery device. Therefore, these 
devices are a promising option for the topical delivery of complex and sensitive 
biomacromolecules [110]. As protein mostly require low doses in the microgram range, MN 
are a suitable platform for their administration [110]. Consequently, MNs were recently 
studied to deliver diverse peptide hormones e.g. insulin [120,121], desmopressin [122], 
erythropoietin [123], or the human growth hormone [124]. Furthermore, the use of MN for 
intradermal vaccination against measles [125] or influenza [126,127] is very appealing. MN 
mediated vaccination is a particularly attractive approach since the vaccines can be directly 
administered into the viable epidermis resulting in a strong and more potent immune 
response due to the rapid targeting of Langerhans  and dermal dendritic cells [114,128,129].  
 
4. Objectives of the thesis 
The goal of the thesis was the development and characterization of three different systems 
for local and targeted intraepidermal delivery of biomacromolecules. As incidences of skin 
diseases like atopic dermatitis are on the rise in the industrialized countries affecting 
especially children, adequate and effective therapies become more and more important. 
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Although the causes for the diseases are often multifactorial, a certain patient population 
suffers from genetic conditions that result in highly down regulated epidermal levels of 
functional proteins. Since these proteins are essential in the viable epidermis for the 
development of a healthy skin barrier, the substitution of the lacking proteins, such as 
transglutaminase or filaggrin, is an interesting starting-point for a new therapeutic concept.  
Therefore, the presented thesis aims to introduce three delivery systems based on innovative 
concepts, which were either adapted or modified for topical and especially dermal protein 
delivery and intensively investigated for their intraepidermal delivery yields and mechanisms.          
The three objectives of the thesis can be summarized as followed: 
1.) In cooperation with the FU Berlin (AG Haag, AG Caldéron), dPG-based nanogels 
were developed and modified to suit the properties of protein encapsulated topical 
and dermal delivery systems. The process and release-trigger adapted dPG nanogels 
were characterized and investigated for controlled protein release and stability. The 
release yield was assessed as a function of skin barrier integrity. dPG nanogel-based 
transglutaminase-1 substitution in a deficient skin model was evaluated as proof-of-
concept. 
2.) HA, a versatile polysaccharide that already demonstrated to promote the dermal drug 
delivery of small-molecule drugs like diclofenac, was explored as topical protein 
delivery system with focus on the influence of HA molecular weight and 
concentration. The delivery yield was investigated as a function of skin barrier 
integrity. To unravel the mode of action, interactions of HA with protein and SC was 
studied.  
3.) As solid stainless-steel MN established a reputation to be valuable tools in vaccine 
delivery, their potential for skin disease treatment was evaluated. Here, the feasibility 
and the adequate MN properties for localized intraepidermal protein application were 
investigated and the MN´s potential for skin irritation was assessed. Furthermore, 
special attention was set on the in-process and storage stability of coated MN, an 
important factor that was thitherto sparsely regarded in literature.  
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Chapter 2 
 
Biodegradable dendritic polyglycerol nanogels for encapsulation 
and release of pharmaceutical biomacromolecules 
 
The following chapter has been published as peer-reviewed article in the Journal of 
Controlled Release and appears in this thesis with the journal´s permission: 
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The personal contribution covers the experimental set-up and contribution to the 
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Abstract 
In this paper we report a novel approach to generate biodegradable polyglycerol nanogels on 
different length scales. We developed a mild, surfactant free inverse nanoprecipitation 
process to template hydrophilic polyglycerol nanoparticles. In situ crosslinking of the 
precipitated nanoparticles by bio-orthogonal copper catalyzed click chemistry allows us to 
obtain size defined polyglycerol nanogels (100 - 1000 nm). Biodegradability was achieved by 
the introduction of benzacetal bonds into the net points of the nanogel. Interestingly, the 
polyglycerol nanogels quickly degraded into low molecular weight fragments at acidic pH 
values, which are present in inflamed and tumor tissues as well as intracellular organelles, 
and they remained stable at physiological pH values for a long time. This mild approach to 
biodegradable polyglycerol nanogels allows us to encapsulate model proteins, including the 
therapeutic relevant enzyme asparaginase, into the protein resistant polyglycerol network. 
Enzymes were encapsulated with an efficacy of almost 100 % and after drug release, full 
enzyme activity and structural integrity were observed. This new inverse nanoprecipitation 
procedure allows the efficient encapsulation and release of various biomolecules including 
proteins and could find broad applications in polymer therapeutics and nanomedicine.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Keywords: Polyglycerol Nanogel, Nanoprecipitation, Biodegradability, Surfactant Free, 
Protein Encapsulation, Stimuli-Responsive Release 
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1. Introduction 
Therapeutically relevant proteins such as antibodies, cytokines, growth factors, and enzymes 
are playing an increasing role in the treatment of viral, malignant, and autoimmune diseases 
[1,2] Therapeutic proteins, however, often suffer from insufficient stability and shelf-life, costly 
production, immunogenic and allergic potential, as well as poor bioavailability and sensitivity 
towards proteases [3]. An elegant method to overcome most of these problems is the 
attachment of polyethylene glycol (PEG) chains onto the surface of the protein [4–7]. 
Covalent PEGylation of the native protein increases its molecular weight and as a result 
prolongs the half-life in vivo [3]. By the molecular weight elevation passive targeting to solid 
tumors can be achieved by the enhanced permeation and retention effect [8,9]. Additionally, 
the resistance to proteases and immunogenic responses is increased by the PEG coating. 
PEGylation of proteins, however, still suffer from the loss of biological activity [5].  
These problems can be circumvented, when proteins are encapsulated non-covalently into 
nanogels [10,11].  Nanogels, which are hydrogel particles on the nanometer scale, are highly 
water swollen scaffolds that exhibit similar properties as many biological objects, thus making 
them excellent candidates for biomedical applications [12–16]. Within the past few years, two 
strategies have evolved for the encapsulation of biomolecules into nanogels. They can be 
encapsulated after nanogel formation by the diffusion of the guest into the nanogel due to 
specific interactions of the guest with the nanogels [17]. Strong interactions with the gel 
matrix, however, might cause denaturation of the encapsulated payloads and diffusion 
limitations lead to low encapsulation efficiencies. Another strategy entraps the encapsulated 
payloads in-situ to the nanogel formation process, which ensures high encapsulation 
efficiencies and a homogenous distribution of the guest within the entire gel particle [11]. 
Additionally, the encapsulated payloads can be embedded very tightly in the gel matrix by 
tuning the degree of crosslinking. Thus, the guest can be transported to the target site 
without any loss of payload by leaching.   
For drug release, nanogels require external stimuli to achieve a controlled release of the 
guests at the target site. Guest liberation by nanogel degradation and resulting network 
dissolution is the most promising strategy. Release kinetics can be tuned by the degradation 
kinetics and the generated low molecular weight degradation fragments can be cleared by 
the kidneys, which reduces the possibility of long term toxicity by organ accumulation [5]. 
Various chemical bonds such as disulfides [18,19], acetals [20,21], ketals [22,23], phosphate 
esters [24], silyl ethers [25], and esters [26] have been introduced into nanogel networks 
which are cleaved in response to specific biological stimuli including pH or reductive 
environments [27].  
In-situ encapsulation, however, requires mild nanogel preparation conditions to retain high 
biomolecule activity especially when dealing with sensitive substances such as proteins. 
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Nanogels are usually prepared by the templation of reactive monomers on the nanometer 
scale and subsequent crosslinking of the templates to obtain hydrogel nanoparticles. The 
most frequently used methods are templations in mini- [26,28–32] and microemulsion 
droplets [33–35]. High energy input by ultrasonication, which is required for the formation of 
miniemulsions, prevents the encapsulation of labile compounds by this technique. The 
formation of microemulsions requires high surfactant loadings, which lead to purification 
problems and thereby also limit applications of this technique.  
Another approach which has been developed by Whitesides et al. [36] and further improved 
by the De Simone group [37] is the templation of polymer macromonomers in soft lithography 
templates. Clean room conditions, however, are required for this approach possibly limiting 
the broad application of this technique. Another widely used approach is based on the 
crosslinking of polymeric micelles [15]. Even though this approach is often called “surfactant 
free” in literature, amphiphilic polymers are required which might interact and denature the 
encapsulated payloads. Additionally, material parameters like size, elasticity and shape are 
difficult to influence. The nanoprecipitation technique has evolved as a powerful tool for the 
preparation of hard polymer nanoparticles built from polystyrene (PS) [38], polymethyl 
methacrylate (PMMA) [39,40], and polylactic acid /polylactic-co-glycolic acid (PLA/PLGA) 
[41–43]. Particles prepared by nanoprecipiation avoids the above mentioned downsides and 
allows hydrophobic drugs to be encapsulated [43]. To our knowledge, however, the 
nanoprecipitation technique has not been applied for the preparation of nanogels, made from 
hydrophilic polymers.  
In this paper we describe for the first time the templation of hydrophilic polyglycerol-
macromonomers by nanoprecipitation and subsequent chemical crosslinking of the 
precipitated particles. We use dendritic polyglycerol (dPG) as nanogel scaffold material, due 
to its outstanding multifunctionality [44,45] and protein resistance [46–48]. Minimal interaction 
with the polymer matrix provides maximal protein stabilization. Additionally, the rigidity of 
dendritic macromolecules generates high diffusion barriers for the encapsulated proteins, 
thereby facilitating stable transport behavior. We call this novel approach inverse 
nanoprecipitation due to the inversion of polarity in the nanoprecipitation process. The 
combination of the mild nanogel preparation method with the biocompatible nature of 
polglycerol material allows us to encapsulate therapeutic enzymes with encapsulation 
efficacies higher than 99% under full retention of activity and structural integrity. Finally we 
show that the incorporation of pH labile, cyclic benzacetal bonds into the nanogel network 
leads to degradation triggered controlled enzyme release at acidic pH values. This novel 
approach to enzyme loaded and protein resistant nanogel particles is an important alternative 
for traditional PEGylation strategies and may find broad application in nanomedicine and 
polymer therapeutics. 
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2. Methods 
2.1 Preparation of dPG7.7 functionalized with 10 p-PBDMA units (dPG7.7-10-p-
PBDMA) 
dPG7.7 (1g, 0.13 mmol) and p-PBDMA (250 mg, 1.3 mmol) were dissolved in NMP (4 mL) 
and anhydrous PTSA (22 mg, 0.13 mmol) was added. The reaction was heated to 120 °C for 
3h and the condensed methanol was removed from the reaction equilibrium by 
cryodestillation. After cooling down to room temperature (RT) the reaction was quenched by 
the addition of aqueous ammonia (1 mL). NMP was evaporated by cryodestillation and the 
residue was re-dissolved in basified water (0.05 wt% aqueous ammonia). The solution was 
dialyzed in basified water (0.05 wt% aqueous ammonia) for 2 d, changing the dialysate every 
3 h. After freeze-drying, dPG7.7-10- p-PBDMA was obtained as a viscous wax (conversion 99 
%, yield 80 %). GPC/SEC: Mn=6.5 kDa, Mw=8.9 kDa, PDI=1.4. Hydrodynamic diameter by 
DLS: 3.8 nm. IR [cm −1]: 3385, 2871, 1613, 1513, 1456, 1304, 1221, 1067, 830. 1H NMR (400 
MHz, CD3OD, 25 °C): δ (ppm) = 7.51–7.32 (broad, aromatic), 7.09–6.95 (broad, aromatic), 
156 5.91–5.72 (d, broad, acetal-H), 4.74 (s, aromatic-O-CH2), 4.46–3.39 (PG backbone), 
2.99 (s, CCH). 
2.2 Preparation of polyglycerol nanogels by nanoprecipitation 
dPG7.7-10-p-PBDMA (5 mg, 0.6 µmol) and dPG7.7[N3]7 (7 mg, 0.9 µmol) were dissolved 
separately in Mili-Q-water (0.5 mL). THPTA (500 µg, 1.15 µmol), CuSO4 (72 µg, 0.3 µmol) 
and NaAsc (228 µg, 1.15 µmol) were added exactly in this sequence to the dPG7.7-7- p-
PBDMA solution. The solutions were cooled down to 4°C, mixed and added quickly to 
magnetically stirred acetone (20 mL). Precipitated polyglycerol nanoparticles were obtained 
as blue shining dispersions and the particle size was determined by DLS (Table 2-1). After 3 
h the reaction was quenched by the addition of excess azidoglycerol (50 mg, 893 µmol). After 
12 h Mili-Q-water (20 mL) was added and acetone was evaporated to obtain blue shining 
nanogel dispersions in water. The nanogels were collected by centrifugation (4000 rpm) and 
washed 5 times with Mili-Q-water. The nanogels were characterized by DLS (Table 2-1) 
optical- and fluorescence microscopy and transmission electron microscopy. 
 
Table 2-1 Size and PDI by dynamic light scattering (DLS). Measurements were performed in triplicate; 
intensity average mean value and standard deviation from the mean value are presented. 
 
CMacromonomer [mg/mL] d [nm] acetone PDI d [nm] water PDI 
12 580 0.03 820 0.07 
6 440 0.02 610 0.03 
3 310 0.06 430 0.08 
1.5 102 0.04 145 0.07 
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2.3 Encapsulation of asparaginase into the nanogels 
dPG7.7-10-p-propargyloxy-benzacetale (2 mg, 0.2 µmol) and dPG7.7[N3]7 (3 mg, 0.3 µmol) 
were dissolved separately in Mili-Q-water (0.5 mL). THPTA (500 µg, 1.15 µmol), CuOAc (37 
µg, 0.3 µmol) were added to the dPG7.7-10-p-propargyloxy-benzacetale solution and 
asparaginase was added to the dPG7.7[N3]7 solution. The solutions were cooled down to 4 °C, 
mixed and added quickly to magnetically stirred acetone (20 mL). After 3 h the gelation 
reaction was quenched by the addition of excess azidoglycerol (50 mg, 893 µmol). After 12 h 
the nanogels were collected by centrifugation (4000 rpm) and washed 5 times with Mili-Q-
water. 
2.4 Determination of nanogel degradation kinetics 
Nanogel dispersions were incubated at 37 °C and at different pH values (pH 4, 5 and 7.4). 
Between 30 min and 48 h, the nanogels were separated from degraded fragments by 
centrifugation (4000 rpm, 30 min) and the UV-absorbance was measured at 350 nm (Fig. 2-
3A). Complete nanogel degradation was confirmed by DLS size measurements. 
2.5 Determination of proteins’ secondary structure - Fourier-transformed-
infrared spectroscopy (FT-IR) 
Experiments were recorded using a Bruker Tensor 27 FTIR spectrometer (Ettlingen, 
Germany) equipped with a Bio ATR measuring cell and a MCT detector. The cell was 
connected to a water bath (Haake, Pfinztal, Germany) for a constant cell temperature of 25 
°C. 25 µL of the sample was spread under dry nitrogen to ensure an equal distribution on the 
crystal surface and analyzed against PBS buffer (pH 5) or water as blank. For each 
experiment, 120 scans were set for the blank and sample with a resolution of 4 cm-1 and 
water vapor correction. The data were analyzed with the OPUS 6.5 software for second 
derivative spectra and vector normalization. 
2.6 Determination of asparaginase activity 
The activity of asparaginase was determined as the specific activity [U/mg] of the enzyme 
according to published procedures [49]. The units of enzyme activity were defined as 
micromoles of ammonia released per minute. 
 
reactioninenzymemgutesmin 10
releasedammoniamicromoles
mgUnits

/  
 
A mixture of 50 µl asparaginase, 100 µl Tris-HCl buffer pH 8.6 and 850 µl L-asparagine 
monohydrate buffer solution was incubated at 37 °C for 10 min. After adding 50 µl 1.5 M 
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trichloracetic acid solution and centrifugation, 100 µl of the supernatant was added to 
Nessler´s solution. After 10 min, the optical density was assessed at 436 nm, compared with 
the standard curve and corrected for total enzyme amount.  
2.7 Drug release study 
The polyglycerol nanogels (10 mg/mL polymer and 0.5 mg/mL asparaginase) were acidified 
with HCl to pH 5 and 4, respectively. The samples were incubated at room temperature (25 ± 
2 °C) under mild agitation (300 rpm). Samples were collected for up to 3 days and 
subsequently analyzed with size exclusion HPLC. To stop the particle degradation, the 
samples were neutralized with 0.1M KOH prior to HPLC analysis. 
2.8 Size exclusion HPLC (SE-HPLC) analysis  
To analyze the drug release of degraded polyglycerol nanogels, 50 µl of the neutralized 
samples were injected into the HPLC system equipped with a TSKgel® G4000 PWXL column 
(dimensions: 300 x 7.8 mm, 10 µm particle size; TOSOH Bioscience, Stuttgart, Germany). 
Isocratic elution with 20 mM Na2HPO4, 150mM NaCl, pH 7.4, 0.003 mM NaN3 was performed 
with a flow-rate of 0.4 ml/min. The concentration of asparaginase was determined using UV 
(280 nm) and fluorescence (ex. 295 nm, em. 348 nm) detection. 
 
3. Results and discussion 
3.1 Nanogel preparation by inverse nanoprecipitation and in situ gelation 
When biomolecules are encapsulated into nanogels insitu to network formation, mildest 
reaction conditions are required. The nanoprecipitation technology, which has been 
successfully applied for several years, is based on the injection of highly diluted polymer 
solutions into polymer non solvents. This technique is surfactant free and works without high 
energy input such as ultrasonication and is therefore an excellent candidate for the 
encapsulation of labile enzymes.  
To our knowledge, however, this technique has not been applied for the preparation of 
hydrophilic nanogel particles. These water swollen polymer networks are highly interesting 
for the stabilization of labile enzymes. We chose dPGs as nanogel building blocks, because 
of its excellent protein resistant properties [46–48]. In such water swollen networks, enzymes 
are entrapped without any interaction with the polymer matrix. Additionally, enzyme diffusion 
is strongly reduced due to the rigid conformation of dPGs, which ensures stable guest 
encapsulation. Another outstanding property of dPG is its multivalent polyhydroxylated 
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surface, which allows the modification with cross-linkable groups under full retention of water 
solubility.  
Copper catalyzed Huisgen 2+3 cycloaddition as model crosslinking reaction due to its bio-
orthogonality, high conversions and fast reaction kinetics. We selected pHBA as a core 
building block for the acid labile crosslinker because it is known that degradation kinetics of 
the corresponding benzacetals is interesting for many biomedical applications. Additionally, 
phenol groups can easily be modified by ether bond formation. After the propargylation of 
pHBA we activated the aldehyde by the formation of the dimethylacetal. Final acid catalyzed 
dPG-acetal formation was achieved under methanol evaporation by cryo-destillation to obtain 
acid labile dPG-crosslinker (Fig. 2-1). DPG, functionalized with 7 azide functionalities was 
prepared according to a modified procedure established in our group.  
 
 
Figure 2-1 Schematic representation of the nanoprecipitation process. A: Injection of aqueous solution 
of alkyne functionalized polyglycerol macromonomers, (blue spheres), azide functionalized 
polyglycerol macromonomers (red spheres) and proteins asparaginase, IgG, Lysozyme and BSA (3D 
structure of α-helixes and β-turns). B: Particle templation by diffusion of aqueous phase (blue arrow) 
into acetone phase (brown). C: Particle gelation by azide alkyne 2+3 cycloaddition. 
 
With this novel pH sensitive dPG-alkyne and the azide functionalized counterpart we 
prepared highly diluted aqueous solutions. After cooling to 4°C and adding a catalytic amount 
of CuAsc/THPA, dPG nanotemplates were formed by precipitation into acetone nonsolvent. 
The fast diffusion of the aqueous phase into the acetone phase causes the collapse of dPGs 
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into nanoaggregates. During this process the polymer concentration increases drastically, 
which induces gelation reactions and dPG network formation. Gelation prior to 
nanoprecipitation can be excluded as no size change was observed by dynamic light 
scattering (DLS). Interestingly, the polydispersity index (PDI) of the formed nanoaggregates 
is low narrow and diameters directly correlate with the macromonomer concentration in 
aqueous phase. Hence, we are able to modulate the particle size, which has proven to be 
one of the most important parameter for many biomedical applications [50,51], in a broad 
range between 100 – 1000 nm (Table 2-1). 
Interestingly, the polydispersity index (PDI) of the formed nanoaggregates is low narrow and 
diameters directly correlate with the macromonomer concentration in aqueous phase. Hence, 
we are able to modulate the particle size, which has proven to be one of the most important 
parameter for many biomedical applications [50,51], in a broad range between 100 – 1000 
nm (Table 2-1). 
After gelation, remaining surface reactive alkyne groups were quenched by adding 
azidoglycerol. Finally, we harvest polyglycerol nanogels are harvested by the evaporation of 
acetone. When nanoparticles are transferred to the aqueous phase the diameter increases 
significantly, which is attributed to nanogel swelling. Interestingly, polydispersities remain low 
in the aqueous phase, which is a strong indication that nanogels are freely dispersible 
without aggregation (Table 2-1, Fig. 2-2). The simple reaction setup allows us to upscale the 
reaction to obtain polyglycerol nanogels in gram quantities. 
 
 
Figure 2-2 Visualization of polyglycerol nanogels by electron microscopy (A), optical microscopy (B) 
and fluorescence microscopy (C). 
3.2 Enzyme encapsulation by co-precipitation  
The traditional nanoprecipitation technique is based on organic polymer solutions, from which 
the polymers are precipitated mostly into water. Because the used polymers like PS, PLA 
and PLGA are only soluble in organic solvents like acetone, dichloromethane and 
dimethylformamide, mostly hydrophobic small molecule drugs were encapsulated by this 
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approach. There are many water soluble biomacromolecular drugs like proteins, DNA and 
RNA. These labile biomacromolecules need to be protected from the harsh environment 
present at many administration sites. Pharmaceutical enzymes in particular show important 
characteristics, which make them superior from small molecule drugs. Their high affinity and 
specificity on their targets as well as their catalytic activity, which enables the conversion of 
multiple target molecules, makes them excellent drug molecules [1].  
To encapsulate, stabilize and transport this important class of therapeutics, we applied our 
inverse nanoprecipitation polymerization technique which allows the co-precipitation and 
encapsulation of biomolecules from aqueous solutions, thus preserving their three-
dimensional structure. As a model enzyme we selected asparaginase, which is an important 
therapeutic enzyme for the treatment of acute lymphocytic leukemia [52–54]. Co-precipitation 
of the enzyme in presence of the PG macromonomers yielded enzyme loaded nanogels. We 
determined the encapsulation efficacy to be almost 100 % as no free enzyme could be 
detected by HPLC analysis. 
3.3 Degradation triggered release under acidic conditions 
Cargo liberation triggered by degradation in acidic environments is one of the most promising 
release strategies. Many interesting biomedical targets like inflamed- and tumor tissue (pH 
6.5 – 6), intracellular endosomes (pH 5) and lysosomes (pH 4) can be used for pH 
dependent release. Protons, which can catalyze hydrolysis reaction, have high diffusion rates 
because of their small size and show high accessibility at the cleavage site. Hence, 
degradability limitations due to diffusion barriers are not an issue in this degradation process. 
In this study we prepared cyclic PG-benzacetals as degradable macro-crosslinkers. While 
other pH labile groups like imines, hydrazones often generate toxic polyamine degradation 
products, polyhydroxylated dPG is reformed after acetal cleavage. In contrast to traditional 
approaches to pH cleavable materials, in which low molecular weight degradable monomers 
are used [20], we use biocompatible macromonomers to build gel networks. By this strategy 
we can minimize the total amount of crosslinking units in the gel, which ensures maximal 
biocompatibility. Our polyglycerol nanogels degrade quickly at pH 4 and pH 5, with 
degradation half-lives of 2 h and 11 h respectively (Fig. 2-3A, Fig. 2-4). Interestingly, nanogel 
degradation kinetics and enzyme release kinetics are almost identical (Fig. 2-3B), which 
proves that release is only triggered by degradation. Additionally, the asparaginase is 
released without interactions between degraded dPG, which proves that these protein 
resistant materials are excellent scaffolds for the encapsulation, transport and release of 
proteins.     
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Figure 2-3 A: Degradation kinetics of polyglycerol nanogels determined by UV/Vis absorbtion in the 
supernatant at pH 4 (black squares), pH 5 (red circles) and pH 7.4 (blue triangles) at 37 °C. B: Protein 
release kinetics determined by HPLC at pH 4 (black squares), pH 5 (red circles), and pH 7.4 (blue 
triangles) at 25°C.   
 
 
Figure 2-4 Schematic representation of degradation triggered release of a therapeutic relevant 
enzyme and its catalytic conversion of asparagine to aspartic acid under ammonia generation. 
 
3.4 Structure-activity assay of encapsulated and released asparaginase 
3.4.1 Determination of proteins’ secondary structure by Fourier-transformed-
infrared spectroscopy (FT-IR) 
To determine the structural composition and especially the secondary structure of the model 
protein asparaginase before and after encapsulation in the polyglycerol nanogels, FT-IR 
spectra were recorded.  
Several bands can be used for structural analysis of asparaginase [55]. The most sensitive 
spectral region for protein secondary structure analysis is the amide I band (1700-1600 cm-1), 
which results mainly from C=O stretch vibrations of the peptide linkages [56]. The major 
component of the native protein belongs to a band at approximately 1657 cm-1, 
36 
 
corresponding to a helical conformation. The band at ~1653 cm-1 corresponds to a 
disordered/irregular part of the molecule. Extended ß strands can be found at ~1637 cm-1 
[57]. Comparable spectra for amide I (~1662-1648cm-1) and II (~1580-1510cm-1) band were 
obtained with the encapsulated and the native protein when evaluating the second derivative 
spectra of the FT-IR measurements (Fig. 2-5A/B, Table 2-2) 
In general, no significant changes of the secondary structure of asparaginase were detected 
after encapsulation and release from the PG nanogels. For the amide I band, the peak 
intensities around 1660 cm-1 and 1635 cm-1 are the same, no significant changes were 
detected (Table 2-2). The same holds true for the negative ß-sheet peak of the formerly 
encapsulated protein at 1637.3-1 which is slightly shifted 2 cm-1 to the left (compared to the 
native proteins at 1635.4 cm-1).  
The amide II spectral region from 1575 -1480 cm-1gives information about the out-of-phase 
combinations of N-H, the in-plane N-H bending, and also about the C-N stretching vibrations. 
In general, this region exhibits much less protein conformational sensitivity compared to the 
amide I region [55,56]. The second derivative of the amide II spectra (Fig. 2-5B) shows no 
significant differences in secondary structures of the native protein and the released 
asparaginase (Table 2-2).  
 
 
Figure 2-5 The second derivative spectra of the amide I (left) and II (right) region of the ATR-FT-IR 
spectra of asparaginase in water (freshly prepared; dashed line), in PBS buffer pH 5 (stored for 1 
week; dotted line) and after release from polyglycerol nanogels (stored for 1 week; connected line) 
162516351645165516651675
Absorbance / Wavenumber [cm-1]
1660cm-1 1665cm-1 1635cm-1
15301540155015601570
Absorbance / Wavenumber [cm-1]
1550cm-1
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Table 2-2 Comparison of peak positions (second derivative FT-IR spectra, wavenumbers [cm
-1
]) 
 
 Amide I band Amide II band 
Asparaginase in water (freshly prepared) 1660.5 1649.9 1634.4 1549.6 
Asparaginase in PBS pH 5.0 (7d storage) 1659.5 1646.9 1635.4 1550.5 
Asparaginase after release (7d storage) 1659.0 1648.9 1637.3 1547.6 
 
3.4.2 Determination of asparaginase activity 
The asparaginase activity assay assessed the protein activity of the freshly prepared solution 
in water with 98.6 U/mg, the same as declared by the supplier (98.2 U/mg). Looking at the 
asparaginase in PBS pH 5.0 a slightly decreased activity (-12.5%) was found (86.1 U/mg, 
Fig. 2-6, Table 2-2).  
For the asparaginase released from the polyglycerol nanogels, the activity (86.2 U/mg) is the 
same as for the non-treated and, thus, native protein in PBS pH 5.0 (Table 2-2). The activity 
assay for the intact PG nanogel with encapsulated asparaginase revealed an enzyme activity 
of 38.9 ± 4.1 U/mg. Based on the former data (asparaginase activity after PG-encapsulation 
and release at pH 5, 87.5 U/mg) this value refers to 44.5 %. As no free asparaginase was 
detectable, it can be concluded that the substrate is able to interact with the asparaginase 
molecules located at the surface of the PG nanogel particles.  
 
 
Figure 2-6 Specific enzyme activity ± SD [U/mg] determined with an asparaginase activity assay.  
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FT-IR measurements of the asparaginase showed no significant changes in secondary 
structure after protein encapsulation in the PG nanogels and subsequent release in a slightly 
acidified buffer (pH 5). As shown in Table 2-1, the peak shifts of our samples (amide I and II 
bands) range between 2 and 3 cm-1. In general, shifts up to 3 cm-1 are inevitable and normal 
due to handling and measurement inaccuracies. Thus, for FT-IR spectra literature often 
refers to peak ranges, due to variations between different proteins, batch variability and 
measurement inaccuracies [56]. 
The asparaginase activity assay showed excellent results concerning the maintenance of the 
protein activity after encapsulation and protein release. Comparing the stored samples to 
freshly prepared asparaginase solution, a lower enzyme activity (- 12.5%) was found. Most 
likely, this decrease is related to a loss of active enzyme due to the storage in PBS pH 5. 
Nevertheless, as the encapsulated and released asparaginase had the same activity as the 
non-processed sample in PBS pH 5.0, it can be concluded that the encapsulation and 
release does not impair enzyme activity. 
 
4. Conclusion 
We have developed a new approach to dendritic polyglycerol nanogels by surfactant free, 
inverse nanoprecipitation. Size defined nanogels were observed, while diameters were freely 
adjustable between 100 and 1000 nm. Applying mild encapsulation conditions we were able 
encapsulate the enzyme asparaginase with an efficacy of almost 100 %. After degradation 
triggered release in acidic environments no structural changes in the released cargo were 
observed and full enzyme activity was retained. Future work will be directed to the 
encapsulation of various biomacromolecules such as DNA, RNA, and proteins.  
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Abstract 
Genetic skin diseases caused by mutations resulting in diminished protein synthesis could 
benefit from local substitution of the missing protein. Proteins, however, are excluded from 
topical applications due to their physicochemical properties.  
We prepared protein-loaded thermoresponsive poly(N-isopropylacrylamide)-polyglycerol-
based nanogels exhibiting a thermal trigger point at 35°C, which is favorable for cutaneous 
applications due to the native thermal gradient of human skin. At ≥ 35°C, the particle size (~ 
200 nm) was instantly reduced by 20% and 93% of the protein were released; no alterations 
of protein structure or activity were detected. Skin penetration experiments demonstrated 
efficient intraepidermal protein delivery particularly in barrier deficient skin, penetration of the 
nanogels themselves was not detected. The proof of concept was provided by 
transglutaminase1-loaded nanogels which efficiently delivered the protein into 
transglutaminase1-deficient skin models resulting in a restoration of skin barrier function.    
In conclusion, thermoresponsive nanogels are promising topical delivery systems for 
biomacromolecules. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Keywords: reconstructed human skin, cutaneous protein delivery, thermoresponsive 
nanogels, dendritic polyglycerol, skin barrier restoration 
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1. Introduction 
At present, nanotechnology is one of the incessantly and fastest growing areas of current 
pharmaceutical research with an enormous potential to generate diverse and efficient drug 
delivery systems [1, 2]. Skin health maintenance benefits from nanotechnology, because 
materials on the nanometer scale are potent tools for dermal and transdermal drug delivery 
enabling specific, effective, and customized treatment options and the diagnosis of 
cutaneous diseases [3, 4].  
A well-defined, monodisperse and stable nanostructure is crucial for biomedical applications. 
This has been achieved by dendritic polymers such as hyperbranched or dendritic 
polyglycerol (dPG) [5]. dPG allows easy preparation combined with good aqueous solubility, 
high biocompatibility, multifunctionality, and protein stabilization against degradation and 
denaturation [6-9]. Fabricated as nanogels, which can be described as a cross-linked 
hydrophilic three-dimensional polymer network, dPG nanomaterials yield useful size ranges 
between 20 to 350 nm [7, 10].  
Stimuli-responsive dPG-based nanogels became of special interest as they respond rapidly 
when being exposed to certain environmental conditions such as changes in temperature, 
pH, electrical or magnetic fields [10-14]. Thermoresponsive nanogels can be obtained by 
combining dPG with thermoresponsive linkers such as poly(N-isopropylacrylamide) 
(PNIPAM). PNIPAM-dPG nanogels undergo a reversible phase-transition at 32-33 °C, the 
lower critical solution temperature (LCST) of PNIPAM. When LCST is exceeded, the 
nanogels decrease in size due to changes in the local environment around the hydrophobic 
isopropyl domains, resulting in the expelling of water and loaded drugs [15]. Since the LCST 
is close to the physiological skin surface temperature (32 °C) which steadily increases with 
skin depth, these thermoresponsive PNIPAM-dPG nanogels may have a potential for topical 
applications [16-18].  
Particularly for severe genetic skin diseases, with the underlying cause often located in the 
viable epidermis, the use of nanocarriers allow new therapeutic options [19]. Examples for 
these genodermatoses are the more common ichthyosis vulgaris caused by loss-of-function 
mutations in the gene encoding for filaggrin (FLG) [20], and the rare autosomal recessive 
congenital ichthyosis which can be caused by mutations in the transglutaminase gene 
(TGM1) [21]. Filaggrin is a highly repetitive structural protein expressed in the stratified layers 
of the skin and a lack in filaggrin impairs the barrier function and results in dryness and 
scaling and often atopic manifestations. TGM1 codes for the enzyme transglutaminase 1 
(TGase-1); a key player in the formation of the skin barrier. So far, therapeutic options only 
allow an alleviation of the symptoms using topically applied creams and ointments. 
Therefore, local substitution of the missing proteins presents an interesting treatment option 
which eliminates the need of parenteral application and high systemic drug levels. For this 
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approach, however, specific drug delivery systems are required as the excellent barrier 
properties of the human skin almost completely restrict the absorption of biomacromolecules 
due to their high molecular weight and hydrophilicity [22, 23].  
To our best knowledge, PNIPAM-dPG nanogels for the delivery of biomacromolecules into 
the skin have not yet been explored. In the present study, we describe the synthesis of 
PNIPAM-dPG nanogels that encapsulate the model proteins bovine serum albumin (BSA) 
and L-asparaginase II (Asp) as well as the therapeutic protein candidate TGase-1. The 
PNIPAM-dPG nanogels were characterized for loading efficiency, protein release, and 
protein stability. UV-Vis spectroscopy, high performance size exclusion chromatography (HP-
SEC), Fourier transformed infrared spectroscopy (FT-IR) measurements and specific activity 
assays were used to determine the protein concentration, protein stability, and to assess the 
bioactivity. To evaluate the cutaneous protein delivery efficiency, penetration studies in 
excised pig skin and reconstructed human skin were performed. Reconstructed human skin 
is increasingly important for skin absorption studies as it resembles native human skin well 
and offers several advantages over in vivo studies which are mostly performed in rodents. 
Rodent skin differs considerably from human skin since, e.g., the respective skin layers are 
significantly thinner and the abundance of hair follicles in rodents result in a distinct 
overestimation of skin absorption [24, 25]. Here, to mimic diseased and impaired skin 
barriers, the pig skin was tape-stripped 30 times [26] and the genes encoding for filaggrin 
and TGase-1, respectively, were knocked down in reconstructed human skin models [27-29].   
 
2. Methods 
2.1 Synthesis, characterization, and protein encapsulation of PNIPAM-dPG 
nanogels  
PNIPAM-dPG nanogels were synthesized according to previously reported methods [10]. 
Briefly, 100 mg of NIPAM, 33 wt% of acrylated dPG (please see Supplementary Materials for 
the synthesis and fluorescent labeling), SDS (1.8 mg), and APS (2.8 mg) were dissolved in 5 
mL of distilled water. Argon was bubbled into the reaction mixture for 15 min. The mixture 
was stirred under argon atmosphere for another 15 min. The reaction mixture was 
transferred into a hot bath at 68 ºC and polymerization was activated after 5 min with the 
addition of catalytic amount of TEMED (120 μL). The mixture was stirred at 500 rpm for at 
least 4 h. The products were purified by dialysis membrane (MWCO 50000) in water for 48 h 
then lyophilized to yield the nanogels as a white solid (total yield 90 %). Alternatively, 
nanogels with MIA/MANT label were synthesized in the similar manner as described above 
using MIA labeled dPG-Ac as cross-linker.  
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1H-NMR of PNIPAM-dPG nanogels: (500 MHz, D2O), δ: 1.13 (s, 6H, isopropyl groups of 
NIPAM), 1.57 (2 H, polymer backbone), 2.00 (1 H, polymer backbone), 3.35 – 4.10 (6 H, 
polyglycerol scaffold protons + 1H NIPAM).    
For protein encapsulation, PNIPAM-dPG nanogels (10 mg mL-1) were swollen in a protein 
solution (10 mg mL-1) for 24 h at 4 ºC. The solutions were purified using Vivaspins 300000, 
(10 min at 6000 rpm; Sartorius AG, Göttingen, Germany). The concentration of the BSA, 
Asp, and TGase-1 was determined by UV measurements at 280 nm and 350 nm (which 
served for background correction). Additionally, the amount of loaded protein was determined 
by a Micro BCA™ Protein Assay Kit following an incubation of the loaded nanogels at 37 °C 
for 1 h.     
For nanogel characterization, 1H NMR spectra was measured by a Bruker DRX 400 (400 
MHz spectra) spectrometer. Typically 10-30 mg of compound was used and deuterated 
solvents were used as standardized procedure. All spectra were recorded at room 
temperature and were analyzed with MestReNova software. 
2.2 Fluorescence labeling of bovine serum albumin (BSA)  
For skin penetration experiments, BSA was labeled with RhB ITC. A 1 mg mL-1 RhB ITC 
solution in DMSO was added to a 6 mg mL-1 BSA solution in 0.1 M sodium bicarbonate buffer 
(pH 9.0) at a ratio of 1:170 w/w (dye : protein). After 2 hours stirring under light protection, the 
labeled BSA was purified and concentrated to 20-25 mg mL-1 using Vivaspins 30000. The 
absence of free dye was confirmed by HP-SEC (TSKgel® SWXL guard column (dimensions: 
6.0 mm x 4.0 cm), TSKgel® G4000 PWXL column (dimensions: 300 x 7.8 mm, 10 µm particle 
size; TOSOH Bioscience, Stuttgart), isocratic elution at 0.4 mL min-1,100 mM Na2HPO4, 150 
mM NaCl, pH 7.4) with UV and fluorescence detection (protein UV = 280 nm, dye UV = 555 
nm; protein fluorescence = exc. 280/ em. 350 nm, dye fluorescence = exc. 540 nm/em. 580 
nm). The degree of labeling (0.95 - 1.3) was assessed according to manufacturer protocols. 
The lysine-dye bond between BSA and RhB ITC is stable up to 10 days [30]. 
2.3 PNIPAM-dPG nanogel size, thermosensitive kinetics, and protein release 
The PNIPAM-dPG nanogel size and dispersity were determined by dynamic light scattering 
(DLS, scattering angle 173°) upon heating from 25 °C to 42 °C at 1 °Cmin-1 using a Zetasizer 
Nano-ZS90 equipped with a He–Ne laser (λ = 633 nm) (Malvern Instruments, Herrenberg, 
Germany). The nanogel stock solutions (protein concentration: 3 - 5 mg mL-1) were diluted to 
a concentration of 1 mg mL-1. To evaluate the release of BSA-RhB ITC, the loaded nanogels 
(1 mg mL-1) were incubated under mild stirring (100 rpm) at 25 °C, 32 °C, and 37 °C for up to 
4 h, respectively. The released amount of protein was measured at UVprotein = 280 nm and  
UVdye = 558 nm using a UV spectrometer equipped with a heatable cuvette chamber (Agilent 
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8453 UV-Vis Spectrophotometer, Frankfurt, Germany). The UV absorption was background 
(UV = 350 nm) and nanogel blank corrected. Additionally, the samples were analyzed via 
HP-SEC (see 2.2)  
2.4 Protein stability testing  
Protein stability over time was investigated by storing Asp loaded nanogels at 2-8 °C and 25 
°C for 2 and 4 weeks. To study the effects of freeze-thaw stress, Asp-loaded nanogels (1 mg 
mL-1), blank nanogel, and Asp solution (1 mg mL-1) were subjected to 4 freeze-thaw cycles (-
20 °C; 1 hour of freezing and 1 h of thawing). Subsequently, the samples were analyzed for 
Asp activity (see 2.6), Asp degradation and aggregate formation via HP-SEC (see 2.2). 
2.5 Determination of protein secondary structure - Fourier transformed infrared 
spectroscopy (FT-IR) 
To investigate the structural integrity of the proteins after nanogel loading and release, FT-IR 
measurements using a Bruker Tensor 27 FTIR spectrometer (Ettlingen, Germany) equipped 
with a Bio-ATR measuring cell were performed. The samples were measured at 25 °C (120 
scans, resolution of 4 cm-1, water vapor correction) using water for reference. The data were 
analyzed with the OPUS 6.5 software for second derivative spectra after vector 
normalization. 
2.6 Asparaginase (Asp) activity 
Asp activity was determined as specific enzyme activity [U mg-1] [7, 31]. Briefly, 50 µl of 
sample were mixed with 100 µl Tris-HCl buffer (pH 8.6) and 850 µl 0.01 M L-asparagine 
monohydrate in 50 mM Tris-HCL buffer (pH 8.6) and incubated at 37 °C for 10 min. After 
adding 50 µl 1.5 M trichloracetic acid solution, 100 µl of the supernatant was added to 200 µL 
Nessler´s solution. After 10 min at 22 °C, the optical density was measured at 436 nm, 
compared with the standard curve and corrected for total enzyme amount determined by 
Micro BCA™ Protein Assay Kit. The units of activity were defined as micromoles of ammonia 
released per minute. Freshly prepared Asp solution served for reference.  
2.7 Skin penetration experiments 
2.7.1 Cutaneous protein delivery efficiency - pig skin 
To investigate the influence of the thermoresponsive PNIPAM-dPG nanogels on the skin 
penetration of BSA-RhB ITC, initial absorption studies using pig skin were performed 
according to validated test procedures (for detailed description see Supplementary 
Information) [16]. Pig skin of the axillary region from donor animals (breed: ‘‘Deutsche 
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Landrasse”, 12-20 weeks old) was provided by the Clinic for Swine, Center for Clinical 
Veterinary Medicine, LMU Munich, Germany (DE091620017X-1).  
To induce an impaired skin barrier, tape-stripping was performed (10 cm length; tesapack® 
4120 PVC, Tesa SE, Hamburg). The stripping was repeated 30 times [26] and SC thickness 
was subsequently measured using an image analysis software showing a SC thickness 
reduction from 13 ± 0.6 µm to 6 ± 0.4 µm.  
2.7.2 Cutaneous protein delivery efficiency - normal and filaggrin-deficient 
reconstructed skin  
Normal and filaggrin-deficient reconstructed human skin models were generated according to 
previously published procedures [27]. To determine the protein delivery efficiency of the 
thermoresponsive nanogels, first we assessed the activity and delivery of the model protein 
Asp in the skin models. Secondly, the effects of the therapeutic protein candidate TGase-1 in 
TGase-1-deficient skin models were evaluated. 
For Asp activity assay, the skin models were mounted onto static-type Franz cells equipped 
with Teflon inserts (diameter: 15 mm, volume 12 mL, 0.385 cm² application area, Gauer 
Glas, Püttlingen, Germany). PBS (pH 7.4) served as acceptor medium. After 30 min, 44 µL of 
the Asp-loaded PNIPAM-dPG nanogels (23 µg cm-²) were applied onto the skin models for 3 
h applying a temperature ramp from 32 °C to 37 °C. Subsequently, the epidermis of the skin 
models was gently peeled off from the collagen matrix, transferred to Eppendorf tubes 
(Eppendorf, Hamburg, Germany) and 200 µL Tris-HCl buffer pH 8.6 were added. The protein 
was extracted from the epidermis using a TissueLyser (Qiagen, Venlo, Netherlands). The 
specific Asp activity was determined as described in 2.6. 
To semi-quantitatively analyze the skin absorption of Asp in normal and barrier-deficient skin 
models, the Franz cells could not be applied. Instead, the skin models were incubated in a 
transwell setup for 3 h in an incubator applying a temperature gradient from 32 °C to 37 °C. 
Afterwards, the skin models were snap frozen using liquid nitrogen and 10 µm cryosections 
were prepared. Subsequently, immuno-staining against Asp (sc-130472, Santa Cruz 
Biotechnology, Heidelberg, Germany) was performed according to standard protocols. After 
staining, the sections were embedded in antifading mounting medium (Dianova, Hamburg, 
Germany) and analyzed under normal and fluorescence light (BZ-8000; Keyence, Neu-
Isenburg, Germany).   
2.7.3 Cutaneous delivery of therapeutic protein TGase-1 in TGase-1-deficient 
reconstructed skin  
Control and TGase-1-deficient reconstructed human skin were generated as described 
previously [32]. To investigate the effects of the therapeutic protein TGase-1, 50 µL of 
protein-loaded nanogels were applied (5 µg cm-² TGase-1) at day 5, 7, 9, and 11 of tissue 
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cultivation, respectively. At day 13, the skin sections were stained against TGase1 as 
described above (TGase-1 antibody sc-166467, Santa Cruz Biotechnology, Heidelberg, 
Germany) and skin permeability was assessed. 
2.8 Skin permeability testing 
To assess the barrier function, skin absorption tests with radiolabeled testosterone were 
performed according to validated procedures [16, 25]. Briefly, a stock solution of testosterone 
(40 μg ml-1, 2 % [v/v] Igepal® CA-630) was spiked with an appropriate amount of the 
radiolabelled compound to a total radioactivity of 2 μCi ml-1. By using the static setup and the 
infinite dose approach, skin permeability tests (Franz diffusion cells, diameter 15 mm, volume 
12 ml; Permegear, Bethlehem, PA, USA) were performed in triplicate. 
2.9 Statistical analysis  
Statistical analysis is based on the Wilcoxon-Mann-Whitney test and the unpaired t-test; *p ≤ 
0.05 indicates a statistically significant difference. 
 
3. Results  
3.1 Particle synthesis and characterization  
The nanogels were prepared by precipitation polymerization with PNIPAM as 
thermoresponsive polymer, 33 % acrylated dPG as macro-crosslinker, SDS as colloidal 
stabilizer, and PS/TEMED as redox radical initiator (Figure 3-1) [10].  
 
Figure 3-1 Synthesis and chemical structure of the PNIPAM-dPG nanogels. 
 
PNIPAM-dPG nanogels were subsequently characterized by DLS, NMR, and UV-Vis 
spectroscopy. To monitor temperature-related size changes, a temperature ramp was 
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applied during DLS heating the samples from 25 °C to 42 °C. The proteins BSA, Asp, and 
TGase-1 were encapsulated into the nanogels by swelling/diffusion at 4 °C. Table 3-1 lists 
the properties of the protein-loaded nanogels; zeta potential measurements revealed a 
neutral surface charge.  
 
Table 3-1 Characteristics of protein loaded nanogels. 
Nanogel / protein Loading  
capacity [%] 
Diameter (nm) at 
         25 °C (PDI)  / 37 °C (PDI) 
(a)
 
Thermal Trigger Point 
 Tp (ºC) 
(b)
 
PNIPAM-dPG - 192 (0.26) / 118 (0.09) 33.0 
PNIPAM-dPG/BSA 70 207 (0.36) / 170 (0.19) 35.0 
PNIPAM-dPG/Asp 30 205 (0.14) / 170 (0.14) 34.5 
a
 determined by DLS, average of 3 measurements from the intensity distribution curves 
b 
determined by UV-Vis transmittance  (λ= 500 nm)     
 
3.2 Protein Release, structural integrity, and maintenance of bioactivity 
The temperature-triggered decrease in nanogel size induced the release of the cargo. At 25 
°C and 32 °C, only minimal amounts of BSA-RhB-ITC were released after 1 h (1.5 ± 0.3 % 
and 4.8 ± 0.8 %, respectively) (Figure 3-2). In contrast, 90.6 ± 0.5 % of the protein was 
released within 1 h at 37 °C; incubation for 4 h did not result in higher release rates (Figure 
S1). No protein aggregation was observed as determined by SEC measurements, no visible 
particles were detected.  
 
Figure 3-2: Release of bovine serum albumin from PNIPAM-dPG nanogels over 1 h at 25 °C (●), 32 
°C (▲), and 37 °C (■) measured with UV-Vis spectroscopy. n=3, mean ± SD 
We also performed structural analysis of released BSA to exclude potential detrimental 
effects of the encapsulation and release process. Figure 3-3 displays the perfect overlay of 
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the spectra of fresh BSA solution and BSA released from the nanogels, including two 
additional controls. With peak positions at ~1657 cm-1 and ~1549 cm-1 and some smaller 
bands between 1613 and 1637 cm-1, BSA shows ~66 % alpha helix and ~20 % beta sheet 
structure, which is in accordance with the literature [33].  
  
Figure 3-3: Second derivative ATR-FT-IR spectra of the (A) amide I (~1650 cm
-1
) and (B) amide II 
(~1550 cm
-1
) region of BSA in water, freshly prepared (solid line), BSA in water, 22 h at 37 °C (grey 
line), BSA loaded PNIPAM-dPG nanogel in water, freshly prepared (dotted line) and BSA  after the 
release treatment for 22 h at 37 °C (dashed line).  
 
Furthermore, released Asp did not show significant loss in bioactivity (98.5 ± 4.1 %) 
compared to freshly prepared Asp solution (100.0 ± 4.4 %) and Asp solution after 4 h 
incubation at 37 °C (100.6 ± 5.0 %). As an additional control, unloaded PNIPAM-dPG-
nanogel was spiked with free Asp and incubated at 37 °C. Again, the bioactivity was not 
reduced.  
To investigate potential protein stabilizing effects of the nanogels, freeze-thaw studies were 
performed. Freeze-thawing is an important stress factor for proteins since cold temperatures, 
ice formation, changes in solute concentrations, and pH can induce protein degradation or 
aggregation [34]. Asp in solution substantially lost bioactivity already after one freeze-thaw 
cycle (95.3 ± 2.8 %) which was further reduced to 92.1 ± 2.2 % after 4 cycles. In contrast, for 
loaded Asp only a slight decrease to 96.3 ± 0.5 % was observed following 4 freeze-thaw 
cycles (Figure 3-4A). Loading of Asp onto the nanogels also preserved its active tetramer 
form upon freeze-thaw stress, whereas Asp in solution experienced a distinct loss of the 
tetramers and a corresponding increase in aggregates and fragments (Figure S2). Similarly, 
storage of free Asp for 2 and 4 weeks at 25 °C resulted in significantly reduced bioactivity 
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(Figure 3-4B), less tetramers, and increased aggregation compared to nanogel-loaded Asp 
(Figure S3). No differences were observed at 4 °C.  
 
Figure 3-4 A) Bioactivity of loaded asparaginase (Asp) (black bars) and free Asp in an aqueous 
solution (white bars) following 4 freeze-thaw cycles. n = 3, mean ± SD. * p< 0.05 B) Bioactivity of 
loaded Asp and free Asp in an aqueous solution of freshly prepared samples (black bars), after 2 
weeks (white bars), and 4 weeks (grey bars) storage at 25 °C.  n = 3, mean ± SD. * p< 0.05 
3.3 Cutaneous protein delivery efficiency of PNIPAM-dPG nanogels 
First, we investigated the protein delivery efficiency of BSA-RhB ITC loaded nanogels, 
nanogels spiked with free BSA-RhB ITC, and BSA-RhB ITC control solution in normal and 
tape-stripped pig skin. To elucidate whether the nanogels themselves are able to overcome 
the SC, the nanogels were fluorescently labeled with N-methylisatoic anhydride dye, resulting 
in a blue fluorescent N-methylanthraniloyl group (MANT) [35].  
In normal pig skin, no epidermal protein delivery was observed for all samples; the protein 
exclusively accumulated in the SC (Figure S4, A-C). In tape-stripped skin, however, the 
PNIPAM-dPG nanogels significantly enhanced intraepidermal protein delivery indicated by a 
distinct red staining of the viable epidermis (Figure S4, E). Again, no penetration was 
detected with the BSA-RhB ITC control solution and the spiked nanogel. The visual 
differences were substantiated by semi-quantitative image analysis (Table S1). Here, the 
fluorescence brightness evaluated as arbitrary brightness units (ABU) revealed a fourfold 
ABU increase in the epidermis of tape-stripped skin for BSA-loaded nanogels. The nanogels 
themselves were not able to overcome the SC even in damaged skin (data not shown).  
 
In the next step, we studied the absorption of Asp in normal and filaggrin deficient skin 
models. Therefore, we applied Asp loaded PNIPAM-dPG nanogels and Asp control solution 
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onto normal and filaggrin deficient skin models for 3 h. To obtain comparable results to the 
pig skin experiment, the incubation time was reduced since skin models have a higher 
permeability due to a weaker skin barrier function [25, 36]. Subsequently, to get a rough 
estimation about the delivery efficiency of the nanogels, we determined the amount of Asp in 
the SC and viable epidermis by assessing the specific Asp activity present in the skin models 
[7]. Following the application of Asp loaded nanogels, 9.5 ± 0.1 µg Asp were detected in the 
SC and viable epidermis. In skin models incubated with the Asp solution, 30 % less protein 
was recovered (6.3 ± 0.1 µg).  
Since this experimental setup did not allow the discrimination of the protein content in the SC 
and the viable epidermis, we subsequently performed immunohistology. The application of 
Asp solution did not result in intraepidermal penetration in normal (Figure 3-5 A) or barrier-
deficient (Figure 3-5 C) skin models. In contrast, significant amounts of Asp were detected in 
the viable epidermis of barrier-deficient skin models following the application of the loaded 
nanogels (Figure 3-5 D) indicated by a marked red staining of the viable epidermis and the 
SC. No penetration was seen in normal skin models (Figure 3-5 B).  
Consistently, the application of TGase-1-loaded nanogels also resulted in efficient protein 
delivery into the viable epidermis of TGase-1-deficient skin models as indicated by a distinct 
red staining (Figure 3-6 C). Immunostaining visualized the physiological distribution of 
TGase-1 in normal skin models (Figure 3-6 A) and its severely reduced expression in 
untreated TGase-1-deficient skin models (Figure 3-6 B). 
 
 
Figure 3-5: Skin penetration of asparaginase (Asp) in normal and barrier-deficient skin models 
following the application of Asp loaded PNIPAM-dPG nanogels and the Asp control solution. SC = 
stratum corneum, Epi = viable epidermis, D = dermis. Scale bar = 100 µm.  
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Figure 3-6: Immunostaining of transglutaminase 1 (TGase-1) in normal skin models (A), TGase-1-
deficient skin models (B), and TGase-1-deficient skin models following the application of TGase-1-
loaded nanogels (C). SC = stratum corneum, Epi = viable epidermis, D = dermis. Scale bar = 100 µm. 
 
Finally, to provide the proof of concept of the local protein substitution approach, the skin 
barrier function of normal, untreated skin models, TGase-1-deficient skin models, and 
TGase-1-deficient skin models after treatment with TGase-1-loaded nanogels was 
determined. In normal skin models with a functional skin barrier, about ~ 1.5 µg·cm-² 
testosterone permeated through the skin. In TGase-1-deficient skin models, about 5-fold 
higher concentrations were measured (~ 7.5 µg·cm-²) reflecting the disturbed skin barrier 
function due to the lack of TGase-1 (Figure 3-7). Following the treatment with TGase-1-
loaded nanogels, however, significantly reduced testosterone permeation (~ 2 µg·cm-²) was 
observed.  
 
 
Figure 3-7: Permeation   and TGase-1-deficient skin models treated with TGase-1-loaded nanogels 
(□).  
 
4. Discussion 
We successfully loaded different proteins onto thermoresponsive, dendritic nanogels and 
systematically investigated them for their suitability and efficiency as topical delivery system 
for labile biomacromolecules. The nanogels were thoroughly characterized for protein loading 
and release. Unloaded PNIPAM-dPG nanogels showed an average diameter of 192 ± 2 nm 
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(PDI 0.26) and underwent size reduction to 118 ± 1 nm (PDI 0.09) at the thermal trigger point 
(TP) of 33 °C. After loading the nanogels with BSA or Asp, the nanogel size increased to 207 
± 3 nm (PDI 0.36) and 205 ± 2 nm (PDI 0.14), respectively (Table 3-1). Although the size 
increase was similar for Asp and BSA, the loading capacity was different with 70 % for BSA 
and only 30 % for Asp due to the different molecular weights (BSA 66 kDa vs. Asp ~140 
kDa). Above TP, the particle size of loaded nanogels was reduced to ~170 nm compared to 
~118 nm of the unloaded nanogels. This can be explained by a higher rigidity of the loaded 
nanogels, as they have to work against a higher inner density resulting from the protein load. 
The thermally triggered size reductions result from the physicochemical characteristics of 
PNIPAM, which exhibits a LCST at 31 - 32 °C [10, 12, 37]. When exceeding the LCST, 
PNIPAM undergoes a reversible phase transition and water is simultaneously expelled. 
Unloaded PNIPAM-dPG nanogels exhibited a slightly higher phase transition at ~33 °C 
compared to pure PNIPAM caused by the dPG fraction which increases the nanogels’ 
hydrophilicity [10]. Loading of the protein resulted in a slight shift of TP to temperatures about 
~35 °C most likely due to hydrophilic interactions between the nanogels and the proteins [7, 
12]. This increased TP can be beneficial for dermal applications. The skin temperature is 32 
°C at the surface and raises constantly with increasing depth [17, 18]. By applying the 
nanogels onto the skin, the surface temperature prevents the immediate drug release and 
the nanogels may interact intensively with the skin surface as previously described for other 
dPG-based nanocarriers [36]. We hypothesize that the nanogels finally reach deeper layers 
of the stratum corneum where the trigger point temperature of ~35 °C is exceeded and 
ultimately the protein is released.  
Since proteins are sensitive molecules, the investigation of potential detrimental effects on 
the structural integrity or bioactivity was crucial in which no negative effects of the nanogels 
were observed (Figure 3-4). In contrast, encapsulating the proteins in the nanogels even 
protected them from freeze-thaw stress and extended their storage stability (Figure 3-4, S3).  
To assess the efficiency of the thermoresponsive nanogels in dermal protein delivery, skin 
penetration experiments using pig skin and reconstructed human skin were performed. Pig 
skin is an accepted alternative for human skin [38]. Although the anatomical and 
physiological properties of pig and human skin are similar, the skin barrier of pigs is stronger, 
which typically leads to underestimation of skin absorption. To overcome this drawback, and 
to study the nanogels in viable skin, selected experiments were carried out in reconstructed 
human skin. These skin models resemble anatomical and physiological properties of native 
human skin [24, 39] and are advantageous over in vivo studies often performed in rodents 
due to the avoidance of interspecies-related variability. Moreover, a knock down of 
ichthyosis-associated genes in keratinocytes used for the reconstructed human skin enables 
the generation of diseased skin [27, 29, 40]. Consequentially, we opted for filaggrin- and 
TGase-1-deficient skin models. Filaggrin deficiency is the underlying cause for ichthyosis 
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vulgaris [20] and a major predisposing factor for the manifestation of atopic dermatitis [41]. 
Filaggrin deficiency causes disturbed epidermal maturation and differentiation, altered skin 
lipid composition and organization, and an impaired skin barrier [27, 28]. TGase-1 is a key 
enzyme in the formation of the cornified envelope of the human epidermis and mutations in 
the gene encoding for TGase-1 are the underlying cause for autosomal-recessive congenital 
ichthyosis which is also characterized by an impaired skin barrier function and generalized 
hyperkeratosis [42, 43]. Hence, these skin disease models mimic barrier-impaired skin which 
is important to consider since the barrier function of diseased skin differs significantly from 
normal skin [44, 45]. 
Our data clearly showed efficient cutaneous delivery of BSA, Asp, and the therapeutic protein 
candidate TGase-1 particularly in barrier deficient skin. Immunostaining of the skin models 
impressively visualized the extent of skin penetration of the different proteins (Figure 3-5, 3-6, 
S4).  
In contrast, cutaneous absorption of the nanogels themselves was not observed. Whether 
nanocarriers are able to penetrate into normal or damaged skin is still up to debate as many 
studies with differing outcome are published [46-48]. For example, Zvyagin et al. [49] showed 
that zinc oxide particles (20-30 nm) stayed in the SC of normal skin and only accumulated in 
skin folds and hair follicles [49] which is also consistent with Luengo et al. [50]. Moreover, 
Ostrowski et al. demonstrated that skin barrier disruptions by either tape-stripping or skin 
diseases had no effect on the penetration of silica nanoparticles [51]. In contrast, Alnasif et 
al. showed pronounced penetration of dendritic core-multishell nanotransporters in damaged 
skin [36].  
Since our results showed no penetration of the nanogels themselves, the mode of enhanced 
protein delivery is still ambiguous. Some studies highlighted the influence of surface charges 
on skin penetration and demonstrated that charged nanoparticles were more efficient due to 
better skin adhesion [52]. Since our nanogels exhibited no surface charge, electrostatic 
interactions can be excluded. As discussed earlier, we hypothesize that the nanogels interact 
intensively with the skin surface most likely due to the amphiphilic polyglycerol-based 
structure which also proved to be beneficial in previous studies [3, 53]. The nanogels finally 
reached deeper layers of the SC that exhibited temperatures ≥ 33 °C and the protein release 
was induced. Another possibility is that the nanogels act as drug release modifiers. Chauhan 
et al. described that poly(amido amines) were able to form stable drug-polymer complexes 
and the resulting solubility enhancement effectively increased the drug flux across the skin 
[54]. Furthermore, nanogels might be penetration enhancers by interacting with the skin 
surface lipids and proteins and, thus, loosening the tightly packed SC structure [55]. Clearly, 
further studies are required to unravel the mode of delivery. 
To provide the proof of concept for the protein substitution approach, nanogel mediated 
delivery of the therapeutic protein candidate TGase-1 into TGase-1-deficient skin models 
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was tested. Following the application of TGase-1-loaded nanogels, the protein was efficiently 
delivered into the viable epidermis of TGase-1-deficient skin models (Figure 3-6) and the skin 
barrier function was restored indicated by a significant reduction of skin permeability (Figure 
3-7).  
Aufenvenne et al., also aimed for a topical enzyme-replacement therapy to restore TGase-1 
activity and correct the architecture of TGase-1-deficiency in skin grafts [42]. Treatment with 
40 ng cm-2 TGase-1 encapsulated in sterically stabilized liposomes resulted in considerable 
improvement of the ichthyosis phenotype and restored TGase-1 activity and epidermal 
barrier function. A further study which underlines the huge potential of a topical protein 
substitution therapy for severe skin diseases was published by Stout et al. [56]. Here, in vivo 
application of a “filaggrin - cell penetrating peptide conjugate” in filaggrin deficient flaky tail 
mice resulted in internalization and processing of the conjugate and a restoration of the 
normal phenotype. However, the carrier systems of both studies clearly have limitations such 
as physical instability and low loading capacities for the liposomes [57, 58] or potential irritant 
or toxic effects of cell penetrating peptides [59, 60]. In contrast, thermoresponsive nanogels 
offer several advantages such as good biocompatibility, high loading capacities, and 
triggered payload release.  
In conclusion, we describe a thermoresponsive PNIPAM-dPG nanogel for cutaneous protein 
delivery, which is particularly applicable for human skin due to its native thermal gradient. We 
demonstrated that the delivery of TGase-1 loaded onto PNIPAM-dPG nanogels into TGase-
1-deficient skin restored the skin barrier function. Although the protein delivery into the viable 
epidermis of normal skin appeared to be insufficient, the nanogels were superior in barrier-
deficient skin (tape-stripped, filaggrin and TGase-1 deficient). Therefore, these nanogels 
have great potential for the approach of local protein substitution. Stress testing also 
revealed the ability of the nanogels to stabilize and maintain the biological function of labile 
proteins. Hence, PNIPAM-dPG nanogels are capable to load sensitive biomacromolecules 
and deliver them in therapeutically relevant concentrations into the viable epidermis of 
barrier-deficient skin without loss of protein integrity and bioactivity. 
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 Abstract  
Hyaluronic acid (HA) hydrogels are interesting delivery systems for topical applications. 
Besides moisturizing the skin and improving wound healing, HA facilitates topical drug 
absorption and is highly compatible with labile biomacromolecules. Hence, in this study we 
investigated the influence of HA hydrogels with different molecular weights (5 kDa, 100 kDa, 
1 MDa) on the skin absorption of the model protein bovine serum albumin (BSA) using 
fluorescence lifetime imaging microscopy (FLIM). To elucidate the interactions of HA with the 
stratum corneum and the skin absorption of HA itself, we combined FLIM and Fourier-
transform infrared (FTIR) spectroscopy. Our results revealed distinct formulation and skin-
dependent effects. In barrier deficient (tape-stripped) skin, BSA alone penetrated into dermal 
layers. When BSA and HA were applied together, however, penetration was restricted to the 
epidermis. In normal skin, penetration enhancement of BSA into the epidermis was observed 
when applying low molecular weight HA (5 kDa). Fluorescence resonance energy transfer 
analysis indicated close interactions between HA and BSA under these conditions. FTIR 
spectroscopic analysis of HA interactions with stratum corneum constituents showed an α-
helix to β-sheet interconversion of keratin in the stratum corneum, increased skin hydration, 
and intense interactions between 100 kDa HA and the skin lipids resulting in a more 
disordered arrangement of the latter. In conclusion, HA hydrogels restricted the delivery of 
biomacromolecules to the stratum corneum and viable epidermis in barrier deficient skin, and 
therefore seem to be potential topical drug vehicles. In contrast, HA acted as an enhancer for 
delivery in normal skin, probably mediated by a combination of cotransport, increased skin 
hydration, and modifications of the stratum corneum properties 
 
 
 
 
 
 
 
 
 
 
 
 
Key words: hyaluronic acid, proteins, skin penetration, skin hydration, epidermal drug 
delivery, FLIM, FTIR  
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1. Introduction 
Over the last decades, biopharmaceuticals such as proteins, peptides, and nucleic acids 
have become increasingly important as therapeutic options for the treatment of diverse 
diseases such as cancer, infections, and autoimmune diseases. The conventional 
administration form of biopharmaceuticals is a directed injection or infusion. Due to limited 
patient compliance and associated side effects, alternative application methods are under 
investigation including pulmonary, nasal, topical, and buccal delivery [1, 2].  
For the treatment of severe skin diseases including psoriasis and atopic dermatitis, efficient 
protein formulations such as Enbrel® (etanercept) or Remicade® (infliximab) are on the 
market, but they can solely be administered by injection [3]. To reduce systemic side effects 
and to increase both patient compliance and local bioavailability, a topical application seems 
beneficial [4]. However, the excellent barrier properties of the skin almost completely restrict 
the absorption of biomacromolecules due to their high molecular weight and hydrophilicity [4, 
5]. To overcome this obstacle, and to allow for efficient protein delivery into the skin, tailored 
drug delivery systems are necessary. This is of particular interest for a topical substitution 
therapy of proteins that are deficient in the skin due to genetic mutations and, hence, are the 
underlying cause of severe skin diseases such as ichthyosis vulgaris [6] or atopic dermatitis 
[7]. This approach, requiring only rather low doses, was pursued for filaggrin delivery in 
atopic skin [8] and for the enzyme transglutaminase I for the restoration of autosomal-
recessive congenital ichthyosis [9] with very promising results. In this context, the different 
properties of normal and diseased skin are of importance since diseased skin is 
characterized by increased transepidermal water loss [10], impaired skin barrier function, and 
altered dermal drug absorption compared to intact skin [11]. To study barrier disrupted skin in 
vitro, tape-stripping is a common and well-established method [10, 12, 13]. 
Hyaluronic acid (HA) based hydrogels have been in the focus for the treatment of skin 
diseases for several years [14, 15] and are an attractive candidate for dermal drug delivery 
[14, 16, 17]. HA is a linear polysaccharide of N-acetyl glucosamine and glucuronic acid in 
alternating sequence with an average molecular weight of approximately 2x105 to 107 Da. It 
forms highly viscoelastic gels in aqueous solution [18], and when applied to the skin it 
provides beneficial effects such as skin hydration, elasticity regeneration, and improved 
wound healing [19]. Moreover, HA may also facilitate dermal drug delivery as shown for anti-
cancer drugs [20, 21] and for diclofenac. In the latter case, HA significantly enhanced the 
partitioning, retention, and localization of diclofenac in human epidermis compared with an 
aqueous solution [4, 22, 23]. 
The mechanisms of HA mediated skin penetration, however, are still poorly understood. 
Various factors are discussed involving an active transport via HA receptors [17, 24] and the 
specific structure of hydrated HA [25]. Alternatively, the general effect of skin hydration may 
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facilitate dermal drug absorption and can aid the retention of drugs within the more hydrated 
epidermal layers [14]. Others hypothesize that the skin penetration of HA itself can facilitate 
drug delivery via a co-transport [14, 26]. Moreover, HA is well suited for biomacromolecules 
as it provides good protein stabilizing properties [16, 17, 21]. Nevertheless, the exact 
mechanism for transdermal transport remains to be elucidated. 
In this study, we set out to identify formulations of HA and the model protein bovine serum 
albumin (BSA) that exhibit improved skin penetration, either transdermal or topical, compared 
to the application of the protein alone. Furthermore, we aimed to understand the mechanism 
by which HA acts on protein penetration. Therefore, BSA skin penetration was investigated in 
normal and tape-stripped skin. Using fluorescence lifetime imaging microscopy (FLIM), we 
localized HA and BSA in the skin and analyzed the effect of different molecular weight HA (5 
kDa, 100 kDa and 1 MDa) on BSA penetration. Interactions between HA, skin lipids, and 
proteins in terms of organization and conformation, and the impact of hydration effects were 
studied by Fourier-transform infrared (FTIR) spectroscopy. Co-localization of HA and the 
protein BSA in the skin were investigated using fluorescence resonance energy transfer 
(FRET)-FLIM. 
 
2. Materials and Methods 
2.1 Materials 
Sodium hyaluronate 5 kDa was obtained from Wellcos Cosmetics (Gladbeck, Germany). 100 
kDa and 1 MDa sodium hyaluronate were a gift from Shiseido Co., Ltd (Shizuoka, Japan). 
Hydroxyethyl cellulose (HEC) Natrosol® 250 HHX PH was purchased from Ashland Aqualon 
(Covington, KY, USA). BSA, dimethyl sulfoxide (DMSO), rhodamine B isothiocyanate (mixed 
isomers), and the buffer reagents were purchased from Sigma-Aldrich (Steinheim, Germany). 
N-methylisatoic anhydride for HA labeling was purchased from Invitrogen Molecular Probes® 
(Darmstadt, Germany). 
For skin penetration experiments, pig skin of the flank region from “Deutsche Landrasse” (30-
50 kg, 10-20 weeks old) was used (Clinic of Swine, Ludwig-Maximilians University, Munich, 
permission no. DE 09 162 0017 X-1).  
2.2 HEC and HA solution Preparation  
2.2.1 Fluorescence Labeling of BSA and HA 
Fluorescence labeling of BSA was performed using rhodamine B isothiocyanate (RhB ITC). 
The dye was dissolved in DMSO to 1 mg/mL and added to a 6 mg/mL BSA solution in a 0.1 
M sodium bicarbonate buffer (pH 9.0). While stirring slowly, protein and dye solution were 
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mixed at a ratio of 1:170 w/w (dye : protein) under light protection. After 120 minutes, the 
solution was transferred to a Vivaspin 20 tube (PES membrane MWCO 30000, Sartorius AG, 
Göttingen, Germany) and centrifuged for 45 min at 4.000 rpm at 5 °C. Subsequently, several 
washing steps were performed to remove unbound dye. The absence of free dye was 
confirmed by high pressure size exclusion chromatography (HP-SEC) (UV (protein) = 280 
nm, UV (dye) = 555 nm; fluorescence (protein) = exc. 280/em. 350 nm, fluorescence (dye) = 
exc. 540 nm/em. 580 nm) and UV spectroscopy of the washing phases at 555 nm. Protein 
concentration (between 20-25 mg/ml) and degree of labeling (between 0.95 - 1.3) were 
determined according to the manufacturer’s protocol. Regarding the stability of the conjugate, 
the lysine-dye bond is stable for up to 10 days [27]. The absorption and emission spectra of 
BSA-RhB were recorded showing an absorption maximum at 558 nm and an emission 
maximum at 585 nm, respectively (Figure SI 1A). 
Fluorescence labeling of HA was performed using N-methylisatoic anhydride (MIA) [28]. The 
dye was dissolved in DMSO to 200 mg/mL and added to a 4 mg/mL HA solution in 0.1 M 
sodium borate buffer (pH 8.0). While stirring slowly, HA and dye solution were mixed at a 
ratio of 1:10 w/w (dye : HA) under light protection. After 15 minutes, the labeled HA was 
precipitated with ethanol 70 %. The precipitate was washed twice, centrifuged at 4.000 rpm, 
4°C and the HA pellet was vacuum dried. The absence of free dye was confirmed by HP-
SEC (UV (HA) = 215 nm, UV (dye) = 351 nm; fluorescence (free dye) = exc. 316 nm/em. 386 
nm, fluorescence (HA-dye conjugate) = exc. 366 nm/em. 440 nm) and fluorescence 
spectroscopy at exc. 366 nm/em. 440 nm. Additionally, the degree of HA modification was 
determined to be 1 molecule N-MANT per 40-50 disaccharide HA units. The labeled N-
methylanthraniloyl (MANT)-HA was reconstituted with PBS (pH 7.4) to stock concentrations 
of 40 mg/mL. Successful labeling was confirmed by UV-Vis absorption (Shimadzu UVPC 
2450) and fluorescence spectroscopy (Cary Eclipse, Varian GmbH, Darmstadt, Germany). 
The absorption maximum was at 350 nm and the emission maximum at 440 nm. The 
absorption and emission properties of HA-MANT samples were independent of the molecular 
weight (Figure SI 1 B). Furthermore, the HA-MANT sample was subjected to fluorescence 
microscopy (instrument-specific DAPI filter setting exc. 360/40 nm, em. 460/50 nm; BZ-8000, 
Keyence, Neu-Isenburg). According to DeAngelis, 2000 [28], the labeling procedure yields a 
stable conjugate. The labeled proteins and HA were stored at -20°C until further use.  
2.2.2 Preparation of Protein-Containing HEC and HA Hydrogels 
2% and 5% w/v HEC solutions were prepared by mixing 4% and 10% w/v stock gels 1:1 with 
PBS or BSA-RhB ITC (20 mg/mL) to reach a final BSA concentration of 10 mg/mL. The 5 
kDa and 100 kDa HA hydrogels were prepared correspondingly. For the 10% w/v HEC and 
HA solutions, 100 mg/mL of the dry HEC or HA material was rehydrated and mixed with 
either PBS or a 10 mg/mL BSA-RhB ITC solution. The gels were kept at 2-8°C for at least 12 
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h before use to guarantee complete rehydration. A solution of 10 mg/mL BSA in PBS pH 7.4 
served for reference. 
2.3 Attenuated Total Reflectance Fourier Transform Infrared (ATR-FTIR) 
Spectroscopy Measurements 
In order to evaluate the effects of HA formulations on skin hydration, keratin secondary 
structure, and the organization of skin lipids, FTIR measurements on isolated stratum 
corneum (SC) sheets were performed. For SC isolation, pig skin was covered with 0.1 % 
trypsin in 150 mM PBS pH 7.4. The samples were kept at 4°C for 20 h and were 
subsequently incubated at 37 °C until the SC could be removed. The isolated SC sheets 
were washed with water and dried for 3 days in a desiccator filled with silica gel (24 °C, 27 % 
relative humidity). Subsequently, the SC sheets were quartered, placed in petri dishes and 
covered with 50 µL/cm² HA formulations (without BSA), respectively. All samples were 
incubated for 6 h at room temperature (23 - 24 °C, 37 % relative humidity). The water content 
in the SC was determined using a TENSOR 27 FT-IR Spectrometer with HYPERION 3000 
FT-IR Microscope connected to an ATR objective (Bruker Optik GmbH, Ettlingen, Germany). 
The spectra were generated from 240 scans collected at 4 cm-1 resolution at 20°C and 
analyzed with the Bruker OPUS software. The exact peak positions were determined after 
vector normalization. The degree of water uptake was defined as the area under the 
secondary O-H stretching (water) absorbance at around 2100 cm-1 in relation to the dry SC 
[29]. Changes in the lipid chain order were defined as redshifts to higher wavenumbers for 
the methylene symmetric and asymmetric stretching vibrations [30, 31]. For keratin 
secondary structure analysis, the second derivative was determined from the normalized 
spectra and evaluated regarding the amide I band [32]. ATR-FTIR control spectra were 
recorded for plain 1 % HEC, 5 % 5 kDa HA, 5 % 100 kDa HA, and 1 % 1 MDa HA hydrogels 
(Figure SI 4, SI 5).  
2.4 Skin Penetration Experiments 
Validated test procedures using the Franz cell set up and the infinite-dose approach were 
performed according to previously published procedures (300 µl test sample onto 1.72 cm2 
skin for 6 h, removal of excess formulation after incubation) [33]. Pig skin was used as it has 
comparable properties like human skin and is a well-established model for skin absorption 
testing in vitro [11, 34]. To create barrier deficient skin, tape-stripping was performed 30 
times by pressing adhesive tape strips (10 cm length; tesapack® 4120 PVC, Tesa SE, 
Hamburg) [35] and SC thickness was measured in skin sections using a Keyence BZ-8100E 
microscope and BZ-Analyzer software (Keyence, Neu-Isenburg, Germany). The SC 
thickness was reduced from 13 to 6 µm. For data analysis, skin sections (5 µm) were 
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prepared by cutting from the dermis to the SC to prevent dragging of HA and BSA from the 
skin surface into deeper dermal layers.  
For initial screening, the skin sections were subjected to normal and fluorescence 
microscopy (100 and 200 x magnification, BZ-8100, Keyence, Neu-Isenburg) and 
representative images were recorded. The fluorescence was recovered in the red band 
exciting the samples at 560 nm for BSA-RhB (instrument-specific TexasRed filter setting exc. 
560/40 nm, em. 630/60 nm). To detect MANT-HA, the fluorescence was recorded in the blue 
band exciting the samples at 360 nm (instrument-specific DAPI filter setting exc. 360/40 nm, 
em. 460/50 nm).  
2. 5 Fluorescence Lifetime Imaging Microscopy (FLIM) 
To investigate the dermal absorption of protein (10 mg/ml BSA-RhB in aqueous solution) and 
HA (5 % 5 kDa, 100 kDa and 1 MDa HA-MANT), sections of normal and barrier disrupted 
skin were subjected to FLIM.  
The time-resolved fluorescence decay curves in each image pixel were obtained by time-
correlated single photon counting (TCSPC) with a confocal laser scanning FLIM setup. The 
setup consists of an Olympus IX71 inverted microscope equipped with a 40x objective lens, a 
confocal scanning unit (DCS-120, Becker & Hickl, Berlin, Germany), and a Ti:Sapphire laser 
system (Spectra Physics, Santa Clara, USA) in the mode-locked picosecond-pulsed regime 
[36–43]. The Ti:Sapphire Tsunami laser was pumped by a 5 W solid state Millenia V laser 
and the laser output was frequency doubled to obtain the excitation wavelength of 488 nm for 
the RhB dye. A pulse picker reduced the repetition rate to 4 MHz. A color glass filter OG515 
and a high quality long pass filter HQ545LP were used as emission filters. To excite MANT 
fluorescence, a pulsed diode laser (BDL-405-SMT; Becker&Hickl) with a wavelength of 405 
nm and a repetition rate of 20 MHz was used. A high quality long pass filter HQ435LP and a 
band-pass filter HQ480/40 were used as emission filters. The time range was set to 20 ns for 
256 channels resulting in a resolution of 78 ps/ch. Single photon counting was performed 
using a TCSPC module (SPC-150, Becker & Hickl, Berlin, Germany). 
For FRET experiments [44], samples containing both HA-MANT and BSA-RhB were excited 
with 405 nm and a high quality long pass filter HQ545LP and a band-pass filter HQ480/40 
were used as emission filters. For reference, BSA-RhB was excited with 488 nm and 
emission was detected using the same emission filter set.  
FLIM images were analyzed using self-written routines in C++. Fluorescence decay curves 
were partitioned into classes (i.e. clusters) using a multivariate pattern recognition method 
[44, 45]. The fluorescence decays of the individual clusters were fitted with a sum of 
exponentials using 2 minimization. False-color images were generated by assigning a 
distinct color to all pixels containing a fluorescence decay curve that belongs to one cluster.  
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Steady-state fluorescence spectra were recorded using an SPEX Fluoromax-3 from Horiba 
Jobin Yvon and the DataMax Software Version 2.20 [38, 42]. 
2.6 Statistical Analysis  
To semi-quantify the penetration enhancing (PEE) or penetration confinement effect (PCE), 
we compared the background-corrected average pixel intensities of the different samples in 
the skin layers of interest (SC, viable epidermis, superficial dermis). The background-
corrected average pixel intensities of a sample treated with BSA-RhB solution served as 
reference and was set to 1. All PEE/PCE values are expressed relative to this value. The 
PEE/PCE results are presented as average results ± SEM obtained from 3 independent 
experiments. Statistical analysis is based on the Wilcoxon-Mann-Whitney test; p  0.05 
indicates a statistically significant difference. 
 
3. Results 
3.1 Penetration of HA into normal and tape-stripped skin 
We investigated the skin absorption of HA in normal and tape-stripped skin to substantiate 
the findings in the literature that HA itself is able to penetrate into the skin [14, 26]. FLIM 
measurements were performed on cryosections of pig skin treated with HA-MANT and the 
penetration of different molecular weights of HA (5 kDa, 100 kDa, and 1 MDa) was assessed. 
With cluster-based FLIM image analysis, one lifetime cluster belonging to HA-MANT was 
identified in both normal (Figure 4-1 A-C) and tape-stripped skin (Figure 4-1 D-F). In normal 
skin, 5 kDa HA was localized in the stratum corneum and epidermis, albeit rather patchy 
(Figure 4-1 A). The higher molecular weight HAs were basically confined to the SC (Figure 4-
1 B, C). In contrast, in tape-stripped skin the lifetime cluster belonging to HA-MANT was 
localized in both SC and epidermis, with slightly higher concentrations for 100 kDa and 
1 MDa HA compared to 5 kDa HA (Figure 4-1 D-F).  
3.2 Penetration of BSA into normal and tape-stripped skin 
Next, the skin penetration of the model protein BSA with a molecular weight of ~ 66 kDa was 
investigated. Again, FLIM measurements were performed on cryosections of pig skin treated 
with BSA-RhB and subjected to cluster-based FLIM analysis. Since dermal absorption of 
proteins is highly limited owing to the proteins’ hydrophilic nature and large size, we did not 
expect high amounts of BSA in normal skin. As expected, BSA skin absorption is much less 
in normal skin compared to barrier deficient skin (Figure 4-1 G and H). Nevertheless, residual 
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fluorescence intensity belonging to BSA-RhB could be identified by cluster-based FLIM 
analysis in normal skin (colored red in Figure 4-1 G). 
 
 
Figure 4-1 Penetration patterns of HA-MANT and BSA-RhB in normal and tape-stripped skin. (A-F) 
HA-MANT penetration in normal (A,B,C) and tape-stripped skin (D,E,F) as determined by MANT 
fluorescence. (G-J) BSA-RhB-ITC penetration into normal (G,I) and tape-stripped (H,J) skin without 
HA (G,H) and with 5 % 5 kDa HA (I,J). Images are false color coded according to the measured BSA-
RhB fluorescence lifetime. Scale bars represent 100 µm. Effect of HA on BSA penetration. (K,L) 
Average of three intensity line scans for BSA-RhB alone (dashed line) and with 5 kDa HA (solid line) in 
(K) normal skin and (L) tape-stripped skin. Arrow indicates increased or decreased BSA penetration in 
the presence of HA. 
 
This cluster is localized in the SC and the epidermis. In tape-stripped skin, two distinct 
lifetime clusters belonging to BSA-RhB were identified (Figure 4-1 H). One is localized in the 
remainder of the SC and part of the viable epidermis (colored cyan in Figure 4-1 H). The 
corresponding lifetime deviates strongly from the auto fluorescent background as well as 
from the lifetime of the single cluster observed for normal skin (Figure SI 2). The second 
cluster is primarily located in the dermis, colored red in Figure 4-1H, and its fluorescence 
70 
 
decay is similar to the one determined for BSA-RhB in normal skin (Figure SI 2). Since the 
cyan colored areas correspond to areas with the highest fluorescence intensity (Figure SI 3), 
the different fluorescence lifetimes may reflect this concentration difference, in particular as 
high fluorophore concentrations may lead to quenching effects. 
3.3. Effects of HA on BSA penetration  
To investigate the effect of HA on BSA penetration, cryosections of intact and tape-stripped 
pig skin treated with different molecular weight HA-MANT together with BSA-RhB were 
analyzed.  
In normal skin, a single lifetime cluster belonging to BSA-RhB was identified for all three HA 
molecular weights (colored in red in Figures 4-1 I and SI 3). For 5 kDa HA, localization of 
BSA-RhB in the SC and the viable epidermis was observed (Figure 4-1I). In the presence of 
100 kDa and 1 MDa HA the localization of BSA was limited to the SC (Figure SI 3). 
In tape-stripped skin, again two clusters with different lifetimes belonging to BSA were 
identified for all HA molecular weights (Figure 4-1I and SI 3). One cluster, colored in cyan, 
was localized in the SC and the other, colored in red, in the epidermis, and to a much lesser 
extent in the dermis. The localization of BSA was independent of the molecular weight of HA.  
To compare the amounts of penetrated BSA with and without HA, we used the fluorescence 
intensity of the identified FLIM clusters belonging to BSA. Averaged intensity line scans for 
BSA alone and BSA with 5 kDa HA were compared (Figure 4-1 K,L). In normal skin, the 
intensity for BSA-RhB with 5 kDa HA (Figure 1 K, solid line) was increased in the SC (first 15 
µm) and epidermis (up to 50 µm) compared to BSA-RhB alone (Figure 4-1 K, dashed line), 
where the observed intensities were close to the auto fluorescent background. In tape-
stripped skin, the intensities observed for BSA-RhB alone were well above the auto 
fluorescent background (Figure 4-1 L, dashed line), in particular close to the surface of tape-
stripped skin, and up to 100 µm into the skin. In the presence of 5 kDa HA-MANT (Figure 4-1 
L, solid line), high peak values close to the skin surface were also found, but the intensity 
dropped to background levels at 50 µm skin depth.  
To quantify the effects of HA on BSA penetration, we evaluated the background-corrected 
average pixel intensities of the different samples in a semi quantitative way. Intensity 
changes in the different skin layers of interest were calculated with respect to the sample 
treated with BSA only, as outlined in Material and Methods. For normal skin, a 2.5 fold 
intensity increase of BSA-RhB fluorescence was observed in the stratum corneum for 5 % 5 
kDa HA (Figure 4-2 A). In the viable epidermis, the penetration enhancement effect of 5 % 5 
kDa HA was even higher with a 7.5-fold increase in BSA-RhB fluorescence intensity (Figure 
4-2 A). Samples with 5 % 100 kDa or 1 MDa HA did not show any penetration enhancement 
effects for BSA (Figure SI 3). For tape-stripped skin, however, a different picture evolved. 
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Comparison with the BSA control (without HA) showed that protein penetration in the 
presence of HA is confined to the SC and the viable epidermis. The BSA-RhB fluorescence 
in the dermis was reduced to 20 % of the intensity found in the control BSA sample (Figure 4-
2 B).  
 
 
Figure 4-2 Penetration enhancing effect (PEE) and penetration confinement effect (PCE) of HA on 
BSA penetration. The penetration of BSA-RhB without HA served for reference, and the respective 
intensity above background was set to 1. (A) PEE of 5 % 5 kDa HA on BSA-RhB penetration into 
normal skin measured by fluorescence microscopy. Mean values are presented for the SC (white bars) 
and the viable epidermis (black bars) (n=3, mean values ± SEM *p ≤0.05). (B) Penetration 
confinement effect (PCE) of HA samples on BSA-RhB penetration in tape-stripped skin. Protein 
penetration into the dermis was significantly reduced with HA (n=3, mean values ± SEM *p ≤0.05). 
Mean values are presented for SC (white bars), viable epidermis (black bars), and dermis (grey bars). 
 
This effect was observed for all three HA molecular weights. Despite a HA independent 
overall localization of BSA, we detected concentration differences in the remaining SC of 
damaged skin. We found a molecular weight dependent effect on the accumulation of BSA 
with decreasing intensity for 5 kDa > 100 kDa > 1 MDa HA. This behavior, however, did not 
affect the penetration yield into the viable epidermis. For all HA molecular weights, we found 
a similar accumulation of BSA in the viable epidermis with about 65 % of the BSA control 
sample intensity.  
3.4 Molecular interactions between HA and BSA in skin 
Since several publications discuss that HA itself penetrates [17, 46-48] and co-transports 
drugs into the skin and into deeper dermal layers [26], we aimed to test this hypothesis. To 
determine whether co-localization of HA and BSA in terms of molecular contact between 
these two molecules in the skin exist, we used FRET [49]. FRET is highly sensitive for 
measuring distances between two fluorophores since the rate constant of energy transfer is 
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proportional to the inverse 6th power of the distance. Typical FRET distances are between 1 - 
10 nm.  
Fluorescence energy transfer from HA-MANT to BSA-RhB can occur, according to the 
spectral overlap between HA-MANT emission and BSA-RhB absorption (Figure 4-3 A).  
Hence, the occurrence of FRET emission was investigated on skin samples containing both 
HA-MANT and BSA-RhB by exciting the samples with 405 nm and detecting the emission 
between 590 nm and 650 nm, termed FRET channel in the following, specific for BSA-RhB 
emission. However, the spectroscopic analysis also showed that BSA-RhB exhibits 
absorption at 405 nm (Figure SI 1 A). Therefore, fluorescence emission detected in the FRET 
channel cannot be solely attributed to FRET between HA-MANT and BSA-RhB.  
In order to determine if the fluorescence signal in the FRET channel contains FRET 
emission, non-FRET and FRET contribution to the total fluorescence signal have to be 
separated. The non-FRET contribution can be determined by excitation of BSA-RhB alone. 
To account for the different laser output powers in the FLIM setup, the RhB fluorescence 
intensity after excitation at 405 nm and 488 nm was measured in a pig skin sample only 
treated with BSA-RhB (Figure 4-3 B). Intensity line scans at identical sample positions 
showed a fluorescence intensity difference between excitation at 405 nm and 488 nm. The 
intensity ratio I405/I488 was 2.5.  
Using this ratio the non-FRET contribution (dashed line in Figure 4-3 D) can now be 
determined from a measurement with 488 nm excitation in BSA-RhB and HA-MANT 
samples. If FRET occurs, the emission detected for 405 nm excitation should be more than 
2.5 times higher than the emission detected for 488 nm excitation, due to the additional RhB 
emission excited by FRET (Figure 4-3 D, additional intensity above the dashed curve (non-
FRET intensity) indicating the FRET contribution). If the ratio of the intensities I405/I488 is 2.5 
(Figure 4-3 C), no FRET occurs as the observed RhB intensity at 405 nm excitation is due to 
non-FRET.  
This approach was employed to analyze skin treated with BSA-RhB together with different 
HA-MANT molecular weights. The false color coded images from cluster-based FLIM 
analysis are presented alongside a comparison of line scans measured at 405 and 488 nm, 
allowing for the detection of FRET emission (Figure 4-3 E-J). An intensity ratio I405/I488 larger 
than 2.5, indicative of FRET, was only observed in normal skin for BSA-RhB in the presence 
of 5 and 100 kDa HA (Figure 4-3 E,F). For all other samples no contribution from FRET 
emission to the total fluorescence intensity was detected (Figure 4-3 G-J). Since we have 
observed a clear penetration enhancement effect for BSA when normal skin was treated with 
5 kDa HA, the FRET measurements indicated that this effect was accompanied by a co-
localization of BSA and HA.  
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Figure 4-3 Measurement of FRET between HA and BSA. (A) Emission spectrum of HA-MANT and 
BSA-RhB in solution. The shaded region indicates the overlap area. (B) Characteristic intensity line 
scan of a sample only treated with BSA-RhB and excited either at 405 nm (upper curve, pulsed diode 
laser) or 488 nm (lower curve, Ti:Sa laser). The correction factor of 2.5 was determined from the 
intensity ratio of the respective peak intensities. Emission filter: HQ620/60. (C) Theoretical emission 
spectra for the situation without FRET from HA-MANT to BSA-RhB under the given excitation 
conditions. (D) Theoretical emission spectra for the situation with FRET, indicated by the increase in 
emission by the 405 nm excitation compared to the situation without FRET as assessed from the 
corrected (correction factor 2.5) emission curve by the 488 nm excitation (dashed curved). (E-J) 
Cluster FLIM images for analysis of FRET induced BSA-RhB emission and characteristic emission 
intensity line scans for excitation at 405 nm (red curve) and 488 nm (blue curve) together with the 
theoretical curve without FRET (dashed black curve) for normal (E-G) and tape-stripped skin (H-J). 
Vertical white lines in the images indicate the position at which the line scan was taken. Scale bars: 50 
μm. 
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3.5 Stratum corneum hydration, keratin conformation, and interactions with the 
skin lipids  
To further elucidate the interactions between HA and the SC, we investigated the effects of 
HA molecular weight and concentration on SC hydration, keratin secondary structure, and 
the lipid chain order using FTIR spectroscopy.      
SC hydration was assessed from the area under the O-H stretching absorbance (~ 2100 cm-
1) which increased significantly by water uptake [50]. Furthermore, the frequency shift of the 
amide I (~1640 cm-1) and amide II (~1565 cm-1) band absorbance maxima in the normalized 
FTIR spectrum indicated the level of hydrogen bonding of the protein amide linkages within 
the SC. The amide I band corresponded to the carbonyl-stretch of the keratin -CO-NH group. 
The stretching was more pronounced when the C=O band was involved in increased 
hydrogen bonding resulting in an absorbance at lower wavenumbers [29]. The amide II band 
reflected the amide N-H in-plane bending mode. Bending of the N-H bond becomes more 
difficult when the amide hydrogen is influenced by increased H-bonding to oxygen from 
water. This could be detected as a shift of the amide II band to higher wavenumbers [29]. 
Figure 4-4 summarizes the changes of SC hydration (calculated from increased areas under 
the O-H stretching absorbance), given as relative water content (%) of the SC, after 
incubation with different formulations (Figure SI 6). After 6 h, the SC hydration increased 
drastically for 2 %, 5 %, 10 % 5 kDa, and 5 % 100 kDa HA formulations to relative water 
contents over 200 % compared to dry skin (Figure 4-4). The evaluation of the amide I and II 
band peak shifts confirmed these findings (data not shown). HEC hydrogels were included 
for comparison but did not show significant effects.  
 
 
Figure 4-4 SC hydration expressed as relative water content within the SC (% uptake compared to dry 
SC) after 6 h incubation with water, HEC, 5 kDa, 100 kDa, and 1 MDa HA (2 %, 5 %, and 10 %, 
respectively). n = 3; mean values ± SEM, *p ≤ 0.05 compared to water treated samples. 
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Next, changes of the keratin secondary structure as a function of different HA and HEC 
formulations were assessed by FTIR. The shape of the amide I band of proteins is 
characteristic for their secondary structure. Changes in the protein conformation are reflected 
by a splitting of the amide I band at ~1650 cm-1 when random coil and α-helical structures 
convert to β-sheet structures. Changes in keratin structure, for example induced by the 
formation of β-sheet structures, can contribute to a decreased skin barrier function [32]. The 
5 kDa HA exhibited the most prominent effects (Figure 4-5 A). With increasing 
concentrations, the conversion from α-helical to β-sheet structures increased drastically from 
25 % to 60 % and even to ~ 90 %. Compared to 5 kDa HA, the other formulations (100 kDa 
HA, 1 MDa HA, and the HEC gels) showed only minor effects on the keratin structure (Figure 
4-5 B-D). Almost no changes were seen for 100 kDa HA (Figure 4-5 B). Compared to the dry 
and water treated SCs, only the 2 % sample showed significant shifts to 50 % β-sheet 
structures, whereas the 5 % and 10 % 100 kDa HA samples formed more random-coiled 
protein structures indicated by a shift of the peak from ~1648 cm-1 to 1640 cm-1.  
 
Figure 4-5 Normalized second derivative FTIR spectra of the SC keratin (amide I region at ~1650cm
-1
) 
after 6 h incubation with 5 kDa HA (A), 100 kDa HA (B), 1 MDa HA (C), and HEC (D). The formulations 
with concentrations of 2 % (dashed line), 5 % (medium dotted line) and 10 % (highly dotted line) were 
compared to dry SC (black line) and water (dotted line). 
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To gain more insight into the effects of HA on the skin lipids, we had a closer look at the 
spectral region between 3100-2700 cm-1. Changes in the intercellular lipid chain order are 
indicated by a shift of the methylene symmetric and asymmetric stretching vibrations 
(~2850.5 cm-1 and ~2920 cm-1 in dry and hydrated SC control) toward higher wavenumbers 
[30]. Besides the shift of the wavenumbers, a flattening of the IR spectra indicates an 
increase in SC hydration [32, 51]. After 6 h, the most prominent shifts of 9.7 ± 2.8 cm-1 and 
8.7 ± 1.3 cm-1 to higher wavenumbers for the symmetric CH2 stretching band were observed 
for SC samples treated with 5 % and 10 % 100 kDa HA formulations (Figure 4-6 A), 
indicating significantly higher shares of disordered lipids compared to all other SC samples.  
  
Figure 4-6 SC lipid chain orders after incubation with water, HEC, 5 kDa, 100 kDa, and 1 MDa HA (2 
%, 5 %, and 10 %, respectively). The SC lipid order is displayed as the change of the wavenumbers 
for the IR methylene symmetric (A) and asymmetric (B) stretching vibration compared to a dry SC 
control after 6 h incubation. n = 3; mean values ± SEM; * p ≤ 0.05. 
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The same holds true for the asymmetric CH2 stretching band (Figure 4-6 B). Here, even more 
pronounced wavenumber shifts for 100  kDa HA occurred (2.2 ± 1.3 cm-1, 16.7 ± 5.4 cm-1 and 
15.3 ± 0.7 cm-1 for 2 %, 5 %, and 10 % HA, respectively) further underlining a significant 
change in the lipid chain order. Minor effects were observed for 2 % HEC, 2 % 5 kDa HA, 
and 2 % 1 MDa HA (Figure 4-6 B). Measurements on tape-stripped SC gave the same 
results. Additionally, reference measurements showed no interactions between BSA and skin 
lipids or proteins.  
 
4. Discussion 
In this study, we compared the effect of HA on the skin penetration properties of the model 
biomacromolecule BSA in both intact and barrier deficient skin. In intact skin, absorption of 
biomacromolecules such as proteins is generally low due to their high molecular weight, 
distinct hydrophilicity and charged state [4, 5]. Up to now, only few studies describe effective 
protein delivery into the skin using nanoparticles, sonophoresis or iontophoresis [52-54].  
HA has been used for topical drug delivery repeatedly, with Solaraze® (3 % diclofenac in 2.5 
% HA) as a prominent example, which is an alternative to the common destructive surgery 
used for the treatment of actinic keratosis. Solaraze® is well-tolerated, shows good efficacy 
and exhibits less side effects compared to photodynamic or cryotherapy [22]. Brown et al. 
[14, 55] have shown that HA enhanced significantly the partitioning of diclofenac into human 
skin as well as its retention and localization in the epidermis. Twice as much diclofenac was 
delivered into the epidermis compared to an aqueous control [56]. Diclofenac, however, with 
a molecular weight of ~300 Da is a small drug compared to a biomacromolecule such as 
BSA with 66 kDa. Hence, the mechanisms by which a protein is delivered into or through the 
skin most likely differs considerably from the delivery of smaller molecules.  
Two decades ago HA was recognized as a protective vehicle for the delivery of proteins such 
as growth factors and interferon [16]. Recently, human growth hormon-HA conjugates were 
delivered through the skin into the blood stream [17]. However, the exact mechanism for 
dermal transport and an explanation for the topical delivery properties of HA still need to be 
elucidated. 
 
Intact skin. HA itself was found to penetrate into the skin in several studies [14, 17, 46]. Our 
imaging results showed a deeper skin penetration of the low molecular weight HA (5 kDa) 
compared to higher molecular weight HA (100 kDa and 1 MDa). This is in agreement with 
recent Franz diffusion cell data also showing a molecular weight dependency on HA 
penetration [46]. 
Regarding the skin absorption of BSA, it is known from the literature that this high molecular 
weight protein cannot penetrate into deeper layers of intact skin [57].  However, an enhanced 
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transport of BSA into the dermis was found when intact skin was hydrated for 4 - 10 h [57]. In 
our experiments, BSA was applied onto intact skin for 6 hours in a Franz diffusion cell. Under 
these conditions skin hydration to a certain extent is expected, which explains the small 
amounts of BSA penetration we observed in normal skin (Figure 4-1 G).  
Binding of HA to BSA is known both from biochemical [58] and physicochemical studies [59, 
60], with binding modes depending on a variety of conditions. Although BSA is overall 
negatively charged at neutral pH, it is known to bind to negative surfaces, probably due to 60 
surface lysine groups [60].  Thus, it is very likely that BSA can interact with the negatively 
charged HA under physiological conditions. The effect of HA on BSA penetration in intact 
skin can be summarized as follows: while 5 kDa HA led to a penetration enhancement of 
BSA into the viable epidermis (Figure 4-1 I) with an enhancement factor of 7.5 (Figure 4-2 A), 
no effect was observed for higher molecular weight HA. There are several hypotheses how 
HA acts as a skin penetration enhancer. Some publications discuss that HA itself penetrates 
[17, 46-48] and co-transports the drug into the skin [26]. Our FRET-FLIM experiments indeed 
revealed a close proximity between HA and BSA (Figure 4-3) under the conditions of 
penetration enhancement. Since it is known that BSA can bind to HA [58, 59], the FRET-
FLIM results and the observation that HA alone penetrated into the epidermis (Figure 4-1) 
indicated that BSA was co-transported into the epidermis by HA.  
Although our results support the theory that HA penetration and co-transport are the driving 
force of enhanced drug delivery, this does not exclude the existence of other mechanisms 
such as skin hydration or the occlusive properties of HA at higher concentrations [14]. To 
further understand the modes of HA action when applied onto skin we performed FTIR 
measurements on isolated SC sheets. Besides evaluating the effect of the different molecular 
weights of HA, we also analyzed the dependence of skin hydration, keratin structure and lipid 
organization on HA concentration.  
At higher HA concentrations and increasing molecular weight, the overall skin hydration 
capacity of the hydrogels decreased as more water was needed to equilibrate the HA gel, 
leaving less free water in the water phase [61, 62]. Our findings support these results. With 
exception of 5 kDa HA, the use of a 10 % HA gel led to lower skin hydration compared to the 
5 % hydrogels (Figure 4-4). The best hydration effects, however, were observed for 5 kDa 
formulations. Under these conditions we found enhanced BSA skin penetration in normal 
skin (Figure 4-1). Thus, skin hydration seems to be another important factor for enhanced 
protein delivery into intact skin. Since a direct interdependence between keratin structure and 
hydration exist, we also had a look at the changes of keratin structure. According to [32] the 
formulation driven keratin conversions from α-helical structure to β-sheet lead to impaired 
barrier properties and thus enhanced skin absorption of substances. Indeed, the most 
prominent structural changes were again observed following the application of 5 kDa HA 
formulations (Figure 4-5 A), in particular at the concentrations of 5 % and 10 % HA. HEC gels 
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that were used as control showed no or only minor effects compared to 5 kDa HA (Figure 4-4 
and 4-5). 
Consequentially, for enhanced protein delivery into intact skin the following picture emerged: 
Formulations containing low molecular weight HA (here 5 kDa HA) altered the SC barrier 
properties through keratin structural changes and increased skin hydration, in particular at 
higher concentrations (5 % and 10 % HA). Under these conditions (5 % 5 kDa HA) transport 
of the model protein BSA into the epidermis was observed that was absent using an aqueous 
control. Since close contact between HA and BSA molecules both in the SC and in the 
epidermis was detected, co-transport is the most plausible explanation. For the case at hand, 
a combination of HA-based skin hydration and co-transport of biomacromolecules was 
observed in conjunction with enhanced protein delivery in intact skin. 
 
Barrier deficient skin. In tape-stripped skin, however, a different picture evolved. We 
showed that proteins can penetrate into the barrier-disrupted skin (Figure 4-1 H). Similar 
effects were shown for highly hydrated skin [57]. HA alone did also penetrate deep into tape-
stripped skin. The highest concentration of HA in the skin was found for 100 kDa HA. This is 
in contrast to the HA penetration properties in intact skin (Figure 4-1 A-F). If the lipid chain 
order in the SC or interactions between HA and the skin lipids played a role was assessed by 
FTIR [29, 30, 51]. These measurements indicated a more disordered lipid organization after 
treatment with 5 % and 10 % 100 kDa HA preparations. We assume that the reduction in SC 
thickness together with a loosened and more disordered state of the SC lipids was 
responsible for better HA penetration in tape-stripped skin compared to intact skin.  
Since both HA and BSA were shown to penetrate well into the tape-stripped skin, the 
observed effect when a mixture of both molecules was applied to barrier disrupted skin was 
surprising. Here, we observed that formulations containing both HA and the protein exhibited 
penetration retardation in terms of a localized epidermal absorption of BSA in barrier 
disrupted skin. This effect was observed for all molecular weights of HA used in this study. 
So called epidermal retention effects were also described by Brown et al. [14, 55] and 
attributed to skin hydration. HA penetration into the skin and the absence of close contact 
between HA and BSA in our investigations of tape-stripped skin support an effect of skin 
hydration. However, the exact underlying mechanism leading to intraepidermal confinement 
and preventing protein penetration into deeper dermal layers remains to be elucidated.  
 
5. Conclusion 
A combination of biophysical spectroscopic and imaging methods enabled us to shed light on 
the penetration behavior of HA, topical delivery of a model protein BSA and underlying 
mechanisms. Our data substantiate the findings in the literature that low molecular weight HA 
80 
 
is able to overcome the disrupted SC. We demonstrated the penetration enhancing effects of 
5 kDa HA for the model protein BSA in intact skin. The enhancement effect was most likely 
based on an interplay of skin hydration, interaction with keratin structure and protein-HA co-
transport, aiding the transport across the SC as well as the skin absorption of HA itself. 
Moreover, we showed HA-facilitated penetration confinement resulting in a localized 
epidermal absorption (stratum corneum and viable epidermis) of proteins in barrier disrupted 
skin. Thus, HA hydrogels seem to be potential delivery systems for barrier-deficient skin.  
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Abstract  
Solid microneedles (MN) are a promising tool for dermal drug delivery. Particular focus lies 
on the field of vaccination due to pain-free, safe, hygienic and patient compliant antigen 
deposition. Diverse coating techniques and formulations have been developed to preserve 
vaccine activity and to enable targeted drug deposition in the skin. Process and long-term 
storage stability of coated MN, however, have not yet been studied in detail. Hence, a 
feasibility study was conducted determining the appropriate needle length (300 µm) for local 
intraepidermal protein delivery. Moreover, a protein-stabilizing coating formulation was 
developed. Coating of the MN resulted in protein concentrations between 10 to 23 µg, 90% 
of the bioactivity of the model protein asparaginase was maintained for 3 months. Skin 
experiments verified the intraepidermal deposition of 68.0 ± 11.7% of the coated model 
protein after single application. Slightly increased interleukin 8 levels right after MN insertion 
indicated minor skin irritation due to the mechanical piercing stress. Thus, specifically 
highlighting protein stabilization during storage, we demonstrated that selective 
intraepidermal deposition of proteins or peptides’ using solid MN is a feasible approach.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Key Words: solid microneedle array, proteins, coating formulation, protein stability, human 
reconstructed skin, skin irritation 
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1. Introduction 
The application of microneedles (MN) into human skin emerged as a popular tool in both the 
cosmetic and pharmaceutical area. Used in the cosmetic sector, microneedling is effective in 
ameliorating conditions such as scars, striae, wrinkles, or dyspigmentation [1–3] since MN 
stimulate the differentiation of fibroblasts resulting in enhanced production of collagen and 
elastin fibers [2]. Besides cosmetic treatments, MN are considered useful  for dermal drug 
delivery, which is particularly appealing for drugs suffering from low skin absorption due to 
hampering physicochemical properties, such as proteins, or for compounds intended for local 
intradermal action [4,5]. Due to needle lengths in the lower micrometer range, topical 
insertion of MN do not activate the nociceptors in the skin allowing a pain free drug 
application or vaccination [5]. Consequentially, MN are widely tested for transdermal delivery 
of proteins like insulin [6,7], desmopressin [8], or the human growth hormone [9] and for 
intradermal vaccination against e.g. measles [10] or influenza [11,12]. The latter is a 
particularly attractive approach since the vaccines can be directly administered into the viable 
epidermis or dermis resulting in a strong immune response [13,14]. 
The major barrier for topically applied compounds is the stratum corneum (SC), the skin´s 
outermost layer. The application of MN enables to overcome the SC easily since the needles 
pierce the SC and generate microchannels [6,15] through which topically applied substances 
can then readily diffuse. Alternatively, the compounds can be coated onto the MN tips and 
directly introduced into the skin [5,16]. As for today, different coating techniques, formulations 
and applications are described in the literature [13,16–18]. Limited data, however, are 
available on the protein stability of coated MN and on potential skin irritation following MN 
application. The stability of coated proteins was either investigated over relatively short 
periods like days up to one month, or the potential induction of immune responses or skin 
irritation was not evaluated [8,19–22].  
Hence, the aim of this work was a comprehensive feasibility study on intradermal protein 
delivery investigating systematically the coating efficiency of stainless-steel MN, MN insertion 
and required forces, a suitable coating formulation for the model proteins bovine serum 
albumin (BSA) and the more labile L-asparaginase II (AsnB) and the establishment of an 
adequate coating method. Subsequently, the protein integrity and bioactivity directly after 
coating and after storage at 2 - 8°C, 25°C and 40°C for up to 3 month was monitored using 
specific activity assays and size exclusion chromatography (SEC). Intradermal protein 
delivery was initially investigated in excised pig skin. Moreover, total protein amounts 
delivered into the skin were determined in reconstructed human skin. Skin models are 
suitable in vitro test systems to study skin absorption of substances and skin irritation 
potential following MN insertion [23]. Hence, to assess the skin irritation potential of MN 
87 
 
insertion, the amounts of the pro-inflammatory cytokines interleukin (IL) 6 and IL-8 were 
quantified.  
 
2. Materials and Methods 
2.1 Materials 
Hyaluronic acid (HA; molecular weight: 1 MDa) was kindly provided by Shiseido Co., Ltd 
(Shizuoka, Japan). AsnB from E. coli was produced by Prof. Dr. Markus Pietzsch. The 
enzyme was isolated from frozen recombinant E. coli cells. 100 g bio wet mass were 
suspended in 1 L of buffer A (50 mM Tris-acetate buffer, pH 5.1) using an ultraturrax 
homogenizer. The cells were disintegrated by high pressure homogenization (APV 2000, 
APV Systems, Albertslund, Denmark) using four passages at a pressure of 1000 bar. The 
suspension was cooled to 4°C before and between the passages and subsequently 
centrifuged (30 min, 5000 g, Avanti J-30i, Beckman Coulter, USA) at 4°C. The pellet was 
discarded. To the supernatant (850 mL), 850 mL ethanol was added and incubated at room 
temperature for 30 min. The precipitate containing AsnB was centrifuged off and dissolved 
again in 550 mL buffer A. Afterwards, the same volume of ethanol was added to the 
supernatant to obtain a 50% (v/v) mixture. After 30 min, the precipitated AsnB was again 
collected by centrifugation and lyophilized. From 100 g bio wet mass, 2.7 g AsnB was 
obtained. The lyophilized enzyme was stored at minus 25°C. 
BSA, dimethyl sulfoxide (DMSO), rhodamine B isothiocyanate (RhB ITC), methylene blue, 
polysorbate 80, L-asparagine monohydrate, trichloracetic acid, and the buffer reagents were 
purchased from Sigma-Aldrich (Steinheim, Germany). Nessler´s reagent was obtained from 
Merck (Darmstadt, Germany).The MN arrays (56 needles, 300 µm needle length) were 
purchased from Microneedle Systems (Georgia, USA).  
For skin penetration experiments, pig skin of the flank region from “Deutsche Landrasse”, 30-
50 kg, 10-20 weeks old was used (Clinic of Swine, Ludwig-Maximilians University, Munich, 
permission no. DE 09 162 0017 X-1). Immediately after surgical removal, the excised skin 
was transferred to the laboratory. Any contact between the skin surface and the lipids of the 
subcutis was avoided. The skin was stored at -20°C for up to 6 month. Prior to use, the skin 
was thawed, gently cleaned with PBS buffer (pH 7.4) and excessive hair was removed with 
clippers. 
2.2 Assessment of Optimal Insertion Depth, Fracture and Insertion Force 
The optimal insertion force for microchannel formation and the maximum force before 
fracture of the MN array were assessed using a texture analyzer TA.XTplus (Winopal, Elze, 
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Germany). The MN arrays were mounted onto the processing arm of the TA.XTplus using 
double-sided tape and subsequently inserted into excised pig skin. To determine the 
minimum insertion force that is required to pierce the SC, the MN arrays were injected with a 
constant speed of 0.05 mm/sec. In case of skin contact, the pressure from the MN array onto 
the skin surface increases. When the MN needles finally pierce the SC, a sharp drop in the 
otherwise gradually increasing force graph can be observed [24]. To visualize the formation 
of microchannels and the insertion depth after MN insertion with varying forces (1, 3, 4, 5 N, 
and manually (~ 3 N)), skin slices (10 µm) were stained with methylene-blue (2% w/v, 15 min 
incubation time) and investigated under the light microscope (VHX-2000, Keyence, Neu-
Isenburg, Germany). To assess the MN fracture force, the MN arrays were moved against a 
flat aluminum block at a rate of 0.05 mm/sec. The data of the insertion and fracture force 
were collected and processed using TestXpert II software.  
2.3 Fluorescence Labeling of Bovine Serum Albumin (BSA) 
Fluorescence labeling of BSA was performed using RhB ITC. 1 mg/mL RhB ITC in DMSO 
was added to 6 mg/mL BSA in 0.1 M sodium bicarbonate buffer (pH 9.0) resulting in a ratio of 
1:170 (dye:protein). After 2 h stirring under light protection, the labeled protein was purified 
and concentrated using Vivaspin 20 tubes (PES membrane MWCO 30,000, Sartorius AG, 
Göttingen, Germany) and subsequently centrifuged for 45 min at 4,000 rpm at 5°C. 
Subsequently, several washing steps were performed by adding fresh PBS buffer pH 7.4 to 
remove unbound dye. The absence of free dye was confirmed by UV measurements at 541 
nm. Protein concentration (between 20-25 mg/ml) and the degree of labeling (between 0.95-
1.3) were determined according to the manufacturer protocols. The labeled proteins (BSA-
RhB ITC) were stored at -20°C until further use. 
2.4 Formulation of the Coating Solution  
An aqueous coating solution consisting of 5% (w/v) sucrose, 2% (w/v) L-phenylalanine, 1% 
(w/v) hyaluronic acid (molecular weight: 1 MDa) and 1% (w/v) model protein was prepared. 
BSA-RhB ITC and AsnB served as model proteins. The formulations were prepared 1 day 
before use and stored at 4 - 8°C. 
2.5 Dip-Coating of the MN 
First, the MN arrays were cleaned with acetone, then rinsed with water, subsequently 
immersed in 0.1% w/v polysorbate 80 in PBS pH 7.4, and air-dried at room temperature. 
Subsequently, the MN tips were coated by dipping a 26Gx ½” syringe needle (Terumo 
Europe N.V., Leuven, Belgium) connected to a 1 ml syringe filled with the coating formulation 
onto the MN, respectively (Fig. 5-1). After coating, the MN were air-dried at room 
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temperature for at least 15 minutes. For multiple coatings, the procedure was repeated twice 
or three times. 
 
 
Figure 5-1 Scheme of the syringe and needle based dip-coating method. The coating solution was 
directly applied onto the MN tips using a 26Gx ½” needle. 
 
To assess the coated protein amount, the MN were immersed in 210 µl water. Subsequently, 
the concentrations of BSA and AsnB were determined by a bicinchoninic acid (BCA) assay 
(Micro BCA™ Protein Assay Kit, Pierce Biotechnology, Illinois, USA). Therefore, 150 µl of the 
coating solution were added to 150 µl of the reaction mixture. After 2 h incubation at 37°C, 
the optical density was measured at 562 nm, blank corrected and compared with the BSA or 
AsnB standard curve.  
2.6 Determination of Protein Activity 
The bioactivity of AsnB following MN coating and drying after one, two, or three coatings was 
assessed as the specific enzyme activity [U/mg] according to published procedures [25]. 
Briefly, a mixture of 50 µl coating solution, 100 µl 50 mM Tris-HCl buffer pH 8.6 and 850 µl 10 
mM L-asparagine monohydrate in 50 mM Tris-HCl buffer pH 8.6 was incubated at 37°C for 
10 min. After adding 50 µl 1.5 M trichloracetic acid solution, 100 µl of the supernatant was 
added to 200 µl Nessler´s solution. After 10 min at 22°C, the optical density was measured at 
UV = 436 nm, compared with the standard curve and corrected for the total enzyme amount 
as determined by Micro BCA™ Protein Assay Kit. The units of activity were defined as 
micromoles of ammonia released per minute. Freshly prepared AsnB solution served for 
reference. 
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2.7 Storage Stability of the MN Coatings and Proteins 
AsnB coated MN were stored at 2-8°C, 25°C, and 40°C for 1 week, 1 month, and 3 months, 
respectively. Subsequently, AsnB activity was determined as described above (see 2.6). The 
amount of AsnB tetramer, the biologically active form, and the formation of protein 
aggregates and fragments was assessed with SEC (TSKgel® SWXL guard column 
(dimensions: 6.0 mm x 4.0 cm), TSKgel® G4000 PWXL column (dimensions: 300 x 7.8 mm, 
10 µm particle size; TOSOH Bioscience, Stuttgart), isocratic elution at 0.4 ml/min,100 mM 
Na2HPO4, 150mM NaCl, pH 7.4) with UV and fluorescence detection (UV = 280 nm, 
fluorescence = exc. 280/ em. 350 nm)). 
2.9 MN Insertion in Pig Skin and Reconstructed Human Skin 
Pig Skin: To investigate protein delivery into excised pig skin, the coated MNs were 
manually inserted and remained in the skin for 5 minutes. After withdrawal, the skin was 
punched into discs of 25 mm diameter (centering the insertion site) and frozen at - 80°C 
using Jung® tissue freezing medium (Leica Microsystems GmbH, Nussloch, Germany). 
Subsequently, cryosections (5 - 10 µm) were prepared using a Leica Cryotome CM 3050S 
(Leica Microsystems, Nussloch, Germany). For data analysis, the slices were subjected to 
normal and fluorescence microscopy (20 x magnification, BZ-8000, Keyence, Neu-Isenburg). 
The fluorescence was recovered in the red band exciting the samples at 560 nm for RhB 
ITC.  
Reconstructed Human Skin: Reconstructed human skin was generated according to 
previously published procedures [26]. On day 13 of tissue cultivation, BSA-RhB ITC coated 
MN were inserted into the skin models. After 5 minutes, the MN arrays were carefully 
removed. Afterwards, the skin models were snap-frozen in liquid nitrogen and cryosections 
(thickness: 10 µm) were prepared (see 2.9.1). 
To quantify the delivered protein amount, AsnB coated MN were inserted into the skin 
models on day 13 (single application), or on day 12 and day 13 (double application) of tissue 
cultivation. At day 14, the epidermis of the skin models was gently peeled off and AsnB was 
extracted using a TissueLyser II (Quiagen, Venlo, Netherlands). The AsnB amount was 
subsequently determined as described above (see. 2.7). 
2.10 Cytokine Release Following MN Insertion 
The secretion of the pro-inflammatory cytokines IL-6 and IL-8 was determined by an enzyme-
linked immunosorbent assay (ELISA). Therefore, 100 µl cell culture medium was sampled 
and analyzed according to standard protocols (Human IL-6 DuoSet, DY206, R&D Systems, 
Minneapolis, MN, USA; Human IL-8 ELISA Ready-Set-Go, eBioscience, Frankfurt am Main, 
Germany).  
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2.11 Statistical Analysis 
The results are presented as average values ± SD obtained from at least 3 independent 
experiments. Statistical analysis is based on a Wilcoxon-Mann-Whitney-Test; *p ≤ 0.05 
indicates a statistically significant difference. 
 
3. Results and Discussion 
3.1 Optimal Insertion Depth, Fracture and Insertion Force 
The needle geometry and material of MN arrays are important factors influencing the 
characteristics of MN insertion. To overcome the SC and penetrate the skin layers, MN need 
to be sharp, robust and need to withstand the penetration pressure subjected by the skin 
tissue. Nevertheless, the needles also should be flexible enough to compensate the skin 
elasticity and have an appropriate length to avoid pain sensation. Additionally, MN arrays 
should be applicable manually with reasonable forces without fracturing [27]. The MN arrays 
used in this feasibility study were made of stainless steel consisting of 56 needles/cm². The 
needle heads were triangularly shaped and arranged in a tip angle of 70° (Fig. 5-1). Since we 
aimed for a delivery into the epidermal skin layer, we determined the appropriate needle 
length by comparing 300 µm and 800 µm MN arrays. Controlled insertion with a speed of 
0.05 mm/sec showed that the MN are able to penetrate the SC at insertion forces of 0.88 ± 
0.01 N and 0.21 ± 0.01 N for 300 µm and 800 µm long needles, respectively (Table 5-1), 
which is in agreement with published data. Here, a general insertion force range of 0.1 to 3 N 
was found, which is low enough to enable manual application [24]. 
 
Table 5-1 Insertion force required for SC penetration at an insertion speed of 0.05 mm/sec evaluated 
for MN arrays with 300 or 800 µm needle length compared to a 26Gx ½” needle. mean values ± SD 
Needle type Insertion force  (N) ± SD* Fracture force (N)** 
MN array (300 µm) 0.88 ± 0.01 3.8 ± 0.01 
MN array (800 µm) 0.21 ± 0.01 - 
26Gx ½” needle 0.69 ± 0.04 - 
* in pig skin 
** against aluminum block 
 
Table 5-2: Insertion depth and channel count dependent on insertion force and needle length.  
MN length (µm) Force (N) Channel count Insertion depth (µm) 
300 
1 20 ± 1 88 ± 5 
3 16 ± 3 77 ± 4 
4 10 ± 1 86 ± 1 
5 20 ± 2 80 ± 3 
manual (~ 3) 20 ± 3 86 ± 2 
800 
5 30 ± 2 200 ± 4 
manual (~ 3) 30 ± 1 280 ± 5 
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Figure 5-2 Microscopic evaluation of the MN channel depth after manual insertion (insertion force ~ 3 
N) for MN arrays with a needle length of 800 µm (A) and 300 µm (B). SC= stratum corneum, E = 
Viable Epidermis, D = Dermis. bar = 50 µm 
 
Manual and automated insertion of the MN arrays resulted in insertion depths ranging from 
80 to 90 µm for the 300 µm MN array and 200 to 280 µm for the 800 µm MN arrays (Fig. 5-2, 
Table 5-2). Consequentially, the 300 µm long MN were most suitable for intraepidermal drug 
delivery given that the human epidermis has a thickness of 130 - 180 µm [28, 29]. 
Since the stability of the MN arrays is important for an injury free application, the fracture 
force was determined. In an experimental setting, where the MN arrays were subjected to 
collision with an aluminum block, the MN tips experienced deformation at a force of 3.8 ± 
0.01 N. Nevertheless, in ex-vivo experiments with pig skin, where insertion forces up to 5 N 
were applied, and no damage of the skin tissue and no differences in microchannel count or 
depth (Table 5-2) were observed. Hence, the MN arrays used in this study proved to be safe, 
which was likewise found for a similar stainless steel MN patch [30]. In addition, successful 
MN insertion also depends on individual skin thickness and elasticity [31]. Regarding the 
applied insertion force, no correlation between force and channel count was observed (Table 
5-2) and the insertion depth was hardly influenced.  
3.2 Dip-Coating, Coating Efficiency and Protein Stability 
In addition to mechanical piercing of the SC, solid MN also enable the deposition of coated 
drugs in the skin [5,16]. Here, specific formulations can be necessary to stabilize labile 
molecules such as proteins or peptides during coating procedure and storage [16,18,29]. 
Furthermore, the protein structure integrity can be challenged during storage since proteins 
are very sensitive and susceptible to degradation, unfolding, or aggregation.  
Successful MN coating also depends on drug concentration, viscosity and surface activity of 
the solution [18]. Since the MN surface often is hydrophobic and, hence, difficult to wet, it 
requires a pre-treatment with surface-active detergents [18]. Here, we immersed the MN 
arrays in a polysorbate 80 solution. To further enhance the coating yield, hyaluronic acid (1 
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MDa) was added as a viscosity enhancer. The arrangement of the needles on the MN array 
inhibited simple dip-coating since the narrow space between the needles caused capillary 
effects or micro-flows resulting in a non-localized coating of the needles. Therefore, we 
employed a modified coating technique using a 26Gx ½” syringe (Figure 5-1). By dipping the 
solution filled syringe onto each single MN tip, a uniform and localized coating was achieved 
(Figure 5-3), that could be repeated until the desired amount of protein loading was achieved.  
 
 
Figure 5-3 Coated MN tips after 1 dip coating cycle; bar = 0.25 mm 
 
As expected, the amount of protein coated on the MN steadily increased with the number of 
coatings. One dip-coating procedure resulted in 11.7 ± 1.1 µg AsnB per MN array, two 
coatings resulted in 18 ± 6.4 µg per MN array and three coatings procedure yielded 22.7 ± 
1.0 µg per MN array, respectively (Fig. 5-4).  
Protein integrity was maintained during coating: AsnB activity was 94.6 ± 2.2% after one 
coating cycle (Fig. 5-4). After the second and third coating cycle, however, the AsnB activity 
diminished to 78.7 ± 2.0 and 80.5 ± 11.0%, respectively. The maintenance of the AsnB 
activity after the coating procedure can be explained by the addition of the excipients. To 
successfully stabilize a protein that is embedded in a dry product, the product matrix needs to 
be amorphous or semi-amorphous, since a crystalline matrix state is known to de-stabilize 
proteins [21]. In this context, sucrose is a commonly used excipient [9,18]. Since the residual 
moisture also affects the product stability during storage, phenylalanine was added. 
Phenylalanine is a poorly water soluble amino acid that proofed to be effective in reducing 
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the residual moisture content of air-dried protein-containing matrices by crystallizing and 
allowing the water  to be removed from the amorphous mass [32]. 
 
 
Figure 5-4  Amount of AsnB on the MN array determined by BCA assay (white bars) and AsnB activity 
after 1 - 3 coating procedures determined by AsnB activity assay (black bars); mean ± SD. * p ≤ 0.05    
 
3.3 Storage Stability of Protein-Coated MN Arrays  
Coated MN arrays intended for pharmaceutical applications require sufficient storage 
stability. To assess the storage stability of the coating formulation, AsnB was chosen as 
model protein. In the case of physical stress, the tertiary structure of the AsnB can be 
compromised by either clustering of several AsnB tetramers (the biologically active form) to 
bigger aggregates or by separation of the tetramer into its homo-dimers, monomers or even 
smaller fragments. In both cases, the secondary products are biologically inactive [33]. 
Hence, we monitored AsnB activity and integrity over 3 month at 2-8°C, 25°C and 40°C, 
respectively. 
The AsnB tetramer amount of a freshly prepared solution was 88.6 ± 6.4% and did not 
change during 1 day storage at 25°C (Fig. 5-5A). After one week, the tetramer amount was 
reduced to 80.3 ± 6.2% (4°C), 73.2 ± 6.2% (25°C) and 76.1 ± 4.5% (40°C), respectively. 
Interestingly, no further reduction of the tetramer content was observed after 1 and 3 months 
storage (Fig. 5-5A). Independent of the storage conditions, the tetramer amount remained 
stable at approximately 75% (1 month: 74.8 ± 2.8% (4°C), 74.9 ± 7.4% (25°C) and 76.3 ± 
5.7% (40°C); 3 month: 78.0 ± 7.6% (4°C), 69.6 ± 5.3% (25°C) and 71.5 ± 1.0% (40°C)).  
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Figure 5-5: Storage stability of AsnB coated MN arrays determined as AsnB tetramer amount (A) and 
AsnB activity (B). The MN arrays were stored for 1 day, 1 week, 1 month or 3 months at 4°C (white 
bars), 25°C (black bars) and 40°C (grey bars), respectively. Mean values ± SD. * p ≤ 0.05    
 
A similar trend was observed for AsnB activity which was well in line with the loss of AsnB 
tetramers. For all three storage conditions, no significant differences in AsnB activity were 
observed. After one day, the AsnB bioactivity dropped from 99.8 ± 0.5 % (fresh formulation) 
to 94.6 ± 2.2% (MN coating). After 1 week, the activity reduced to 91.6 ± 0.3% (4 °C), 91.2 ± 
0.1% (25°C) and 91.9 ± 1.0% (40°C), respectively. Likewise the tetramer amount, the activity 
did not further decrease over storage time: 1 month: 93.6 ± 1.2% (4°C), 91.6 ± 0.1% (25°C) 
and 91.6 ± 0.0% (40°C) and 3 months: 90.5 ± 0.4% (4°C), 89.6 ± 0.3% (25°C) and 89.5 ± 
0.3% (40°C) (Fig. 5-5B). 
Our data demonstrate that the development of coating formulations, which are able to 
stabilize labile compounds, is generally feasible. We stabilized the model protein AsnB and 
maintained its structural integrity and biological activity for up to 3 months. Similar findings 
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were described by Ameri et al. who described the successful stabilization of human growth 
hormone (22 kDa) coated onto solid MN using 20% w/w sucrose and 0.2% polysorbate 20. 
After 6 months, SEC analysis revealed the maintenance of the monomer (approximately 
96%) during storage at 40°C / 75% humidity [9]. We were able to achieve similar results even 
with the larger biomacromolecule AsnB (138 kDa). Another example is the study of Choi et 
al. observing a significantly higher residual hemagglutinin activity of 40 – 50% in trehalose-
containing formulations compared to simple phosphate buffer (residual activity: 12.5%). Here, 
the addition of the viscosity enhancer carboxymethyl cellulose exhibited further stabilizing 
effects [21]. Hence, an increased viscosity seems to be beneficial for stabilization.  
3.4 Application of Protein Coated MN into Pig Skin and Reconstructed Skin 
Models 
To proof the applicability of the coated MN in terms of coating dissolution and protein 
disposition in epidermal skin layers, insertion experiments in pig skin were performed. 
Following the manual insertion of the coated MN, the MN coating dissolved within few 
minutes in the epidermal skin layers and the protein diffused homogeneously in the tissue 
around the insertion channel (Fig. 5-6). Only minor amounts of the fluorescently-labeled 
protein remained on the SC surface indicating that the coating was stable enough to 
withstand the insertion process. After MN withdrawal, only minor amounts if the coating 
remained on the MN base, whereas all the coating dissolved from the needle tip since no 
residual fluorescence was detectable. 
 
 
Figure 5-6: Fluorescence and light microscopy overlays of the BSA-RhB ITC deposition in pig skin 
after MN insertion. BSA-RhB ITC (white color) was coated onto the MN with an effective concentration 
of ~ 10 µg/ MN array. Scale bar = 50 µm 
 
To quantify protein deposition in the skin, MN were also applied into reconstructed human 
skin. Following one application of a single coated MN array (AsnB concentration ~11.7 µg), 
we recovered 8.0 ± 1.4 µg (68.0 ± 11.7%) AsnB intraepidermally (Table 5-3). Repeated 
application of coated MN did not result in significantly higher AsnB amounts in the skin:  
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following two insertions of AsnB coated MN, only 10.3 ± 3.8 µg (44.0 ± 16.1%) were 
recovered.  
Although MN are designed for a pain-free drug delivery, the mechanical disruption of the skin 
barrier can cause skin irritation [34]. Here, reconstructed human skin could be a useful tool 
since skin models are viable and respond to irritating stimuli [26,35]. Thus, to investigate 
whether MN insertion triggers inflammatory responses after intradermal application, the 
secreted of the pro-inflammatory cytokines IL-6 and IL-8 were quantified. After one MN 
insertion, IL-6 levels only marginally increased from 102.1 ± 11.8 ng/ml to 114.4 ± 20.7 ng/ml. 
A second MN insertion did not result in further IL-6 secretion (94.1 ± 18.2 ng/mL) (Fig. 5-7A). 
For IL-8, significantly higher values were measured (Fig. 5-7B). Again, the second MN 
insertion did not further stimulate IL-8 release. These data indicate that MN insertion causes 
a slight skin irritation.  
 
Figure 5-7: IL-6 and IL-8 release following the application of AsnB coated MN. Mean values ± SEM; * 
p ≤ 0.05    
 
Currently, little is known about potential side effects of repeated MN insertion especially 
when aiming for long-term use, which might be necessary for specific applications. Although 
MN application is considered a non-invasive method, repeated MN microporation may have 
an influence on the patient’s skin barrier. In few studies, the short-term effects of 
microneedling have been assessed describing local irritation and erythema minutes after the 
treatment. Nevertheless, a complete recovery of the skin barrier function and vanishing of the 
erythema after MN removal was observed, too [27,30,34].  
 
4. Conclusion  
In this feasibility study, we demonstrated that solid MN arrays are an efficient tool for 
intraepidermal delivery of proteins. By choosing the coating formulation carefully and by 
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application of a localized and product sparing coating method, reproducible MN tip coatings 
with protein concentrations between 10 to 23 µg were generated. Moreover, the protein 
activity was maintained for up to 3 months. Aiming for an intraepidermal delivery of the 
protein, MN with a needle length of 300 µm proved suitable and yielded an effective delivery 
of 68.0 ± 11.7% of the coated model protein. Following intradermal application, the coating 
formulation dissolved rapidly resulting in homogeneously distributed protein in the epidermal 
layers. Only minor skin irritation occurred.  
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Chapter 6 
Final Conclusion 
1. Dendritic PG-based nanogels with trigger-mediated protein 
release 
Concerning the dPG-based nanogels, the objective of the thesis was the implementation and 
modification of the nanogels to suit the requirements for topical and dermal drug delivery of 
sensitive biomacromolecules such as proteins, peptides and enzymes. Therefore, two 
different kinds of drug release modified dPG-based nanogels were characterized and 
investigated. In the end, their suitability as possible drug delivery vehicle for localized intra-
epidermal protein substitution of a therapeutic relevant protein (TGase 1) was to be 
evaluated.  
1.1 Acid-cleavable dPG-based nanogels for targeted protein delivery 
The focus was firstly set on the development of a protein-gentle technique for the 
manufacturing of acid-cleavable PG-based nanogels, which was done by the project partners 
from the FU Berlin (Dirk Steinhilber, Prof.Dr. Rainer Haag), and secondly the characterization 
of encapsulated and released asparaginase in terms of stability and bioactivity, which was 
part of the PhD thesis. As a surfactant free method, nanoprecipitation was for the first time 
applied to form hydrophilic dPG-based nanogel particles. The hydrated polyglycerol network 
creates a hydrophilic environment which is thought to stabilize labile enzymes and proteins 
[1–3]. With the developed preparation method, size-tunable (100 – 1000 nm) nanogels with 
high yields were obtained. The nanogels were freely dispersible in aqueous solution without 
signs of clustering or aggregation. In the past, a major concern for protein integrity during 
encapsulation was the harsh organic environment as organic solvents like acetone are 
inevitable to dissolve the polymers. In this study, inverse nanoprecipitation polymerization 
was applied to avoid damage of the labile asparaginase during encapsulation. Thus, we were 
able to obtain enzyme loaded dPG nanogels with an encapsulation yield of almost 100 %. By 
introducing a pH sensitive benzacetal group into the dPG nanogel network, the nanogels 
responded with rapid degradation to a low pH environment. This feature makes these 
nanogels highly interesting as delivery vehicles for the application in tissues, where a medical 
condition induces an acidic environment, such as inflammation and tumor tissues (pH ~ 6.0 - 
6.5), or physiological compartments where a low pH is present, like intracellular endosomes 
(pH ~5), lysosomes (pH ~4) and the SC/ skin barrier (pH ~5 - 5.5). 
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Upon the pH trigger, we confirmed immediate release of the protein payload. At pH 4 and 5, 
drug release coincided with nanogel degradation. No significant changes in protein 
secondary structure and activity were observed upon encapsulation and release at pH 5. 
1.2 Thermoresponsive dPG-based nanogels for targeted protein delivery 
In a second approach, dPG based nanogels with a different trigger mechanism were 
investigated. Working with thermoresponsive PNIPAM-dPG nanogels, we succeeded in 
incorporating bovine serum albumin and asparaginase. Loading efficiencies between 30 % 
and 70 % were achieved, depending on the molecular weight size of the used proteins. 
Unloaded nanogels underwent a decrease in size at the thermal trigger point of 33 °C, which 
is at a slightly higher temperature than for pure PNIPAM due to the hydrophilic input by the 
dPG moieties [4–6]. The shrinkage of protein loaded nanogels was less pronounced with 
protein load which presumably counteracts the shrinkage. In addition, the transition 
temperature was increased to ~35 °C as the protein further increased the hydrophilicity. As a 
temperature of ~ 33 to 35 °C in expected in the upper skin layers, the nanogels should thus 
selectively release their payload after skin application in the lower SC / upper epidermis, but 
stay stable at room temperature.  
The proteins maintained their biological activity and structure during nanogel manufacturing 
as well during freeze-thaw and storage stress of the loaded nanogels, which highlights the 
excellent stabilizing properties of the nanogel for sensitive proteins. The dermal protein 
delivery efficiency was analyzed in ex-vivo pig skin and in viable reconstructed human skin. 
The latter offered the opportunity to analyze the drug release and delivery in TGase-1-
deficient skin models that were obtained by gene knock-down in keratinocytes [7–9]. Our 
study showed that the two selected model proteins as well as the therapeutically interesting 
candidate TGase-1 were significantly enhanced in their skin deposition using the nanogels. 
Reviewing our data and considering that the nanogels themselves did not travel beyond the 
SC, we were not able to elucidate the mode of action of protein skin penetration. As our 
nanogels had a neutral surface charge, improved skin adhesion as a result of surface 
charges is unlikely [10]. In all probability, the investigated nanogels improve the skin 
penetration by interacting through their amphiphilic polymer groups with lipophilic SC parts 
[11,12]. Furthermore, the nanogels may act as penetration enhancers in terms of modulating 
and untightening the stiff SC protein and lipid organization [13]. 
Replacement therapy of underdeveloped or missing proteins and enzymes in the skin has 
emerged as a promising tool for treatment of some skin diseases like congenital ichthyoses, 
where the overall therapy options are rather poor [14]. Aiming for a restored TGase1 activity 
and a remodeling in the skin structure, especially focusing on the SC, we applied TGase1-
loaded PNIPAM-dPG nanogels on TGase-1-deficient skin models. The protein was efficiently 
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delivered locally into the epidermis. Additionally, the skin barrier function was restored as 
assessed by a skin permeability test. To conclude, we could demonstrate that the 
preparation of thermoresponsive PNIPAM-dPG nanogels is a suitable tool to incorporate and 
to deliver labile biomacromolecules locally into the viable epidermis. As the protein’s 
biological activity was maintained and the delivery of the therapeutic relevant TGase1 verified 
the feasibility of a protein substitution approach in TGase1-deficient skin conditions, these 
nanogels have great potential as dermal drug delivery vehicles. 
 
2. HA hydrogels as dermal drug delivery vehicles for proteins 
Ever since the versatile polysaccharide HA has been used in the cosmetics sector for skin 
hydration and rejuvenation, it also become important in the treatment of skin diseases like 
actinic keratosis and related secondary symptoms such as skin dryness or irritation and 
inflammation [15–18]. As HA can enhance the dermal uptake of diclofenac in actinic 
keratosis treatment, a potential beneficial effect of HA for dermal delivery of 
biomacromolecules was a further objective [15–18]. We explored the delivery capacity to 
intact and barrier-deficient skin for BSA using HA of different size and at different 
concentration. Besides the delivery yield of both HA and BSA, the focus was set on 
unraveling the mode of action of HA-facilitated delivery, as up to now no clear and 
satisfactory explanation can be found in literature. 
Low molecular weight HA (5kDa) penetrated into deeper dermal layers of intact skin as 
compared to high molecular HA species, a finding that is supported by lately published data 
[15,19,20]. In contrast, barrier impairment by tape-stripping facilitated the absorption of the 
100 kDa HA to a greater extend. Without HA, BSA only accumulated in minor fractions in 
intact skin when it was applied and incubated over a longer time range on well-hydrated skin 
samples, whereas tape-stripping enabled an easy protein penetration regardless of the 
hydration state. Combining HA and BSA, the penetration of the protein into the viable 
epidermis of intact skin could only be provided by the 5kDa HA. FRET-FLIM analysis 
revealed that the HA and BSA molecules had a close proximity, which hints to interactions 
between both molecules at physiological conditions despite their mostly negative surface 
charges [21–23]. As a result, a HA-mediated co-transport of the scarcely penetrating BSA is 
highly likely in intact skin. To our surprise, HA-BSA hydrogels tended more to a penetration 
confinement effect in barrier impaired skin localizing the BSA mainly into the viable 
epidermis. Here, no interaction between HA and BSA was observed by FRET-FLIM. Given 
that HA shows good penetration yields and other publications observed similar retention 
effects and hypothesized underlying hydration-related contributions [15,17], it is possible that 
skin hydration may be the driving factor.  
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Concluding, FRET-FLIM results suggest an HA accompanied co-transport of the model 
protein into intact skin and revealed the easy accessibility of barrier disrupted skin for both 
HA and protein. Nevertheless, we saw that further driving forces contribute to skin 
penetration. Diverse previous studies demonstrated enhanced delivery of actives in the 
presence of HA, the delivery of HA-active conjugates or even the penetration of HA itself 
based on concepts like penetration enhancer properties or co-transportation, yet a distinct 
mode-of-action therefor could not be identified [19,20,24,25]. Hence, we included a closer 
look on the HA-skin interactions using isolated SC sheets and FTIR analysis. 
As most proteins are hydrophilic and encounter penetration problems in intact skin due to the 
high extend of lipophilic moieties, increasing the water content in the SC might serve as an 
option for improved penetration results. After application, HA hydrogels create an occlusive 
film on the skin surface, which contributes to an increase in skin hydration. Depending on the 
HA molecular size and concentration, the hydration capacity of the SC sheet competed with 
the HA gel equilibration, as was seen by a decrease in skin hydration with HA concentrations 
exceeding 5%. Hydration of the SC was pronounced for gels with low molecular weight HA (5 
kDa). With these formulations we observed the anticipated enhanced BSA penetration into 
intact skin. Skin hydration is accompanied by structural changes in the skin´s keratins [26]. 
This could be demonstrated for SC sheets, especially when incubated with low molecular 
weight HA and at higher HA concentrations (5-10 %). Those also showed the best skin 
penetration properties. This change in keratin structure may contribute to a weakened skin 
barrier and as a result may facilitate a better skin penetration. Another way to impair the 
barrier and enhance penetration is the alteration of the skin lipid organization. Regardless of 
being intact or tape-stripped, we observed significantly less lipid rigidity after application of 
100 kDa HA at higher concentrations. 
Thus, HA, especially the low to medium molecular weight forms formulated at more than 5 % 
has a beneficial effect on the skin partitioning of topically applied proteins in both intact and 
barrier deficient skin. Although the exact mechanism could not be clarified, the data obtained 
with FRET-FLIM and FT-IR strongly suggest the theory of a HA-mediated co-transport of the 
protein. In addition, the protein penetration is further facilitated by more hydrophilic 
environment due to SC hydration and by an interference with the skin lipid organization and 
keratin structure. The observed penetration confinement in barrier impaired skin, however, 
could not be explained.  
 
3. Solid MN arrays for the intra-epidermal delivery of proteins 
Over the last decades, solid stainless steel MN arrays became interesting devices for topical 
delivery systems for vaccines, pain medication and hormones. We aimed for a feasibility test 
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of the use of solid MN arrays for dermal protein delivery. As literature scarcely describes 
coating formulation development with regard to process and storage stability we had a closer 
look at this aspect. Not only should MNs be of a robust, inert and sharp construction to 
smoothly insert into skin, but they also need to come with an easy handling and minimal pain. 
Comparing needles of 300 µm and 800 µm length, MN arrays with 300 µm needles were 
most suitable to locally target the epidermis resulting in punctures of 80 to 90 µm depth 
(epidermis thickness130 - 180 µm) [27,28]. The manual insertion with reasonable force 
resulted in reproducible channel depth and count which is prerequisite for a reproducible 
drug delivery.  
A biocompatible coating which stabilizes the protein drug is inevitable for a successful drug 
delivery as proteins are generally very sensitive towards external stress factors like heat, 
moisture or oxygen leading to unfolding, aggregation and degradations. Hence, the stabilizer 
sucrose was added that provides an amorphous matrix for the proteins [29–31]. By adding 
phenylalanine, the residual moisture content in the final dry coatings can kept low which is 
beneficial for protein stability [30]. Polysorbate 80 was added to prevent the protein drug from 
surface induced aggregation and to reduce the surface tension for improved wetting of the 
MN during the coating process [32]. In addition, 1 MDa HA served as viscosity enhancer to 
increase the coating efficiency on the MN tips. With an in-house developed manual coating 
technique, we were able to yield ~ 12 µg for single coated arrays, ~18 µg for twice and ~ 
23µg for tree-times coated MN arrays without loss of protein bioactivity. Despite the protein 
stabilizing excipients in the coating formulation, the coated MNs are presumably still 
susceptible to environmental stress factors like humidity and oxygen. As the coating needs to 
ensure the maintenance of the protein activity over a longer storage time, a 3 month stability 
study at 2-8°C, 25°C and 40°C was executed and the biological activity of asparaginase as 
well as the tetramer amount, the biologically active species, was monitored. The tetramer 
contend stayed stable at ~ 75 % for all storage conditions (naive state: 89 % tetramer 
content). Likewise, the biological activity remained high during the 3 month of storage 
independent of the storage temperature with an overall activity of ~92 % (naive state: 99.8 % 
activity). Hence, it is possible to prepare a MN array with coating which provides adequate 
protein dosing and stability for medical treatment.  
The coated MN arrays were furthermore manually assessed for application to pig and 
reconstructed skin. Shortly after the insertion, the coatings evenly dissolved and distributed 
the model proteins in the tissue around the insertion sides in both skin models. Only minor 
residues were left on the MN arrays, mainly on areas where the coating was not precisely 
placed on the needles themselves but spread to the MN base as well. This phenomenon 
might be prevented by coating the MN with an automated process which was beyond in the 
scope of the thesis. Protein quantification in reconstructed skin yielded delivery 68.0 ± 11.7% 
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(8.0 ± 1.4 µg / 4.7 µg per cm²) of the loaded model protein asparaginase for single coated 
MN arrays which is similar to other published data [33–35]. 
In contrast to vaccination, where immunization can be obtained after one MN application, the 
use of MN in skin disease treatment will most likely comprise repeated applications to the 
same skin area. Consequently, irritation effects, as described in literature [36–38], due to 
application of our MN arrays were examined in this study via the secretion of the pro-
inflammatory cytokines IL-6 and IL-8 from the viable epidermis into the culture medium. The 
data indicated that a first MN application led to slight skin irritation, but a second insertion did 
not result in a further increase of the IL levels. Thus, close follow-ups by trained physicians 
and disinfection may be crucial to avoid infections and the development of scarified skin 
tissue in a possible treatment of skin diseases with MN arrays [39].  
 
4. Prospects 
Although the dPG-based nanogels turned out to be promising vehicles for dermal drug 
delivery of labile biomacromolecules, especially in barrier impaired skin, further studies are 
necessary. Starting with the acid-cleavable nanogels, we succeeded in generating nanogels 
that offer a quick protein release at a physiologically useful pH. Bioactivity and structural 
integrity of the protein payload were maintained. Skin penetration experiments need to follow, 
as these nanogels are not yet characterized for in-vitro or ex-vivo skin delivery. Adequate 
skin models need to be chosen, as for example ex vivo pig skin may no longer exhibit the 
physiologically occurring skin pH of 5.5 due to cleaning or freezing steps. The use of 
reconstructed skin may be preferred. Overall, future work needs to focus on the long-term 
stability of the nanogels. It is necessary to evaluate the benefits of adding stabilizers to 
facilitate longer shelf-lives. In aqueous solution, the probability of deterioration and nanogel 
clustering is high. Therefore, freeze-drying could be a valuable option. To unravel the mode 
of action of the dPG nanogels, FRET-FLIM as well as FT-IR measurements could be 
valuable tools.  
Although HA hydrogels successfully delivered loaded model proteins into barrier-disrupted 
skin, further studies need to be performed to close the gap in understanding the mode of 
action of HA in the SC and the upper skin, focusing especially on the penetration retardation 
in barrier–impaired skin. As an addition, mixtures of 5kDa and 100 kDa could be investigated 
to combine all skin barrier altering effects for a potential increase in delivery efficiency. 
Finally, the effectiveness of HA hydrogels as dermal protein delivery vehicles in skin disease 
adapted skin models with therapeutically relevant proteins should be tested. 
MN arrays are very versatile devices for localized and systemically delivery of low and high 
molecular weight drugs. The coating formulations developed in this thesis provided promising 
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storage stability and quick release of the loaded proteins after insertion in the skin. However, 
the coating technique and the resulting applied protein concentration should be further 
improved to yield even and more reproducible delivery of higher protein payloads. 
Subsequently, as proof of concept these proteins coated MN arrays need to be applied to 
diseased skin models to study whether the skin barrier at the insertion site or in the whole 
model is restored. When the distribution of the dissolved coating and thus the proteins is 
insufficient, a switch to dermal rollers for narrow and repeated skin piercing might be an 
option. 
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Chapter 7 
Summary 
Local and targeted delivery of labile biomacromolecules, such as proteins, peptides, and 
enzymes, is of high interest and needs to take the well-known instability and delivery 
problems of these APIs into account. To offer new options for local and targeted 
intraepidermal and dermal drug delivery, the goal of the thesis was the development, 
investigation and characterization of promising delivery devices and vehicles. Efficient protein 
delivery into the skin may enable a substitution therapy approach of skin diseases like atopic 
dermatitis which come along with a lack of certain structural proteins. 
For the first time, dPG-based nanogels were investigated for their suitability to encapsulate 
and release proteins. Using two different types of release trigger mechanisms, we succeeded 
in developing biocompatible dPG nanogels with high protein load. Acidic-cleavable and 
thermoresponsive nanogels offered mild encapsulation conditions, where proteins were kept 
intact without activity loss during manufacturing and after the triggered release. Furthermore, 
the thermoresponsive PNIPAM-dPG nanogels were able to deliver TGase1 locally to the 
epidermis of TGase-1-deficient skin models. Here, the restoration of a normal skin barrier 
function was observed, which verifies their feasibility in delivering therapeutically relevant 
concentrations into diseased skin. 
The very versatile polysaccharide HA was investigated for its beneficial effects on the 
enhanced dermal delivery of low molecular weight drugs in the past. Successful topical 
delivery of biomacromolecules using HA gels was demonstrated using FRET-FLIM and FT-
IR analysis. Substantiating literature findings on HA skin penetration, we observed enhanced 
BSA delivery to intact skin with 5 kDa HA, presumably as a result of protein-HA co-transport 
supported by SC hydration as well as keratin and lipid structure interactions. In barrier-
disrupted skin, we observed a localized penetration confinement of the protein to the 
epidermis, which could not be unraveled so far, but demonstrates the supposedly great 
potential of HA in dermal drug delivery. 
Finally, solid stainless steel MN arrays were characterized and analyzed for their feasibility to 
locally deliver proteins. 300 µm long MN arrays were coated with an optimized aqueous 
protein formulation and technique to yield up to 68 % of the protein payload (8.0 ± 1.4 mg per 
skin model / 4.7 ± 0.8 mg/cm²) in the skin tissue after dissolution. The coated protein was 
stable up to 3 month storage without loss of activity and integrity. Following MN repeated 
insertions, reconstructed skin showed minor increases in interleukin levels, which indicates a 
slight but not critical skin irritation.  
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Annex 
 
1. Biodegradable dendritic polyglycerol nanogels for encapsulation 
and release of pharmaceutical biomacromolecules 
1.1 Experimental section – general considerations 
All moisture sensitive reactions were carried out in flame-dried glass-ware under a positive 
argon pressure. Organic solvents were removed using a rotary evaporator and is referred as 
concentrated in vacuo. 1H NMR and 13C NMR spectra were recorded on a Bruker ECX 400 
spectrometer (400 and 100 MHz for 1H and 13C respectively), at 25 °C using deuterated 
water, acetone, and chloroform as solvent. UV/Vis spectra were recorded on a Scinco S-
3100 UV/Vis spectrometer. Fluorescence spectra were recorded on a Jasco FP-6500 
fluorometer. Optical microscopy measurements were performed and micrographs were 
recorded on a Zeiss Axioskop microscope. Melting points were determined using a Büchi 510 
melting point apparatus. Transmission electron microscopy samples were prepared on 
carbon coated copper grids by blotting samples in 1% aqueous phosphotungstic acid and 
visualizing them with a Philips CM12 electron microscope.  
1.2 Materials 
Anhydrous solvents were purchased as “extra dry” from either Acros or Aldrich and used as 
received, or taken from MBraun MB SPS-800 solvent purification system. Trizma 
hydrochloride (Tris-HCl pH 8.6), trichloracetic acid and L-asparagine monohydrate CuOAc, 
trimethylorthoformate, NaHCO3, anhydrous N-Methyl-Pyrolidone (NMP), sodium ascorbate 
(NaAsc), CuSO4, dialysis tubes (2 kDa cut-off), and p-toluenesulfonic acid (PTSA) were 
purchased from Sigma-Aldrich (Steinheim, Germany). Dry PTSA was obtained by Dean 
Stark distillation from toluene. The anhydrous PTSA was stored in a NMP stock solution. 
Aqueous ammonia (25 wt%) was obtained from ROTH. Ammonium sulfate and Nesslers 
Reagent were purchased from Merck (Darmstadt, Germany). Recombinant L-asparaginase II 
derived from E.choli (95% pure) was a gift from Prof. Dr. Markus Pietzsch, Martin-Luther 
University Halle-Wittenberg. dPG with a number average molecular weight (Mn) of 5 kDa and 
a weight average molecular weight (Mw) of 7.7 kDa (dPG7.7) was prepared as reported 
previously [1]. THPTA [2], and dPG7.7 Heptaazide (dPG7.7[N3]7) [3] and alkyne modified 
rhodamin B [4] have been prepared according to literature procedures.  
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1.3 Synthetic procedures 
1.3.1 Preparation of p-propargyloxy-benzaldehyde (pPBA) 
In a 100 ml two-necked flask with drop funnel and magnetic stirrer 4-hydroxybenzaldehyde 
(pHBA) (2.00 g, 16.38 mmol) was dissolved in acetone (50 ml). K2CO3 (15.15 g, 109.62 
mmol) was added and the suspension was stirred for 30 min under reflux. After the solution 
cooled down to RT propargylbromide (2.12 ml, 19.10 mmol) was added over 2.5 h.  Then the 
suspension was heated to reflux for 1.5 h. The suspension was filtrated and the solvent of 
the filtrate was evaporated in vacuo. DCM (50 ml) was added and the organic phase was 
washed twice with 1 M NaOH (20 ml) and once with water (20 ml). The organic phase was 
dried over MgSO4. The crude product was recrystallized from toluene three times to obtain a 
white crystalline solid. (Full conversion, yield: 91 %). 
1H NMR (400 MHz, CDCl3, 25 °C): 1H NMR (CDCl3, 400 MHz): d (ppm) = 9.90 (s, 1H, 
aldehyde-H), 7.93-7.68 (m, 2H, aromatic), 7.14-6.91 (m, 2H, aromatic), 4.77 (d, 2H, 
benzaldehyd-O-
162.2, 131.8, 130.4, 115.0, 77.4, 76.3, 55.8. ppm; IR: 3206, 2749, 2360, 2121, 1677, 1600, 
1573, 1505, 1454, 1426, 1395, 1378, 1314, 1300, 1247, 1237, 1213, 1166, 1107, 1006, 968, 
860, 808, 792, 762, 658, 651  = cm-1; EIMS (40 °C) found for C16H28O6 (calcd. 160.05): 
m/z experimentally found: 160.7. Melting point: 81 °C.  
1.3.2 Preparation of p-propargyloxy-benzdimethylacetale (pPBDMA) 
pPBA (1g, 6.29 mmol) was dissolved in trimethyl orthoformate (10 mL) and dry  LiBF4 (108 
mg, 1.16 mmol) was added. The reaction was heated at 65 °C for 1h and quenched by 
addition of saturated NaHCO3 solution (25 mL). The mixture was extracted 3 times by 
ethylacetate (25 mL) and the fractions were combined and dried over Na2SO4. Ethylacetate 
was evaporated and pPBDMA was obtained as yellow oil (full conversion, yield 90 %). 1H 
35-7.33 (m, 2H, aromatic), 6.98-6.95 (m, 2H, 
aromatic), 5.33 (s, 1H, benzacetal) 4.72-4.71 (d, 2H, benz-O-CH2), 3.29 (s, 6H, O-CH3), 
80.7, 78.0, 58.2, 53.6 ppm; IR: 3288, 2936, 2829, 1611, 1588, 1509, 1446, 1351, 1302, 
1216, 1171, 1098, 1048, 980, 823  =  cm-1; EIMS (40 °C) found for C16H28O6 (calc 206.1): 
Experimental value m/z: 206.35. 
1.3.3 Preparation of fluorescent nanogels  
dPG7.7[N3]7 (7mg, 0.79 µmol) and alkyne modified rhodamine B (0.03 mg, 0.06 µmol) was 
dissolved separately in Milli-Q-water (0.05 mL). THPTA (500 µg, 1.15 µmol), CuSO4 (72 µg 
,0.3 µmol), and NaAsc (228 µg, 1.15 µmol) were added exactly in this sequence to the 
solution. After 12 h (complete conversion was confirmed by IR) additional Milli-Q-Water was 
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added (0.45 mL). dPG7.7-10-p-PBDMA (5 mg, 0.6 µmol) was also dissolved in Milli-Q-Water. 
The solutions were cooled down to 4 °C, mixed, and added quickly to magnetically stirred 
acetone (20 mL). Precipitated polyglycerol nanoparticles were obtained as blue shining 
dispersions and the particle size was determined by DLS (table 1). After 3 h the reaction was 
quenched by the addition of excess propargylalcohol (50 mg, 893 µmol). After 12 h Milli-Q-
water (20 mL) was added and acetone was evaporated to obtain blue shining nanogel 
dispersions in water. The nanogels were collected by centrifugation (4000 rpm) and washed 
5 times with Milli-Q-water. The nanogels were characterized by DLS (table 1) optical and 
fluorescence microscopy. 
1.3.4 GPC characterization of dPG7.7-10- p-PBDMA 
Molecular weight distributions were determined by size exclusion chromatography coupled to 
a refraction index detector to obtain the complete distribution (Mn, Mp, Mw, DI). 
Measurements were performed under highly diluted conditions (10 mg / mL, injected volume 
20 μL) from a SEC consisting of an Agilent 1100 solvent delivery system with dosing pump, 
manual injector, and an Agilent 1100 differential refractometer. Three 30 cm columns (PSS 
SUPREMA, 5 μm particle size) were used to separate polymer samples using water at a flow 
rate of 1.0 mL/min. The columns were operated at room temperature and the differential 
refractometer at 50 °C. WinGPC Unity from PSS was used for data acquirement and 
interpretation. 
1.3.5 Dynamic light scattering measurements 
Dynamic light scattering measurements were performed on a Malvern Zeta-sizer Nano-ZS 
ZEN 3600 instrument equipped with a He-Ne laser (633 nm) and a fixed detector oriented at 
173°. Nanogel dispersions (0.5 mL, 0.5 mg/mL) were analyzed in quartz fluorescence 
cuvettes with a round aperture. The autocorrelation functions of backscattered light were 
analyzed using the Zetasizer DTS software from Malvern to determine the size distribution by 
intensity and the polydispersity index. The measurements were performed at 25 °C in 
acetone or water, equilibrating the system at this temperature for 120 s. Measurements were 
performed in triplicate with the error given as standard deviation from the mean value. 
1.3.6 Circular dichroism (CD) measurements 
All CD measurements were performed on a Jasco-J810 spectropolarimeter by the use of 1 
mm path-length cuvette at 20 °C (Jasco PTC-348 WI peltier thermostat). CD spectra were 
the average of 4 scans obtained by the collection of data from 190 to 240 nm with a 1 nm 
interval on 50 nm per minute. 
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1.4 Figures 
1.4.1 NMR spectra 
 
Figure S1 1H NMR (CDCl3, 400 MHz) p-propargyloxy-benzaldehyde (pPBA). 
 
Figure S2 13C NMR (CDCl3, 400 MHz) p-propargyloxy-benzaldehyde (pPBA). 
 
Figure S3 1H NMR (CD3OD, 400 MHz) p-propargyloxy-benzdimethylacetale (pPBDMA). 
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Figure S4 13C NMR (CD3OD, 400 MHz) p-propargyloxy-benzdimethylacetale (pPBDMA). 
 
Figure S5 1H NMR (CD3OD, 400 MHz) dPG7.7-10-p-propargyloxy-benzacetale. 
 
1.4.2 Asparaginase release measured by HPLC 
L-asparaginase can be determined quantitatively and qualitatively via HPLC analysis 
without interference with polyglycerol fragments. Chromatograms of the intact, 
asparaginase-loaded nanogel showed that the encapsulation efficiency is 100%, as 
no free L-asparaginase II was detected. The asparaginase activity assay of the intact 
and loaded PG nanogel gave an enzyme activity of 44.5%. The activity is related to 
asparaginase molecules located at the surface of PG nanogel particles, as no free L-
asparaginase II was detectable. The release study verified the pH dependent 
degradation / release of the PG nanogels. 100% drug release was obtained at pH 4 
after 3 days. At pH 5, particle degradation and drug release was slower. 
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Figure S6 HPLC chromatogram – UV detection at 280 nm; blue line: PG Nanogel; red line: 
PGNanogel intact spiked with L-asparaginase 1 mg/mL 
 
 
Figure S7 HPLC chromatogram – fluorescence detection at 348 nm; blue line: asparaginase-loaded 
nanogel intact; red line: nanogel intact spiked with L-asparaginase 1 mg/mL. 
1.4.3 Circular dichroism spectra of proteins  
 
Figure S8 CD spectra of fresh BSA in water (lower line) and released BSA (upper line) 
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Figure S9 CD spectra of fresh lysozyme in water (lower line) and released lysozyme. 
 
Figure S10 CD spectra of fresh IgG (c), released IgG (b), and antibody precipitated without stabilizing 
dPG (a). 
 
2. Thermosensitive dendritic polyglycerol-based nanogels for 
cutaneous delivery of biomacromolecules 
2.1 Materials 
The chemicals were used as purchased: N-isopropylacrylamide (NIPAM), acryloyl chloride 
(Ac, 96 %), ammonium persulphate (APS, 98 %), N,N,N',N'-tetramethylenethylendiamine 
(TEMED, 99 %), bovine serum albumin (BSA), sodium chloride (NaCl), L-asparagin 
monohydrate, trichloracetic acid, Nessler´s solution, Igepal® CA-630, the buffer substances, 
and rhodamine B isothiocyanate (RhB-ITC) were purchased from Sigma-Aldrich Corporation, 
Taufkirchen, Germany. Extra dry dimethylformamide (DMF, 99.8 %), dimethyl sulfoxide 
(DMSO), triethylamine (TEA), and sodium dodecyl sulphate (SDS, 98 %) and the Micro 
BCA™ Protein Assay Kit were obtained from Fisher Scientific GmbH, Schwerte, Germany. 
N-methylisatoic anhydride was purchased from Molecular Probes®, Invitrogen, Darmstadt, 
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Germany. Human TGase-1 was purchased from Zedira, Darmstadt, Germany, 1,2,6,7- ³H-
testosterone was obtained from Amersham, Glattbrugg, Switzerland. 
2.2 Synthesis and fluorescence labeling of acrylated dPG (dPG-Ac 5 %) 
dPG with an average Mw of 10 kDa (PDI 1.3) was synthesized according to previously 
reported methodologies 32. The dPG was dried overnight under vacuum prior to the 
acrylation reaction. A solution of acryloyl chloride (0.65 mmol, 52 μL) in dry DMF (1 mL) was 
added drop wise to a stirred solution of dPG (1 g, 10 kDa, 13.51 mmol OH equivalent) and 
TEA (1.08 mmol, 150 μL) in DMF (7 mL) at 0 ºC. The reaction mixture was stirred at room 
temperature for at least 4 h and subsequently purified by dialysis (MWCO 2000) in water for 
at least 48 h. The dPG-Ac with a yield of 90 % was preferably used directly after purification. 
Otherwise the product was stored in dark at room temperature in the presence of p-
methoxyphenol, which was dialyzed out before usage. 1H-NMR spectra were recorded with a 
Bruker DRX 500 MHz instrument. D2O was used as the deuterated solvent. Chemical shifts 
δ are given in ppm relative to TMS as an internal standard or relative to the resonance of the 
solvent (1H-NMR: D2O:  = 4.79 ppm). 1H-NMR (500 MHz, D2O), δ: 3.20 – 4.30 (m, 5 H, 
dPG scaffold protons), 5.88 – 6.00 (m, 1H, vinyl), 6.08 – 6.28 (m, 1H, vinyl), 6.32 – 6.44 (m, 
1H, vinyl).  
Alternatively, dPG was labeled with N-methylanthraniloyl group (MANT) before the acrylation 
reaction. This method is a modiﬁcation of a previously described synthesis of ﬂuorescent 
polysaccharide 33. 50 mg of dPG (20 mg mL-1) in milliQ water was adjusted to 50 % 
dimethyl sulfoxide (DMSO) (v/v). A stock solution of 10–20 mg ml-1 high-purity N-
methylisatoic anhydride (MIA) (w/v) in neat DMSO was prepared by vortexing. This stock 
solution was used immediately. The MIA stock solution is added to the polymer solution, 
mixed thoroughly, and incubated at room temperature overnight. The successful labeling 
reaction was probed by thin layer chromatography, 2-propanol/ammonium hydroxide/water, 
(6:3:1) was used to separate free hydrolyzed reagent from the MANT-labeled polymer. The 
ﬂuorescent compounds were detected on the plate by excitation with long-wave ultraviolet 
(366 nm) light. The label dPG was further purified by dialysis against water for 48 h. 
2.3 Skin penetration tests 
The pig skin was punched to 1.5 cm discs, and mounted onto static-type Franz cells 
(diameter 15 mm, volume 12 ml, 1.72 cm² application area, PermeGear Inc., Bethlehem, PA, 
USA) filled with phosphate buffered saline pH 7.4 (PBS). After 30 min equilibration, 200 µL of 
the test formulations (350 µg cm-²) were applied onto the skin surface. A temperature ramp 
of 32 °C - 37 °C was applied during incubation to mimic the temperature gradient in native 
skin. After 6 h, the skin was dismounted and excessive formulation was gently removed. For 
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data analysis, 5 µm skin sections were prepared by cutting from the dermis to the stratum 
corneum (SC). The cross-sections were subjected to normal light and fluorescence 
microscopy (100 and 200x magnification, BZ-8100, Keyence, Neu-Isenburg) and the 
fluorescence of RhB ITC (filter setting: exc. 560/40 nm, em. 630/60 nm) and MANT-labeled 
nanogels (filter setting: exc. 360/40 nm, em. 460/50 nm) were detected. The exposure time 
was set to values, where no auto-fluorescence of the skin was detectable. The pixel 
brightness was assessed as arbitrary brightness units (ABU) using the image analysis 
software BZ Analyzer 3 .  
2.4 Figures 
 
Figure S1 The amount of free BSA-RhB ITC was determined after 0 min (white bars), 5 min (light grey 
bars), 15 min (grey bars), 30 min (dark grey bars), 1 h (black bars), and 4 h (shaded bars) following 
incubations at 25 °C, 32 °C, and 37 °C, respectively. n=3, mean ± SD. 
 
Figure S2 Protein species distribution of Asp loaded onto nanogels and free Asp in an aqueous 
following 4 freeze-thaw cycles: tetramer (black bars), aggregates (white bars), and fragments (grey 
bars). n = 3, mean ± SD. *p < 0.05. 
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Figure S3 Protein species distribution of asparaginase (Asp) loaded onto nanogels and free Asp in an 
aqueous solution after 2 weeks and 4 weeks of storage at 25 °C: tetramers (black bars), aggregates 
(white bars), and fragments (grey bars).  n = 3, mean ± SD, * p < 0.05. 
 
 
Figure S4 Skin absorption of BSA-RhB ITC in normal (A-C) and tape-stripped (D-F) pig skin following 
the application of BSA-RhB ITC solution (A, D), BSA-RhB ITC loaded PNIPAM-dPG nanogels (B, E), 
and PNIPAM-dPG nanogel spiked with free BSA-RhB ITC (C, F). Scale bar = 50 µm. 
 
Table S1: BSA-RhB-ITC content in the SC and viable epidermis following the application of BSA-RhB 
ITC solution, PNIPAM-dPG nanogels spiked with free BSA-RhB ITC, and BSA-RhB ITC loaded 
PNIPAM-dPG nanogels depicted as arbitrary pixel brightness units (ABU). n=3 donor 
  SC ± SD [ABU] Viable Epidermis ± SD [ABU] 
N
o
rm
a
l 
s
k
in
 
BSA-RhB ITC solution 154.1 ± 6.8 0 
BSA-RhB ITC loaded nanogel 125.0 ± 13.5 0 
nanogel spiked with 3 mg mL
-1
 free BSA-RhB ITC 118.8 ± 9.5 0 
T
a
p
e
-
s
tr
ip
p
e
d
 
s
k
in
 
BSA-RhB ITC solution 151.5 ± 11.9 5.8 ± 0.7 
BSA-RhB ITC loaded nanogel 202.1 ± 7.6 23.6 ± 2.3 
nanogel spiked with 3 mg mL
-1
 free BSA-RhB ITC 140.5 ± 11.9 4.6 ± 2.3 
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3. Interactions of Hyaluronic Acid with the Skin and Implications for 
the Dermal Delivery of Biomacromolecules 
3.1 Figures 
 
Figure SI 1 Spectral characteristic of HA-MANT and BSA-RhB samples. (A) Absorption spectra, 
shown as solid line, and emission spectra, depicted as dashed lines, of HA-MANT samples (5 kDa, 
100 kDa, 1 MDa). For comparison the absorption spectrum of MIA is also shown. (B) Absorption 
spectra, shown as solid line, and emission spectra, depicted as dashed lines, for BSA-RhB and RhB. 
 
Figure SI 2 Fluorescence lifetime decay curves of BSA-RhB in the respective skin regions as shown in 
Figure 1. The BSA-RhB fluorescence lifetime decay curve (upper line) was observed in both normal 
and tape-stripped skin, while the decay curve (lower line) was only observed in tape-stripped skin 
      
Figure SI 3 Overlays of false color coded FLIM images and bright field images for BSA-RhB 
penetration into normal skin (A,C,E,G) and tape-stripped skin (B,D,F,H). Scale bars represent 100 µm. 
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Figure SI 4 Normalized FT-IR spectra of incubated SC samples (6h incubation; 5% 5 kDa HA, 2% 1 
MDa HA, 2% HEC, 5% 100 kDa HA) versus the corresponding plain hydrogel controls (5% 5 kDa HA, 
5% 100 kDa HA, 1% 1 MDa HA and 1% HEC,) recorded in the amide I and II region between 1700-
1500 cm
-1
. mean values of n=3 
 
Figure SI 5 Normalized FT-IR spectra of incubated SC samples (6h incubation; 5% 5 kDa HA, 2% 1 
MDa HA, 2% HEC, 5% 100 kDa HA) versus the corresponding plain hydrogel controls (5% 5 kDa HA, 
5% 100 kDa HA, 1% 1 MDa HA and 1% HEC) recorded in the CH stretching region between 3000-
2800 cm
-1
. mean values of n=3 
 
Figure SI 6 Normalized FT-IR spectra of incubated SC samples (6h incubation) recorded in the OH 
stretching region between 2500-1800 cm
-1
. mean values of n=3 
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